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1 Introduction 
 
1.1 Staphylococcus aureus: Pathogenicity and clinical relevance 
Staphylococci are eubacteria, belonging to the phylum fermicutes and to the class of 
bacilli. The coccal bacteria grow facultative anaerob, are catalase-positive and form 
grape-like clusters (Ogston, 1881). A main characteristic for a further differentiation of 
staphylococci is their ability to produce the enzyme coagulase, which is responsible 
for agglutination of blood. One of the coagulase-positive species is Staphylococcus 
aureus. S. aureus is a common representative of the microbial flora at mucosal 
surfaces, like the nasal mucosa of around 30 % of humans. A passage of the 
bacteria through a break in the mucosal or skin surface and subsequent entry into 
the blood stream may lead to severe systemic infections. As an opportunistic 
pathogen S. aureus causes a range of infections that reach from superficial skin 
lesions to serious life-threatening diseases, such as endocarditis, toxic-shock 
syndrome, pneumonia or sepsis (Lowy, 1998, Diekema et al., 2001).  
The severity of infection often depends on the humans’ immune system. Patients with 
a suppressed immune system are especially susceptible to S. aureus infections, but 
also healthy patients get infected, which makes S. aureus one of the main causative 
pathogens of nosocomial infections (Laupland et al., 2003). Beneath coagulase       
S. aureus is able to produce over 50 known virulence factors, which are differentially 
expressed in dependence of growth conditions (Arvidson and Tegmark 2001). This 
enables the bacterium to adapt to a variety of host niches and to cause a multitude of 
diverse symptoms. Functions of these virulence factors include adherence to host 
cell structures, evasion from the host immune system and active damage on host 
cells that allows S. aureus to establish the infection.  
Adhesion to components of the host extracellular matrix, such as fibrinogen, 
fibronectin or collagen, is mediated by adhesion proteins of the MSCRAMM 
(microbial surface component recognizing adhesive matrix molecules) family. These 
are cell wall-anchored proteins (CWA), which are often covalently linked to 
peptidoglycan (Foster and Hook, 1998). All CWA proteins contain a secretory Sec-
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dependent signal sequence at the N-terminus and a sorting signal, which comprises 
an LPXTG sortase cleavage motif and a stretch of positively charged residues at the 
C-terminus. The last two subdomains retain the protein in the membrane during 
secretion (Foster et al., 2014). Common MSCRAMMs are the fibrinogen-binding 
protein clumping factor A (ClfA) and the fibronectin-binding proteins (FnBP) A and B.    
Another protein containing the LPXTG motif is protein A (SpA), which is 
multifunctional and ubiquitous in S. aureus. SpA is a B-cell superantigen that binds to 
the Fc γ region of human immunoglobulin (Ig) G1 and IgG2 with high affinity, as well 
as mouse IgG2a and IgG2b (Daum and Spellberg, 2012). SpA can interfere with the 
role of antibody in opsonization and phagocytosis, which protects S. aureus as a 
factor of the pathogen’s strategy to modulate host adaptive immune response 
(Forsgren, 1968). SpA also binds VH3 B-cell receptors and limits their antibody 
manufacturing capacity (Spellberg et al., 2008). 
Besides the mentioned SpA, superantigens, such as enterotoxins of S. aureus are 
secreted to bind T-cell receptors and MHC class II proteins on antigen-presenting 
cells resulting in helper T-cell activation and the release of proinflammatory cytokines 
(Llewelyn and Cohen, 2002). Such secreted toxins cause food poisoning 
(enterotoxins A-O), the toxic shock syndrome (TSST-1) or the staphylococcal scalded 
skin syndrome, which is triggered by the exfoliative toxins A and B (Ladhani et al., 
1999). Invasins, such as haemolysins (e.g. α-toxin, β-haemolysin) and leukocidins 
(e.g. Panton-Valentine leukocydine, PVL) are secreted cytotoxic proteins that 
oligomerize to form pores on the surface of host cells (Walev et al., 1993). 
Heamolysins lyse erythrocytes and parenchyma cells, whereas leukocidins destruct 
macrophages and leukocytes, especially neutrophils (Lina et al., 1999).   
Other CWA proteins are the near-iron transporter motif (NEAT) proteins that are 
involved in iron-uptake from the iron-limited environment and help S. aureus to 
survive in the host (Foster et al., 2014). Here, the pathogen developed the strategy to 
sequester iron by synthesis of high affinity iron chelators, siderophores and 
corresponding membrane associated ABC-transporter systems or covalently linked 
iron-regulated surface determinants (Isd) for the sequestration of heme-complexed 
iron (Maresso and Schneewind, 2006). S. aureus also secretes numerous lipases 
and proteases that degrade host components and proteins that sequester antibodies 
or inactivate antibiotics (Foster, 2005).  
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Beside covalently-bound and secreted virulence factors, also anchorless cell wall 
proteins with no special signal motif or sorting signal (such as LPXTG) have been 
identified on the surface of S. aureus (Chhatwal, 2002, Gatlin et al., 2006, Glowalla et 
al. 2009). These intracellular or cytoplasmic membrane proteins are known to 
associate with the bacterial surface. Some of these non-covalently bound cell wall 
proteins are described in 1.5.  
An overview of the best known virulence factors of S. aureus is shown in figure 1.1. 
The genetic diversity and the ability to acquire new exogenous genes allow S. aureus 
to adapt to a variety of changing environmental conditions and to modulate its 
pathogenicity. Humans are the primary reservoir of S. aureus with asymptomatic 
carriage from which these organisms are easily spread and cause infection. 
(Kluytmans et al., 1997; Moellering, 2012). All these facts highlight S. aureus as a 
dangerous and clinically important pathogen. 
 
             
Figure 1.1: Staphylococcus aureus virulence factors that serve as targets for the current class of 
antistaphylococcal biologics being developed. These targets include surface-bound adhesins, immuno-
globulin-binding proteins, surface-associated and secreted proteases, immune-stimulatory superantigens of the 
family of exotoxins, leukocidal toxins and immunogenic cell wall autolysins. Figure from Sause et al. (2016).    
 
1.2 Acquired antibiotic resistance of S. aureus  
Besides the tremendous amount of virulence factors, a threatening trend is the rapid 
emerge of S. aureus’ resistance to several classes of antimicrobial agents. The first 
isolates of methicillin-resistant Staphylococcus aureus (MRSA) were characterized in 
1961, only two years after the initial clinical use of methicillin (Jevons et al., 1961).  
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S. aureus became resistant against penicillin quickly through the acquisition of genes 
encoding β-lactamases, which are able to cleave β-lactam antibiotics (Murray et al., 
1978). After the application of semisynthetic penicillins, such as methicillin and 
oxacillin the first MRSA strains appeared (Jevons et al., 1961). Methicillin-susceptible 
strains (MSSA) acquired the mecA gene that encodes an additional penicillin binding 
protein (PBP2a) with a low affinity to β-lactams, so that cell wall synthesis takes 
place in the presence of β-lactams. The mecA gene is located on a mobile DNA 
element termed staphylococcal cassette chromosome mec (= SCCmecA). The origin 
of mecA has been found in the coagulase-negative Staphylococcus scuiri group, 
which is not present in humans, but in animals and food products. One of the group’s 
species S. fleuretti with the highest homology to MRSA strains developed the mecASf 
gene in an environment, where β-lactam antibiotics served as a selective pressure 
during the speciation process (Tsubakishita et al., 2010). MRSA was possibly 
generated under conditions where β-lactam antibiotics have been used in humans 
and animals. The mecA gene from S. fleuretti was combined with the SSCmec 
element in a coexistent species of MSSA and could be easily transferred to other 
human strains.  
Since its identification, a number of MRSA clones have spread worldwide. Data from 
2011 showed that MRSA accounts for more than 25 % of bloodstream infections in 
one-third of the European countries studied (European Centre for Disease prevention 
and control, EARSS).  
Prior to 1990s, most MRSA were associated with hospitals or other healthcare units 
(Hospital-associated- (HA-) MRSA), but in the early 90s the first MRSA infections in 
patients without previous healthcare exposure (community-associated (CA-) MRSA) 
were reported (David et al., 2010). CA-MRSA strains developed additional virulence 
factors, such as the in 1.1 described PVL, which is responsible for serious infections 
in healthy humans. In the USA a single clone of CA-MRSA (USA-300) has become 
the most prevalent cause of staphylococcal soft tissue infections acquired in the 
community (King et al., 2006; Tenover et al., 2006) and has entered the inpatient 
setting, causing also invasive diseases (Davis et al., 2006; Gonzalez et al., 2006; 
Klevens et al., 2007). 
The glycopeptide antibiotic vancomycin is currently the first-line treatment for severe 
CA- and HA-MRSA infections. However, due to the selective pressure during 
treatment, vancomycin intermediate resistant S. aureus (VISA) evolved, which was 
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first identified in 1997 (Hiramatsu et al., 1997). In 2002, the first vancomycin resistant 
strains (VRSA) were identified (Weigel et al., 2003). The vanA gene, conferring 
resistance to vancomycin was horizontally transferred from a vancomycin resistant 
Enterococcus faecalis during co-infection. Although still rare, VRSA have been 
reported in the USA and in some countries of Asia (Tenover et al., 2004; Tiwari and 
Sen, 2006, Askari et al., 2012). Another glycopeptide teicoplanin and recent 
antibiotics as daptomycin, linezolid and tigecyclin have been discovered and proven 
to be effective against MRSA (Rivera and Boucher, 2011). However, there are also 
already existing strains with resistance against these agents.  
With this increasing propensity of S. aureus to develop resistance to essentially all 
classes of antibiotics, alternative strategies have to be pursued.  
 
 
1.3 Vaccination against S. aureus as alternative strategy 
The development of prophylactic and therapeutic vaccines as an alternative against 
S. aureus infection seems to be the most effective way to control the life-threatening 
infections caused by MRSA where antibiotics failed.  
 
1.3.1 Induction of an immune response by vaccination 
The adaptive immune system with its two parts, cytotoxic immune reponse (cytotoxic 
T-cell, CD8+, CTL) and humoral immune response (B-cells) are both dependent on 
helper T-cells (CD4+). CTLs are able to detect infected or malignant cells through 
recognition of MHC class I molecules that are complexed to peptides derived from 
proteins expressed within the cell (e.g. viral origin). Helper T-cells (Th-cells) 
recognize MHC class II molecules that are complexed to peptides derived from 
exogenous proteins. MHC II molecules are found on specialized antigen-presenting 
cells (APCs), such as dendritic cells or macrophages. In both cases, the T-cell 
receptor of T-cells binds the MHC I- or MHC II-epitope complex (see figure 1.3). 
These interactions are co-stimulated by CD8- or CD4-receptor recognition, 
respectively (Purcell et al., 2007).  
Extracellular pathogens are opsonized by specific antibodies binding to their surface 
and supporting additional complement activation or phagocytosis by interaction with 
IgG-Fcγ receptors on phagocytes (van Kessel et al., 2014). Other functions of 
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antibodies are the neutralization of adhesion to host cell tissue by interfering with the 
respective pathogen- or host cell associated binding protein and the neutralization of 
bacterial toxins. Immune complexes of antibodies and toxins, which are not sufficient 
to induce an uptake by phagocytes, are eliminated by activation of the classical 
pathway of complement activation. Antibodies have also been shown to amplify or 
suppress the inflammatory response depending on their specificity, isotype and 
concentration (Casadevall and Pirofski, 2003).  
In the process of opsonophagocytosis, Th-cells are important for the generation of 
opsonizing antibodies, because T-cell help is required for antibody affinity maturation 
and class switch (McHeyzer-Williams et al., 2012; Bröker et al., 2016). Additionally, 
Th-cells promote phagocytosis. They produce different kinds of cytokines for 
recruiting neutrophils and macrophages from the bone marrow to the side of infection 
(O’Shea, 2013). 
 
     
 
 
Figure 1.2: Generation of antigen-specific humoral and cellular immune responses. Exogenous antigens, 
such as subunit vaccines were taken up by professional antigen presenting cells (APC). The protein is degraded 
to peptides that are presented by MHC class II molecules (MHC Cl). Helper T-cells (CD4+) recognize MHC II-
peptide complexes with their T-cell receptor, are activated and provide help in the presence of cytokines. 
Activation of cytotoxic T-cells (CTL, CD8+) is dependent on peptides that associate with MHC Cl I molecules. 
These peptides are degradation products of intracellular proteins encoded by foreign DNA after e.g. viral infection. 
For antibody response, B-cells recognize antigens that are either presented extracellularly or exposed 
extracellularly. Figure modified from Liu (2003). 
1 Introduction 
 
 
9 
 
In case of an S. aureus infection, the role of T-cells as the cellular arm of adaptive 
immunity seems to be more important than previously thought. Cytokines produced 
by Th cells, such as interferon-gamma (IFN-γ) released by Th1 cells and interleukin-
17 (IL-17) released by different cell types (e.g. IL-17A by Th17 cells) have been 
proven to be important for protection from S. aureus (Cho et al., 2010; Bröker et al., 
2016). For example, IFN-γ deficient mice were hypersusceptible to infection when   
S. aureus was injected intravenously (Lin et al., 2009). Cho et al. (2010) reported γδ-
cells to be main producers of IL-17. A deficiency in γδ-cells increased the bacterial 
burden in skin infection in a murine wound model (Molne et al., 2003).  
For vaccine development it is suggested that the stimulation of a CD4+ T-cell 
response (especially Th1 and Th17) in addition to the humoral response may be 
advantageous. Because S. aureus is able to invade host cells and is persistent in 
these cells, the role of CD8+ T-cells should also be mentioned in case of vaccination 
(Figure 1.3).  
 
 
            
 
 
Figure 1.3: Model of B- and T-cell in anti-staphylococcal immune defense. Immune response against          
S. aureus crucially depends on the bactericidal activity of macrophages and neutrophils, facilitated by 
opsonization of the bacteria by B-cell generated antibodies and/or complement. T-cells can contribute by 
providing help for B-cells, recruiting phagocytes to the site of infection and promoting the bactericidal potential of 
macrophages. Cytotoxic T-cells are required to kill cells infected with S. aureus, which will otherwise persist in the 
host cell as an intracellular niche. Figure from Bröker et al. (2016).   
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1.3.2 Vaccination strategies 
Immunization can be achieved in an active or passive manner. Passive immunization 
describes the transfer of antibodies to an organism against acute infections, but they 
only achieve a short-lasting effect.  Active vaccines can be classified in five different 
types: live-attenuated and inactivated microorganisms, toxoids, subunit and genetic 
based vaccines induce a long-lasting immune response (Ada, 2005). 
Live-attenuated pathogens induce both, humoral and cellular immune responses, but 
take the risk of a reversion into a virulent strain, so that they cannot be administered 
to immunocompromised patients. Killed microorganisms were able to induce only 
humoral immune responses (e.g. typhic vaccine), so that multiple boosters are 
inevitable. Vaccines with live-attenuated and inactivated pathogens often contain 
many hundreds of proteins, whereas only a few of them are responsible for a 
protective activity. The majority is redundant and may induce allergenic or 
reactogenic responses of the host. 
Subunit vaccines comprise purified antigenic proteins from the pathogen (e.g. surface 
proteins) and can be produced in large scales in a cost effective way. They are often 
weakly immunogenic by themselves and require adjuvants to enhance the antigen-
specific immune response (Li et al., 2014).  
Toxoids are inactivated bacterial toxins that induce neutralizing antibodies against 
these virulent factors. The manufacturing issues, such as detoxification and adverse 
reactions are disadvantageous.  
Genetic based vaccines containing a transgene that encodes the sequence of the 
target protein from the pathogen under control of a eukaryotic promoter for inducing 
long-lasting humoral and cellular immune responses without using an adjuvant 
(Ingolotti et al., 2010). DNA vaccines can also be delivered through viral, non-
replicating vector systems. This is more detailed described in 1.3.4.  
 
1.3.3 Advantages of peptide vaccination 
Subunit vaccines containing novel identified target antigens have shown to be highly 
immunogenic and conferred protection in animal models. However, every of these 
candidates contain many hundreds of antigenic epitopes. Most of them are not 
necessary or even may be detrimental to the induction of protective immunity, 
because they might be very immunogenic but confer no protective effect.  To avoid 
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this inclusion of redundant components a peptide vaccine is a safe and economical 
strategy. A peptide vaccine of approximately 20 amino acids can contain only 
epitopes capable of inducing strong, desirable B-cell and T-cell responses (Sesardic, 
1993). Peptide vaccines have provided a cost effective and safe alternative. There 
are currently many peptide vaccines under development but mainly against viral 
pathogens like HIV, hepatitis C or malaria (Lui et al., 2007; Kolesanova et al., 2013; 
Epstein et al., 2007). 
Immunodominant epitopes can be chosen in context of B-cells, cytotoxic or helper-T 
cells. Therefore, it is important to evaluate whether an epitope-based peptide 
immunogen can induce protective B-cell and T-cell immunity. In addition, a peptide 
vaccine can be designed to comprise various epitopes from different antigens of the 
same pathogen or multiple determinants of several pathogens in order to potentiate 
its efficacy.  
One of the most suited approaches is the generation and selection of protective 
monoclonal antibodies against conserved regions in in vivo infection models (Li et al., 
2014). Identification of the targeted epitopes can then be helpful in designing 
protective vaccine (reverse vaccinology). Due to their small size, peptides are often 
poorly immunogenic. In order to raise effective peptide antibodies, it is necessary to 
conjugate them via a bifunctional linker to a characterized carrier protein, such as 
bovine serum albumin (BSA) or keyhole limpet hemocyanin (KLH) being used in 
many preclinical studies (Hermanson, 2008). Their efficiency frequently requires 
repeated injections of high doses of the vaccines coupled to adjuvants. Water and 
mineral oil emulsions as Freund’s complete adjuvant (FCA) or Freund’s incomplete 
adjuvant (FIA) are a favored delivery method for various peptides to increase 
humoral and cellular immunity in animals (Awate et al., 2013). FCA is composed of 
inactivated mycobacteria, whereas FIA is devoid of this component. The process of 
emulsification is conducted by homogenization of antigen and adjuvant. 
In summary, a peptide vaccine would be an effective way to combine protective 
epitopes for the design of a polyvalent vaccine against S. aureus. Immunization with 
highly purified antigens, such as B-cell-epitope-based peptides would lead to mono-
specific polyclonal antibodies, which are supposedly as protective as the parental, 
protective, monoclonal antibodies. In addition, a combination with a suitable T-cell 
epitope to assure helper T-cell- (CD4+) response is essential to provide long-lasting 
protection against S. aureus infection by production of memory B-cells.  
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1.3.4 DNA vaccines 
The first evidence of immunologic use of DNA was the injection of human growth 
hormone (hGH) DNA into the skin of mice leading to specific anti-hGH-antibodies 
(Tang et al., 1992), which discovered that DNA may also be a suitable route for 
induction of an immune response against pathogenic infection. 
A DNA vaccine plasmid contains the transgene and a promoter, which is often a viral 
one, such as cytomegalovirus (CMV) that drives the expression of the transgene in 
mammal cells. So, DNA immunization can mimic natural viral infection (Ingolotti et al., 
2010). In contrast to the conventional vaccination strategy the antigen is produced 
endogenously (see figure 1.2).  
DNA encoding the sequence of an antigen can be delivered through viral, non-
replicating vector systems. Vaccination with viral vectors as heterologous antigen 
delivery system is primary interesting for intracellular pathogens (Lui, 2010). In this 
case, an induction of a humoral immune response to prevent the spread of the 
pathogen, as well as a CD8+ T-cell response for the eradication of infected cells is 
induced. The humoral immune response can be increased by an additional antigen 
display, e.g. on the viral capsid (Rybniker et al., 2012). This allows recognition by B-
cell receptors and the loading of MHC II molecules by antigen-presenting cells.  
In contrast to subunit vaccines, viral vectors have an intrinsic adjuvant capacity. 
Vectors are modified to be non-replicating in mammalian cells, which allows for 
impaired synthesis of viral gene products (Altenburg et al., 2014). 
DNA vaccination against S. aureus using viral vector systems was not investigated 
as yet. Induction of a humoral, as well as a cellular immune response against the 
extracellular pathogen that also invades host cells might be a promising alternative to 
subunit vaccination. 
 
1.3.4.1 Modified Vaccinia virus Ankara (MVA) 
The Modified Vaccinia virus Ankara (MVA) is an attenuated poxvirus used for 
vaccination against smallpox. MVA was first used licensed by the Bavarian State 
Vaccine Institute from 1968-1985 as a human smallpox vaccine by increasing the 
safety of the conventional smallpox vaccination (Stickl et al., 1974).  
MVA was derived from Chorioallantois vaccinia virus Ankara (CVA) through serial 
passaging in chicken embryo fibroblasts. The serial passage of MVA resulted in 
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major deletions in the viral genome. During over 570 passages, MVA became host-
restricted to avian cells and unable to replicate in almost all tested mammalian cell 
lines, including those of rodent and human origin (Sutter and Moss, 1992).   
MVA holds great promise as a vaccine platform encoding one or several foreign 
antigens and inducing humoral and cellular immune responses (Altenburg et al., 
2014). MVA has already been investigated as a platform for viral vaccines, such as 
influenza and HIV, which entered clinical trials (Kreijtz et al., 2014; Garcia et al., 
2011; Volz and Sutter, 2013). The humoral immune response induced by influenza 
virus vaccination was mainly directed against the surface protein hemagglutinin (HA) 
by the production of neutralizing antibodies (Corti et al., 2010; Lee et al., 2012). 
Virus-specific T-cell responses (CD4+ and CD8+) have also been demonstrated and 
contributed to protective immunity (Hillaire et al., 2013). Preclinical studies of a new 
vaccine against MERS coronavirus using MVA as delivery system in mice detected a 
strong antibody-based immune response (Song et al., 2013).  
In MVA vaccines the target gene sequences are transcribed under control of poxviral 
promotors that are only recognized and activated by virus encoded enzymes and 
transcription factors (Altenburg et al., 2014).  
The target gene is cloned into an MVA shuttle vector plasmid containing flanking 
ends to allow recombination into the MVA genome (Sutter et al., 1994). The shuttle 
vector is then transfected into cells infected with MVA. Through homologous 
recombination the gene encoding the antigen is inserted into the genome. The rMVA 
is clonally isolated and amplified by serial passaging in chicken embryo fibroblasts. 
Advantageous for MVA as vaccine delivery system is its high immune-stimulating 
potential by triggering rapid immigration of monocytes, neutrophils and CD4+ cells to 
the side of inoculation (Lehmann et al., 2009), which makes adjuvants dispensable.  
 
1.3.4.2 Adeno-associated virus (AAV) 
Adeno-associated (AAV) vectors already have a long history in gene therapy but 
have also emerged in the vaccination field. AAV containing 13 serotypes is a member 
of the parvovirus family and is thus classed into the genus dependovirus. All 
serotypes contain a single-stranded DNA genome as about 5 kb within a non-
enveloped protein capsid. Amino acid composition of the viral capsid proteins 
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determines serotype tropism as well as recognition by the host’s immune system 
(Asokan et al., 2012). 
AAV 2 is the most studied serotype. It contains inside of its capsid a linear single-
stranded DNA genome. The wildtype genome includes the three open reading 
frames (ORFs) rep, cap and aap flanked by inverted terminal repeats (ITRs). The 
regulatory proteins (Rep) have several functions, which are important for the control 
of viral gene expression, replication and packaging of viral genomes into the 
preformed capsids. They also possess DNA helicase, endonuclease and ATPase 
functions (Pereira et al., 1997; Zhou et al., 1999; Büning et al., 2008). The assembly-
activating protein (AAP) is required for the capsid assembly, which takes place in the 
nucleus. The viral capsid is built up by the three capsid proteins VP1, VP2, and VP3 
(Büning et al., 2008). All capsid proteins are important for the generation of infectious 
particles, although virus-like particles can be formed without the VP1 or VP2 protein 
(Girod et al., 2002; Warrington et al., 2004). The ITR sides are essential cis-active 
sequences in the AAV biology. ITRs contain a Rep binding site as the origin of DNA 
replication. Additionally, they are essential for genome packaging, transcription, 
negative regulation under non-permissive conditions and site-specific integration 
(Daya and Berns 2008). 
AAV is non-pathogenic since it cannot replicate without a helper virus. Thus, the virus 
is unable to multiply in unaffected cells. Recombinant AAV vectors (rAAV) have 
almost the entire viral genome removed for yielding a delivery vehicle with enhanced 
safety and transfer capacity (Choi et al., 2005). Except for the ITRs, all viral genes of 
the recombinant vector genome are substituted by the transgene expression cassette 
of interest.  
As multiprotein complexes the viral capsids induce immune responses irrespective of 
viral gene expression. Rybniker et al. (2012) have shown that combining antigen 
display on a modified capsid with vector-mediated antigen overexpression resulted in 
a single-shot-prime-boost vaccine and an induction of a faster humoral immune 
response than achieved with conventional vaccine strategies.  
AAV vectors require a coinfection with an unrelated virus for providing the helper 
functions VA, E2A, E4 for the productive life-cycle. Recombinant AAV vectors of 
Rybniker et al. (2012) are produced by a helpervirus-free method, using a helper 
plasmid delivering the adenoviral helper functions. E2A and VA act to enhance the 
viral mRNA stability and efficiency of translation, E4 is involved in facilitating the AAV 
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DNA replication (Xiao et al., 1998). A second helper plasmid is required for delivering 
the ORFs rep, cap and aap under control of the wildtype promoter but lacking the 
viral ITR sides. For a display on the viral surface it was shown that proteins can be 
incorporated into the AAV capsid via N-terminal fusion to VP2 on the viral surface 
without compromising viral infectivity (Lux et al., 2005; Münch et al., 2013).  
 
1.4 Approaches in vaccine development against S. aureus infection 
Since the detection of first MRSA strains, the definition of the risk population has 
changed (David et al., 2010). Since the epidemic occurrence of CA-MRSA, 
responsible for several infections of also healthy individuals in the community, not 
only people with suppressed immune systems, such as HIV patients, old people or 
neonates, patients with cystic fibrosis in hospitals are at high risk to get infected 
(Daum and Spellberg, 2012). Based on this fact that also healthy humans belong to 
the new risk population, the development of a prophylactic vaccine has become 
indispensable.  
Currently, there is no licensed prophylactic anti-S. aureus vaccine available for 
human use. A successful vaccine has to prevent infections by S. aureus strains from 
a broad range of genetic backgrounds with a high variability of virulence factors that 
are known to be differently expressed. Therefore, a polyvalent vaccine that targets 
several different antigens would be more effective, due to the fact that targeting one 
single virulence factor cannot reduce the pathogenicity by its functional redundancy 
or the appearance of escape mutants. Stranger-Jones et al. (2006) analyzed the four 
antigens IsdA, IsdB, SdrD and SdrE as vaccine candidates and obtained significant 
protection with a combined vaccine in contrast to monovalent immunization. These 
results point towards a polyvalent vaccine as the most promising strategy to combat 
S. aureus infections. 
 
1.4.1 Active immunization  
The development of a staphylococcal vaccine is complicated because of the 
bacterium’s complex mechanism of pathogenesis. The first studies for the 
establishment of an active vaccine used whole bacteria, followed by vaccination 
using staphylococcal phage lysate (Greenberg et al., 1987; Giese et al., 1996), but 
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none of them achieved protective effects. Further strategies focused on immunization 
with subunits, such as capsular polysaccharides or well-known virulence factors 
possessing LPXTG motif. To date, only two vaccines have proceeded through all 
clinical phases. StaphVAX (Nabi) is a bivalent polysaccharide- and protein-
conjugated vaccine. It is composed of capsular polysaccharide types 5 and 8 (CP5 
and CP8) conjugated to a recombinant, non-toxic variant of exotoxin A (ETA) of 
Pseudomonas aeruginosa to increase immunogenicity. By prevention of phagocytic 
activity the CPs represent an important factor in the pathogenicity of S. aureus 
(Kampen et al., 2005). With approximately 80 % serotypes 5 and 8 are the most 
prevalent of the 11 different serotypes among S. aureus isolates (Sompolinsky et al., 
1985; Poutrel et al., 1988). StaphVAX was evaluated in two phase 3 studies to 
prevent bacteremia in renal dialysis patients and resulted in no differences between 
immunized patients and placebo controls (Fattom et al., 2004). The main reason of 
the second study’s failure is explained by manufacturing inconsistencies between 
different vaccine lots used for the two trials (Fattom et al., 2015). The candidate V710 
(Merck) describes the cell-wall-anchored protein IsdB (compare 1.1), which was 
evaluated in a phase 3 with patients scheduled for cardiac surgery. The clinical trial 
was suspended after the detection of a significantly increasing mortality rate due to  
S. aureus infection and a higher rate of other adverse events (Fowler et al., 2013).  
There are further active vaccines that entered clinical trials, such as Pfizer’s SA4Ag 
(phase 2b), which is a polyvalent polysaccharide-protein vaccine of CP5 and CP8, 
manganese transport protein C (MntC) and Clumping factor A (ClfA). The purpose of 
this study is to evaluate the safety and efficacy of the vaccine to determine, if it 
prevents postoperative invasive S. aureus infections in patients undergoing elective 
spinal fusion surgery (October 2016, https://clinicaltrials.gov/ show/NCT02388165). 
The vaccine candidate Pentastaph (GlaxoSmithKline) is a combination of CP5 and 
CP8 and the two virulence factors PVL and teichoic acid and passes phase 1 
(http://www.nabi.com).  Another candidate named NDV-3A (NovaDigm) is based on 
the recombinant protein Als3p and passes phase 2a (September 2016, 
https://clinicaltrials.gov/show/ NCT 01926028). Als3p is an adhesion protein of 
Candida albicans and has a structural similarity to the staphylococcal ClfA, which 
makes the bacterium able to bind at Candida biofilms (Peters et al., 2012). Als3p 
showed protection against S. aureus skin and soft tissue and bloodstream infection in 
a preclinical model (Spellberg et al., 2008). 
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1.4.2 Passive immunization 
As an alternative to active vaccination that often requires further booster 
immunizations to achieve protection, a passive vaccine is applied against acute       
S. aureus infection or as prophylaxis for patients with a suppressed immune system 
or for premature infants during hospital stays. Passive immunization strategies 
utilizing both polyclonal and monoclonal antibodies (moAbs). Several antibody 
candidates have been developed against different target molecules and evaluated in 
late stage clinical studies, but none of them demonstrated efficacy yet. 
The passive vaccine candidate Altastaph (Nabi) containing polyclonal anti-CP5 and 
anti-CP8 IgGs obtained from patients immunized with StaphVAX (see 1.4.1) failed to 
prove efficacy in phase 2. Aurograb (NeuTec Pharma), a single chain variable 
fragment of an IgG (scFv) targeting ATP-binding cassette transporter (Burnie et al., 
2000, Garmory et al., 2004), as well as Tefibazumab (Aurexis/Inhibitex) as a 
humanized anti-ClfA monoclonal antibody also failed in clinical trials (Weems et al. 
2006). Aurograb combined with vancomycin did not show efficacy. Tefibazumab 
tested in adults with bacteremia showed decreased relapses, but no lower mortality 
has been shown.   
The candidate Veronate (Inhibitex) is a human IgG preparation from plasma donors 
with naturally occurring high titers of IgG to ClfA and to the S. epidermidis fibrinogen 
binding protein (SdrG). Although protective in animal models (Vernachio et al., 2006), 
it showed only 50 % reduction in late onset S. aureus bacteremia in low birth weight 
neonates of phase 3 (DeJonge et al., 2007). Biosynexus has developed a humanized 
mouse chimeric IgG1 monoclonal antibody (Pagibaximab) with in vitro 
opsonophagocytosis activity to S. epidermidis lipoteichoic acid, a membrane bound 
glycolipid extending into the cell wall. Clinical phase 3 in low birth weight neonates for 
the prevention of bacteremia was completed in 2010, but no significant decrease in 
staphylococcal sepsis was found  (Weismann et al., 2011; Daum and Spellberg, 
2012; https://clinicaltrials.gov/show/NCT00646399).  
The described active and passive vaccine approaches that are passing through 
clinical trials or already failed, concentrated on well-known virulence factors, including 
proteins exhibiting the LPXTG sorting signal. On the contrary, Glowalla et al. (2009) 
focused on the identification of novel anchorless cell wall proteins that lack of 
conserved signal sequences.  
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Figure 1.4: Overview of vaccine candidates targeting virulence factors that have been tested in animal 
and human studies. The immunization studies performed in humans are depicted in the boxes. A: Active 
immunization. P: Passive immunization. The protein hp2160 is explained in 1.5. Orange and green boxes 
indicated already analyzed vaccine candidates and status at 2011 (orange: failed vaccine candidates; green: in 
progress). The actual status revealed that Pagibaximab and Merck V710 also failed in clinical trials. Figure from 
Verkaik et al. (2011). 
 
 
1.5 Identification of novel anchorless cell wall proteins as vaccine  
      candidates              
A large number of classical cytoplasmic proteins are described to be found on the 
surface of microbial pathogens. These non-covalently bound cell wall-associated 
proteins perform a variety of unrelated functions designated ‘moonlighting activity’ 
(Alderete et al., 2001; Pancholi 2001, Cchatwal, 2002). Moonlighting proteins are 
found to have two or more different functions and can occur at different locations 
(Jeffery, 1999). Because of their lack of typical signature sequences it is not known 
how they are transported to the cell surface.  
Most of these proteins localized in the cytoplasm, being involved in metabolic 
pathways but also in adhesion or binding of e.g. blood components, which turns them 
into potential virulence factors (Pancholi and Chhatwal, 2003). For the development 
of new potential vaccine candidates Glowalla et al. (2009) identified several of these 
anchorless S. aureus surface proteins by a method called subtractive proteome 
analysis (SUPRA) using a human intravenous immunoglobulin preparation (IVIG).  
IVIG is a pool of immunoglobulins from healthy humans that contains a broad 
spectrum of opsonizing antibodies against various pathogens. IVIG induced an 
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increased phagocytosis of S. aureus by isolated human neutrophils. Whereas, an 
IVIG preparation depleted of S. aureus-specific opsonizing antibodies (dSaIVIG) by 
incubation with an excess of S. aureus and subsequent separation showed a nearly 
completely abolished phagocytic activity. S. aureus surface proteins were isolated 
and separated by 2-DE gel electrophoresis, which was followed by an 
immunoblotting using IVIG or dSaIVIG, respectively, to identify antigenic proteins. 
Protein spots reacted with complete IVIG but not with dSaIVIG were considered as 
potential vaccine candidates, based on the assumption that those are recognized by 
naturally occurring S. aureus specific IgGs, hence representing in vivo expressed 
immunogenic proteins. Protein spots strongly reacting with both IVIG and dSaIVIG 
were excluded because they were thought to be recognized by IgGs that were not 
specific for S. aureus antigens.  
The resulting spots were analyzed by MALDI-TOF and 39 proteins have been 
identified. Except for four of them, all proteins are present in the currently available 
completely sequenced genomes of S. aureus, which demonstrates their broad 
distribution among S. aureus isolates. Several of them were cloned and 
overexpressed in E. coli. Groups of mice were immunized with each of the purified 
proteins, respectively and challenged with S. aureus. Immunization with some of 
these proteins leads to a protection against S. aureus infection. The first vaccine 
candidates were identified as enolase, oxoacyl reductase and hypothetical protein 
2160 (hp2160). The most promising candidate hp2160 is described as an esterase-
like protein of unknown function and showed protection in a murine sepsis model. 
The more detailed function of hp2160 in the cytoplasm, as well as on the bacterial 
surface has to be defined.  
Further investigation of the remaining recombinant proteins in the active 
immunization model for enlarging the pool of potential vaccine candidates lead to the 
proteins triosephosphate isomerase (Triiso) and protoporphyrinogen oxidase (pOxi), 
which showed the strongest protection after S. aureus infection (Tosetti, PhD thesis, 
2010 and unpublished data). 
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1.5.1 Triosephosphate isomerase (Triiso) 
In the cytoplasm, the homodimer Triiso is a metabolic enzyme that catalyzes the 
reversible conversion of dihydroxyacetone-phosphate into glyceraldehyde-3-
phosphate in the glycolysis. Additionally, Triiso was identified on the surface of        
S. aureus as cell wall-associated protein by 2-DE gel electrophoresis of the isolated 
non-covalently bound cell wall protein fraction and mass spectroscopy (Gatlin et al., 
2006; Glowalla et al., 2009,). Electron microscopies also detected Triiso with a low 
density on the surface of S. aureus (Yamaguchi et al., 2010).  
This unexpected localization has also been described for other enzymes of the 
glycolysis, such as glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and 
enolase (Pancholi and Fischetti, 1992, Glowalla et al., 2009). GAPDH has been 
reported to be a transferrin-, fibronectin-, laminin- and plasmin-binding protein 
(Modun and Williams, 1999; Modun et al., 2000; Gozalbo et al., 1998). Cell surface 
expression of GAPDH by erythromycin-resistant Streptococcus pneumoniae was 
increased compared to strains that are erythromycin-sensitive (Cash et al., 1999) 
An agent of endocarditis, Streptococcus gordonii secretes GAPDH by increasing the 
pH (Nelson et al., 2001). Therefore, GAPDH proteins have already been investigated 
as potential vaccine candidates against microbial infection, including Streptococcus 
uberis in dairy cattle (Fontaine et al., 2002).   
Pancholi and Chhatwal (2003) described the importance of housekeeping enzymes 
as virulence factors for a variety of pathogens. In this context Triiso was already 
described as a plasminogen-binding protein (Furuya and Ikeda, 2011) that is involved 
in the processes of blood coagulation and fibrinolysis. Coagulation is induced by the 
staphylococcal enzyme coagulase that activates prothrombin into thrombin, which let 
to polymerization of fibrin, so that S. aureus has enough space to proliferate in the 
wound, protected from the immune system (Figure 1.5). When a defined cell density 
is reached the expression of the enzyme staphylokinase (SAK) is increased. This 
process is regulated by quorum sensing. SAK activates plasminogen into plasmin, 
which initiates fibrinolysis. This enables S. aureus to proliferate in the surrounding 
tissue. Furuya and Ikeda described Triiso as an antagonist of staphylokinase which is 
therefore able to inhibit fibrinolysis as long as it is favourable for S. aureus. Besides 
Triiso, also enolase is described to be involved in these processes but as a possible 
inhibitor of coagulation.  
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Figure 1.5: Potential moonlighting role of the glycolytic enzyme Triiso in plasminogen inhibition. Blood 
coagulation is initiated by the enzyme coagulase. S. aureus can proliferate in the wound and is protected from the 
host’s immune system. When a defined cell density is reached expression of staphylokinase (SAK) increased. 
SAK activates plasminogen into plasmin, which initiates fibrinolysis allowing S. aureus to proliferate in the 
surrounding tissue. It is described that Triiso, as well as enolase influences these processes of inhibition and 
activation.  
 
1.5.2 Protoporphyrinogen oxidase (pOxi) 
In the cytoplasm the protein pOxi is involved in the synthesis of heme (Frankenberg 
et al., 2003). Heme is an essential cofactor for proteins involved in the transport of 
electrons (e.g. catalases, cytochromes). The respiratory pathways of some gram-
positive pathogens rely entirely on the ability of the bacteria to scavenge exogenous 
heme. S. aureus differentially utilizes heme depending on its metabolic needs. In 
conditions of iron starvation, exogenously acquired heme is degraded to release free 
iron. When iron is abundant, heme is acquired and utilized intact to populate 
cytochromes of the electron transport chain. This reduces the requirement for 
endogenous heme synthesis and decreases the metabolic burden on the bacterium 
(Hammer and Skaar, 2011). 
The enzyme pOxi (HemY) is O2-dependent in S. aureus, whereas other prokaryotes 
express O2-independent pOxi, named HemG (Panek et al., 2002). Hence, pOxi is 
only operative under aerobic conditions. For a long time it was thought that pOxi from 
S. aureus catalyzes the conversion of protoporphyrinogen IX into protoporphyrin IX 
by the removal of six electrons, which requires FAD as cofactor (Dailey et al., 1994; 
Hansson and Hederstedt, 1994). Then Lobo and colleagues exposed that S. aureus 
does not use the classical pathway of heme synthesis (Lobo et al., 2015). They 
discovered a transitional pathway for heme synthesis in S. aureus. HemY (pOxi) is 
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described as a coproporphyrin synthase that oxidizes coproporphyrinogen III into 
coproporphyrin III, whereas it is unable to oxidize protoporphyrinogen (Figure 1.6). 
Lobo et al. also showed that pOxi can be inhibited by several herbicides, highlighting 
pOxi as a suitable target for drug development against S. aureus.  
Interestingly, HemY of gram-positive Bacillus subtilis is described as a peripheral 
membrane protein that is also able to oxidize both coproporphyrinogen III and 
protoporphyrinogen IX, whereas coproporphyrinogen III is the major substrate 
(Hansson and Hederstedt, 1994).  
Since Glowalla et al. (2009) found antibodies in IVIG to be reactive against pOxi, the 
protein is identified to be displayed on the bacterial surface. Additionally, the fact that 
recombinant pOxi alone provided protection in the murine sepsis model after active 
immunization compared to other candidates (B. Tosetti, 2010, PhD thesis), leads to 
the conclusion that pOxi seems to have an important moonlighting activity on the     
S. aureus surface in vivo. 
 
            
 
 
Figure 1.6: Diagrammatic representation of heme biosynthetic pathways, focusing the transitional heme 
pathway of S. aureus. The classic pathway is highlighted in in orange, the alternative pathway in grey and the 
transitional pathway in blue dots. Figure from Lobo et al. (2015). 
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1.5.3 Generation of monoclonal antibodies directed against the novel vaccine   
         candidates 
Encouraged by the results obtained with the S. aureus proteins Triiso, pOxi and 
hp2160 used as vaccine candidates for active immunization of mice, providing 
protection against a subsequent S. aureus infection, these recombinant proteins 
were chosen for the generation of monoclonal antibodies (moAbs) by hybridoma 
technology (Kohler and Milstein, 1975) to be used for passive immunization. After an 
infection of mice immunized with one of the recombinant proteins, respectively, the 
spleens of the survivors were removed. Isolated splenocytes were fused to myeloma 
cells to obtain hybridoma clones, which were subsequently separated from unfused 
myeloma cells. The hybridoma clones are immortal and have the ability to produce 
one particular antibody, respectively (monoclonality). The generated monoclonal 
antibodies (moAbs) were selected to be used as passive vaccine with the goal to 
provide protection in a murine sepsis model (A. Klimka, unpublished data). Out of 
several tested monoclonals the lead candidates anti-Triiso moAb H8, anti-pOxi moAb 
D3 and anti-hp2160 moAb 16-2 were selected. The three antibodies were humanized 
by grafting the CDRs into a human IgG backbone and also de-immunized by 
excluding constructed, potential human T-cell epitopes, to reduce the possibility for 
an adverse immune response in humans. The resulting humanized antibodies 
(humAbs) retained their binding specificity and their capability to protect mice against 
deadly S. aureus infection (Figure 1.7). Currently, anti-pOxi humAb D3 is chosen to 
be produced under GMP-conditions by the Fraunhofer institution ITEM 
(Braunschweig, Germany) to enter clinical trials in the near future.   
 
 
 
 
 
 
     
 
 
Figure 1.7: Survival upon passive immunization using monoclonal murine (moAb) or humanized (humAb) 
anti-pOxi, anti-Triiso and anti-hp2160 antibodies. BALB/c mice received the respective moAb or humAb before 
the lethal challenge with S. aureus MRSA strain USA300. Survival of mice was monitored for 8 days (A. Klimka, 
unpublished data). 
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1.7 Aim of this work 
Multidrug resistance of the hospital- and community-associated pathogen is 
increasing drastically and thereby limiting therapeutic options. Vaccination as 
alternative strategy for treatment and prophylaxis would be important, but there is 
currently no vaccine against S. aureus infection available. All active and passive 
immunization approaches to date have failed at the clinical trial stage. 
 
The aim of this study was to further characterize our previously generated S. aureus-
specific monoclonal antibodies anti-pOxi D3, anti-Triiso H8 and anti-hp2160 16-2, 
which have been demonstrated to protect mice against lethal S. aureus infection. 
These antibodies should be investigated concerning their binding capacity to the     
S. aureus surface and their mode of action leading to their protective effect. This is of 
special interest, as Triiso and pOxi are well-known cytoplasmic proteins of metabolic 
pathways and it had to be analyzed, which in vitro conditions were necessary for the 
proteins’ occurrence at the bacterial surface, a moonlighting activity, which was not 
analyzed as yet.  
The mode of action of moAbs additionally included an analysis of the function of our 
three identified vaccine candidates as moonlighting proteins on the bacterial surface. 
The aim of the second part of this thesis was the epitope identification of the three 
mentioned moAbs for a following application as active peptide vaccine against MRSA 
in a preclinical mouse model. This included an expedient combination of the epitope 
peptides with carriers and adjuvants and an analysis of their capacity to induce an 
antigen-specific humoral, as well as cellular immune response. Furthermore, the 
protective effect of such a vaccine should be investigated by reduction of bacterial 
colonization in murine tissues and by survival of mice after S. aureus challenge. With 
the aim to generate a polyvalent vaccine, epitope peptides should be fused to a 
polyepitope peptide and investigated for their protective effect. Additionally, 
vaccination of a polyepitope using the viral vector platforms MVA and AAV as 
alternative delivery systems should be investigated concerning their humoral immune 
response. 
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2 Material and Methods 
 
 
2.1 Material 
2.1.1 Chemicals and Enzymes  
Chemicals were of research grade and purchased from Sigma-Aldrich (Steinhausen, 
Germany), AppliChem (Darmstadt, Germany), Merck (Darmstadt, Germany), Thermo 
Fisher Scientific (Dreieich, Germany) or Roth (Karlsruhe, Germany) unless stated 
otherwise. Buffers and solutions were prepared using bidestilled H2O from EASYpure 
UV/UF H2O purification unit (Werner Reinstwassersystem, Leverkusen), degassed 
and sterilized by autoclaving or filtration through a 0.2 µm filter membrane, if 
necessary.  
Restriction enzymes, T4 ligase and polymerases were obtained from Thermo Fisher 
Scientific (Dreieich, Germany) and used in recommended buffers. Benzonase was 
obtained from Merck and recombinant lysostaphin from Sigma-Aldrich. 
 
2.1.2 Bacteria and culture media 
 
Strain Genotype   Provider 
 
E.coli  
  
DH5α φ80lacZΔM15 recA1 endA1 gyrA96 thi-1 
hsdR17 (rK-, mK+) supE44 relA1 deoR 
ΔlacZYA-argF)U169 
  Invitrogen 
Top 10 F- mcrA Δ(mrr-hsdRMS-
mcrBC)φ80lacZΔM15 ΔlacX74 recA1 
araD139 Δ(araleu)7697 galU galK rpsL 
(StrR) endA1 nupG 
  Invitrogen 
DB3.1 F- gyrA462 endA1 Δ(sr1-recA) mcrB mrr 
hsdS20(rB-, mB-) supE44 ara-14 galK2 
lacY1 
proA2 rpsL20(SmR) xyl-5 λ-leu mtl1  
  Invitrogen 
BL21 F- dcm ompT hsdS (rB-mB-) gal   Stratagene 
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Strain Resistance  Provider 
 
S.aureus 
  
ATCC29213 MSSA ATCC, USA 
USA300 MRSA NARSA, USA 
MW2  MRSA NARSA, USA 
JE2 MRSA NARSA, USA 
JE2 ΔspA Erythromycin NARSA, USA 
JE2 ΔpOxi Erythromycin NARSA, USA 
JE2 Δhp2160 Erythromycin NARSA, USA 
ATCC29213-GFP Erythromycin Inst. for Med. 
Microbiology, Köln,       
S. Leggio 
MW2-Δagr Tetracycline Inst. for Med. 
Microbiology, Köln,       
B. Tosetti 
 
 
Culture Media / Antibiotics Composition / Manufacturer 
  
LB-Medium 1 % Tryptone, 0.5 % Yeast Extract, 0.5 % NaCl,  
pH 7.0 
LB-Agar LB-Medium + 15 % Agar, pH 7.0 
TSB-Medium 1.7 % Tryptone, 0.5 % NaCl, 0.3 % Soytone,         
0.25 % Glucose, 0.25 %, K2HPO4 , pH 7.3 (± 0.2) 
SOC-Medium 2 % Tryptone, 0.5 % Yeast extract, 0.5 % NaCl,     
100 mM MgCl2, 20 mM Glucose, pH 7.0 
Mueller-Hinton agar plates Oxoid 
Blood agar plates Oxoid 
Ampicillin  stock solution: 50 mg / ml in H2O 
final concentration 50 µg / ml 
Kanamycin stock solution: 50 mg / ml in H2O 
final concentration 50 µg / ml 
Erythromycin  stock solution: 10 mg / ml in 95 % Ethanol 
final concentration 10 µg / ml 
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2.1.3 Cell lines and culture media 
 
Cell line  Provider 
  
HeLa ATCC (CCI-2) ATCC, USA 
 
Culture media / media-additives Composition / Manufacturer 
  
Dulbecco`s MEM (1x) Biochrom AG 
RPMI (1x) Biochrom AG 
Hanks Balanced Salt Solution (HBSS)  Life Technologies 
Fetal Calf-Serum (FCS)  BioWest 
Penicillin-Streptomycin (10x) Biochrom AG 
Trypsin (10x)  Biochrom AG 
Na-Pyruvate  Biochrom AG 
PBS (10x) Biochrom AG 
 
2.1.4 Buffers and solutions 
 
Denotation Composition / Manufacturer 
  
Agarose gel 
 
TAE buffer (1x) 0.8 mM Tris, 0.4 mM Acetic acid,  
0.04 mM Na2EDTA, pH 8.5  
Loading buffer (1x)   Thermo Fisher Scientific, ready to use solution 
1 kb DNA-ladder Thermo Fisher Scientific, ready to use solution  
Agarose gel 1% (w/v) Agarose (Roth), 1 x TAE-buffer,  
0.5 µg / ml Ethidium bromide 
SDS-PAGE  
 
Laemmli buffer (5x) 60 mM Tris-HCl, pH 6.8, 2 % SDS,                    
25 % Glycerol, 0.2 % Bromphenol Blue, 
10 % β-Mercaptoethanol 
Protein Size Marker Page Ruler, Thermo Fisher Scientific 
Running buffer (20x) MOPS-Buffer, Life Technologies    
Coomassie staining solution 2.5 % Serva blue R250, 45 % Ethanol,              
15 % Acetic acid 
Destaining solution  45 % Methanol, 15 % Acetic acid 
Immunoblotting 
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TBST (1x) 150 mM NaCl, 50 mM Tris, 0.05 % Tween 20; pH 7.4 
Blocking buffer 5 % Skim milk powder (Roth), 2 % BSA in TBST 
Transfer buffer 25 mM Tris-HCl, 192 mM Glycine, 20 % Methanol 
 
Affinity Chromatography 
 
Recombinant Proteins 
 
PBS (10x) 1.4 M NaCl 100 mM Na2PO4, 27 mM KCl, 
18 mM KH2PO4; pH 7.4 
Resuspension buffer 1 x PBS, 500 mM NaCl, 5 % Glycerol, 
EDTA-free complete protease inhibitor (Roche) 
Binding buffer 1 x PBS, 500 mM NaCl, 40 mM Imidazole; pH 7.4 
Elution buffer 1 x PBS, 500 mM NaCl, 250 mM Imidazole; pH 7.4 
Dialysis buffer 1 x PBS, 10 % Glycerol; pH 7.4 
  
Polyclonal antibody enrichment 
 
Wash A (NHS column) 0.5 M Ethanolamine, 0.5 M NaCl; pH 8.3 
Wash B (NHS column) 0.1 M NaOAc, 0.5 M NaCl; pH 4.0 
PBS (1x, binding buffer) 140 mM NaCl, 2.7 mM KCl, 10 mM NaH2PO4,        
1.8 mM KH2PO4; pH 7.4 
Elution buffer 0.1 M Glycine-HCl; pH 2.5  
Neutralization buffer 1 M Tris-HCl; pH 9.0 
Storage Buffer 0.05 M Na2HPO4, 0.1 % NaN3; pH 7.0 
 
ELISA 
 
Coating buffer 15 mM Na2CO3, 35 mM NaHCO3; pH 9.6 
Blocking buffer  StartingBlock TM T20 (PBS), Thermo Scientific 
PBST (1x) 140 mM NaCl, 2.7 mM KCl, 10 mM NaH2PO4,        
1.8 mM KH2PO4, 0.02 % Tween 20, pH 7.4 
FACS 
 
Blocking buffer PBS + 1 % BSA, pH 7.5 
FACS assay buffer PBS + 1 % BSA + 0.5 mM EDTA, pH 7.5 
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2.1.5 Antibodies 
 
Name Characteristics Provider 
   
Primary Antibodies   
Octagam® (IVIG) 
1:500 
Human intravenous 
immunoglobulin preparation 
Octapharma GmbH, 
Langenfeld 
Anti-pOxi moAb D3          
(1 mg/ml) 1:5000  
Murine monoclonal IgG2a  Inst. for Med. Microbiology, 
Köln,  A. Klimka 
Anti-Triiso moAb H8 
(1 mg/ml) 1:5000 
Murine monoclonal IgG1 Inst. for Med. Microbiology, 
Köln,  A. Klimka 
Anti-Triiso moAb C4 
(1 mg/ml) 1:5000 
Murine monoclonal IgG1 Inst. for Med. Microbiology, 
Köln,  A. Klimka 
Anti-Triiso moAb C8 
(1 mg/ml) 1:5000 
Murine monoclonal IgG2b Inst. for Med. Microbiology, 
Köln,  A. Klimka 
Anti-hp2160 moAb 16-2 
(1 mg/ml) 1:5000 
Murine monoclonal IgG1 Biogenes GmbH, Berlin 
Anti-pOxi humAb D3 
(1 mg/ml) 1:5000 
Human monoclonal IgG1 Antitope Ltd, UK 
Anti-Triiso humAb H8 
(1 mg/ml) 1:5000 
Human monoclonal IgG1 Antitope Ltd, UK 
Anti-hp2160 humAb   16-2 
(1 mg/ml) 1:5000 
Human monoclonal IgG1 Antitope Ltd, UK 
   
Secondary antibodies 
  
Anti-mouse IgG-HRP 
1:3000 
HRP-conjugated goat anti-mouse 
IgG  
Sigma-Aldrich 
Anti-mouse IgG1-HRP 
1:3000 
HRP-conjugated goat anti-mouse 
IgG  
Caltag 
Anti-mouse IgG2a-HRP 
1:3000 
HRP-conjugated goat anti-mouse 
IgG  
Caltag 
Anti-mouse IgG-PE-Cy5.5; 
1:100 
Goat F(ab)2  anti-mouse IgG 
(H+L) PE-Cy®5.5 conjugate
 
Life Technologies 
Anti-mouse IgG-
AlexaFluor488 
1:100 
Goat F(ab)2  anti-mouse IgG 
(H+L) Alexa Fluor® 488 
conjugate 
Life Technologies 
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Anti-human IgG-HRP 
1:3000 
HRP-goat anti-human IgG BioRad 
Anti-human FCγ-PE 
1:100 
PE-goat anti-human FC γ F(ab)2 Dianova 
Anti-6-His-tag-HRP HRP-conjugate Invitrogen 
Strep-Tactin-HRP HRP-conjugate IBA 
 
  
2.1.6 Technical equipment 
Device Specification Manufacturer 
Cell Counter CountessTM Life Technologies 
Cell Disrupter Constant Cell Disruption 
Systems 
IUL 
Colony Counter Countermat  IUL 
Documentation Chamber  MF-ChemiBIS 3.2 Berthold Technologies 
Documentation Chamber AGFA Curix AGFA 
Electrophoresis chamber Criterion Cell BioRad 
Flow Cytometer FACScalibur BD Biosciences 
FPLC system ÄKTATM Purifier GE Healthcare 
Gel documentation Gel Doc 2000 BioRad 
High-speed centrifugation Discovery RC26 plus Sorvall 
Incubator (bacteria) Kelvitront Thermo Scientific 
Incubator (cells) Hera cell 240 Thermo Scientific 
Microcentrifuge Centrifuge 5417R Eppendorf 
Microscope Axiovert 25 Zeiss 
Multimode Reader TrisStar LB941 Berthold Technologies 
PCR cycler Thermocycler T3 Biometra 
Power supply Power Pac 3000 BioRad 
Roller-mixer CATRM5 Zipperer 
Spectralphotometer NanoVue GE Healthcare 
Spectralphotometer Genesis 2 Thermo Scientific 
Spiral platter EddyJET IUL 
Tank Blotter Criterion Blotter BioRad 
Thermomixer Comfort Eppendorf 
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2.1.7 Oligonucleotides 
 
Purified oligonucleotides were obtained from Sigma-Aldrich and resuspended in TE 
buffer at pH 8.0 and stored at -20°C. Primers were used in a final concentration of    
5 pmol/µl for cloning. The restriction sides are printed in bold. 
 
Name Sequence (5’- 3’) 
  
SP1 Triiso 5’-AGCGGCTCTTCAATGAGAACACCAATTATAGCTG-3’ 
MibIII-N-ASP 5’-AGCGGCTCTTCTCCCAGTTTGACGTACAAATGCACAC-3’ 
SP2-C-MibIII 5’-AGCGGCTCTTCAATGAAAGCACAAGGTTTAGAAATCG- 3’ 
ASP2 Triiso 5’-AGCGGCTCTTCTCCCTTTTGCACCTTCTAACAATTGTACG-3’ 
ASP-C-17-MibIII 5’-AGCGGCTCTTCTCCCGTTAGGTTTAACACTACCACC- 3’ 
SP2-C-19-MibIII 5’-AGCGGCTCTTCAATGAATGGTGCGTTCACAGGTGAAAC-3’ 
ASP-C-19-MibIII 5’-AGCGGCTCTTCTCCCATCAATATCAGTTTGTGCCAT-3’ 
SP-Pep1-MibIII 5’-AGCGGCTCTTCAATGACGTCTCCAGTTGCATTAG-3’ 
SP-Pep2-MibIII 5’-AGCGGCTCTTCAATGAAATACGTTGTTATCGGTC-3’ 
SP-Pep3-MibIII 5’-AGCGGCTCTTCAATGGAATTATTCCACGAAACAG-3’ 
SP-Pep4-MibIII 5’-AGCGGCTCTTCAATGGATGAAGAAATTAACAAAAAAG-3’ 
SP-Pep5-MibIII 5’-AGCGGCTCTTCAATGAAAGCGCACGCTATTTTC-3’ 
SP-Pep6-MibIII 5’-AGCGGCTCTTCAATGAAACATGGAATGACTCCA-3’ 
SP-Pep7-MibIII 5’-AGCGGCTCTTCAATGATTATTTGTGTTGGTGAA-3’ 
pOxipep-TriisoN 
sense 
5’-AGCGGCTCTTCAATGACCGATAACGAACTGGTGAGC           
ATTGTGCGTCGCGATAAAGCGCACGCT ATTTTCAAACAT-3’ 
Hp2160pep-
TriisoC-antisense 
5’-AGCGGCTCTTCTCCCTTTATAGAAGAAACGTTCCACATC 
CTGATCGTTTTTGTTAGGTTTAACACTACCACCATA-3’ 
pOxi-anti-
senseTriisoC 
5’-AGCGGCTCTTCTCCCATCGCGACGCACAATGCTCACCAG 
TTCGTTATCGGTGTTAGGTTTAACACTACC ACC-3’ 
AAV-Triepitop 
KpnI sense 5’-TAGGTACCCACCGGCCACCATGGATAACGAACTGG-3’ 
AAV-Triepitop NotI 
AS 5’-GAGCGGCCGCTCTATTTATAGAAGAAACGTTCCAC-3’ 
AAV-Triepitop 
AgeI sense 5’-TAACCGGTCACCGGCCACCATGGATAACGAACTGG-3’ 
AAV-Triepitop 
BsrGI AS 5’-GTGTACACTTTATAGAAGAAACGTTCCAC-3’ 
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2.1.8 Plasmids 
Name Provider 
  
pET29b-pOxiHis A. Klimka, Inst. for Med. Microbiology, Köln 
pET29b-TriisoHis A. Klimka, Inst. for Med. Microbiology, Köln 
pET29b-hp2160His A. Klimka, Inst. for Med. Microbiology, Köln 
pENTRY-IBA51 IBA  
pPSG-IBA43 IBA  
IBA-Triepitop This work 
IBA-OTO This work 
IBA-pOT This work 
IBA-TpO This work 
pGFP-Anne H. Büning, MH Hannover 
pEGFP-VP2 H. Büning, MH Hannover 
AAV-pTriepitop-Anne This work 
AAV-pTriepitop-VP2 This work 
 
2.1.9 Anesthesia 
 
Ketavet-Rompun narcotic 
 
87.5 % physiological NaCl solution (0.9 %) 
10 % Ketavet (100 mg/ml Ketaminhydrochloride) 
2.5 % Rompun (2 % Xylazinhydrochloride) 
intraperitoneal application (i.p.), 200 μl/20 g mouse weight 
 
2.1.10 Kits 
 
Designation Manufacturer 
  
AmershamTM ECLTM Detection Reagent GE Healthcare 
BCA Protein Assay Kit Thermo Scientific 
ECL™ Detection Reagents GE Healthcare 
Endo Free Plasmid Maxi Kit Qiagen 
LumiGLO ReserveTM Chemiluminescent Substrate Kit KPL 
PureTaq™ Ready-To-Go™ PCR beads GE Healthcare 
QIAprep Spin Miniprep Qiagen 
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QIAquick PCR Purification Qiagen 
TMB Substrate Reagent Set BD Biosciences 
DuoSet ELISA Mouse IFN-γ R & D Systems 
DuoSet ELISA Mouse IL-4 R & D Systems 
DuoSet ELISA Mouse IL17A R & D Systems 
BrdU Cell Proliferation ELISA Kit Abcam 
 
2.1.11 Consumables 
 
Designation Manufacturer 
  
Amersham Hyperfilm ECL GE Healthcare 
Bottle-Top-Filter Nalgene 
Cell Culture Plastic  TPP 
Centricon-Plus 70, 30 000 MWCO Millipore 
CountessTM Counter Chamber Life Technologies 
Discofix® Three-way cock Braun 
EddyJET Tips  IUL 
HiTrap TM FF crude Columns GE Healthcare 
HiTrap TM NHS-activated HP Columns GE Healthcare  
Maxisorp TM flat-bottom 96-well plates Nunc 
Nitrocellulose GE Healthcare 
Novex® Midi Gel adapters Life Technologies 
NuPAGE® Novex® 10 % Bis-Tris Midi Protein Life Technologies 
Petri dishes Sarstedt 
Poly-Prep® Chromatography Columns BioRad 
Slide-A-Lyzer Dialysis Cassette 10000 Thermo Scientific 
Sterifix® Injection Filter, 0.2µm Braun 
Syringes and Needles Braun, BD Biosciences 
Whatman Paper ALBET LabScience 
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2.1.12 Software 
 
Designation Manufacturer 
  
CellQuest™ Pro BD Biosciences 
Chromas Pro Technelysium 
GelCapture DNR Bio Imaging Systems Ltd. 
GraphPad Prism 5 GraphPad Software, Inc. 
Flash & Grow Advanced Colony Counting IUL 
Image Lab BioRad  
NanoDrop 2000 ThermoScientific 
MikroWin2000 Mikrotek Laborsysteme GmbH 
Vector NTI Invitrogen 
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2.2. Methods 
2.2.1 Microbiological methods  
2.2.1.1 Cultivation of E. coli 
E. coli from -80 °C stocks was grown for 8-16 h at 37 °C on LB agar plates. When 
growing the bacteria in liquid medium, one colony was picked and grown in LB 
medium. An Erlenmeyer bottle was filled up to 25 % with LB medium and next day 
bacteria were inoculated 1:100 and incubated at 37 °C with shaking at 220 rpm. 
 
2.2.1.2 S. aureus growth curves (planktonic) 
S. aureus from ON culture was inoculated 1:100 into LB or TSB broth, supplemented 
with the corresponding antibiotic and cultured at 37 °C with shaking at 220 rpm. The 
OD was measured every hour at 600 nm. 
 
2.2.1.3 S. aureus growth under biofilm conditions 
S. aureus from ON culture was inoculated into TSB broth containing 0.5 % glucose 
and cultured in flat-bottom cell culture plates (usually 6-well) at 37 °C for 24-72 h 
without shaking. 
 
2.2.1.4 Quantification of biofilm formation  
For quantitative biofilm analysis S. aureus cells were stained with crystal violet.        
After growth of S. aureus in 96-well microtiter plates, biofilm was carefully washed 
with 1 x PBS and air-dried. Biofilm was then fixed with 100 % ethanol for 15 min, air-
dried again and stained with 0.2 % crystal violet for 2 min. 
After removal of crystal violet biofilm was washed 10 x with dH2O. Bound crystal 
violet was extracted by extraction buffer containing 40 % ethanol and 10 % acetic 
acid. The absorbance was measured in a plate reader at 590 nm using extraction 
buffer as blank. 
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2.2.2 Molecular biological methods 
2.2.2.1 Polymerase chain reaction (PCR) 
PCR was used for the amplification of protein fragments and epitope sequences, 
respectively, from our vaccine candidates. Plasmids pET29b-TriisoHis, pET29b-
pOxiHis and pET29-hp2160His (constructed by our AG) were used as DNA 
templates. The reactions were performed as follows: 
10 x Buffer 5 µl 
dNTPs 5 pmol 
Sense Primer 10 pmol 
Antisense Primer  10 pmol 
DNA 100-150 ng 
Pfu Polymerase 2.5 U 
ddH2O ad 50 µl 
 
The PCR program for Pfu Polymerase is used as follows: 
95 °C          3 min 
95 °C          1 min 
50-65 °C     0.5 min      x 25 
72 °C          2 min 
72 °C          10 min 
10 °C          forever 
 
Annealing temperature of primers was calculated individually. First, melting 
temperature (Tm) of primers was calculated with the following formula: 
                                 Tm = 2 °C x (A+T) + 4 °C x (G + C)  
The starting point for the PCR annealing step is Tm – 5 °C. If too many unspecific 
side products appeared in subsequent gel electrophoresis, temperature was 
increased around 1-3 °C.  
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2.2.2.2 Purification of PCR products and plasmid DNA 
Purification of PCR products and plasmid DNA, respectively, was performed using 
PCR Clean-up Kit and NucleoSpin Plasmid Kit, respectively, according to 
manufacturer’s instructions. The methods are based on cell lysis by SDS and binding 
of the DNA to a silica membrane following removal of contaminations by washing 
with ethanolic buffer and subsequent elution of the DNA under low ionic strength 
conditions (Macherey-Nagel, 2015). 
 
2.2.2.3 Quantification of nucleic acids 
Concentrations of the purified DNA were determined with a NanoDrop microvolume 
UV/VIS spectrophotometer (Thermo Scientific). Therefore, 1 µl of DNA was applied 
on the device after adjusting the reference with elution buffer. The concentration was 
determined at a wavelength of 260 nm. Additionally, the quality of the DNA was 
determined by measuring the quotient of absorptions of DNA and contaminants such 
as proteins and phenols (A260/280). Pure DNA samples are expected to have a 
value ranging from 1.8 - 2.0 (Thermo Fisher Scientific, 2009). 
 
2.2.2.4 Restriction endonuclease digest of plasmids 
Digestion with restriction endonucleases was performed to ligate amplified DNA and 
vector or to control identity of purified plasmids. Reaction was performed using Fast 
digest enzymes according to manufacturer’s instructions (Fermentas) in a 10-20 µl 
solution containing 1 U enzyme per 1 µg of DNA, 1x reaction buffer and 1 U per 1 µl 
Fast Alkaline Phosphatase. 
 
2.2.2.5 Agarose gel electrophoresis 
Agarose gel electrophoresis was conducted to analyze restriction enzyme reaction. 
Gels were prepared as 1 % agarose gels with TAE buffer and 0.0005% EtBr. A total 
volume of 8-10 µl of sample plus 1x loading dye was loaded per slot. Electrophoresis 
was performed at 100 V for 1 h and gel was analyzed under UV-light using the Gel 
Doc2000 with the Quantity One Software. 
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2.2.2.6 Ligation of amplified DNA and expression vectors 
In the ligation process insert and the vector are joined to each other by hybridization 
of compatible ends generated by restriction endonucleases following formation of 
phosphodiester bonds between the 3' hydroxyl and 5' phosphate of neighboring DNA 
residues, which is catalyzed by ligase. Antibiotic resistance genes serve as selective 
markers for identification of positive clones. The amount of utilized vector and insert 
was calculated according to the following equation, given that the amount of used 
vector DNA is 100 ng and the ratio of insert and plasmid is 4:1. 
       massinsert DNA [ng] = base pairs (insert) / base pairs (vector) x 4 x 100 ng 
Consistent with this formula, the utilized volume of insert DNA can be calculated 
according to the corresponding DNA concentration. The mixtures were prepared 
according to manufacturer’s instructions (T4-Ligase rapid ligation, Fermentas) and 
incubated for 30 min at RT and then used for transformation. As a control to detect 
religation of the vector molecule, a sample containing 100 ng of vector (w/o insert) 
was prepared.  
 
2.2.2.7 Production of heat-shock competent cells  
To take up foreign plasmid DNA E. coli cells had to be made artificially competent. 
This means that the cells were exposed to a special chemical, such as calcium 
chloride to make the cell wall permeable by creating pores.   
E. coli cells were grown ON in LB medium at 37 °C and 220 rpm. Next day ON 
culture was inoculated 1:100 into fresh LB medium and grown to an OD600 of 0.7 at 
37 °C. Subsequent cooling down for 10 min on ice followed and cells were pelleted 
for 10 min at 4 °C and 2500 x g. Supernatant was discarded and pellet was 
resuspended in 4 ml ice-cold 0.1 M CaCl2 + 15 % glycerol. The suspension was 
incubated for 20 min on ice and spun down for 15 min at 4 °C and 2500 x g. The 
pellet was again resuspended in 4 ml ice-cold 0.1 M CaCl2 + 15 % glycerol and 
incubated for 10 min on ice. Aliquots of 100 µl transformation competent cells were 
transferred into pre-chilled tubes, shock frozen in liquid nitrogen and stored at -80 °C 
until further use. 
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2.2.2.8 Heat-shock transformation of competent cells 
For transformation 100 µl of competent cells were added to each of the ligation mixes 
(20 µl) or to 10 ng plasmid following incubation for 30 min on ice. Subsequently the 
cells were heat-shocked at 42 °C for 90 sec and then incubated on ice again for 2 
min. The mix was then supplemented with 800 µl SOC-medium each and incubated 
for 1 h at 37 °C to let the cells express antibiotic resistance. Depending on the 
resistance gene located on the different vectors, incubation time with shaking at 350 
rpm was between 30 and 60 min. The mix was centrifuged at 13 000 x g for 3 min. 
The pellet was resuspended in 100 µl remaining supernatant, plated on LB-agar 
plates containing the corresponding antibiotic and incubated ON at 37 °C.  
 
2.2.2.9 Colony PCR  
Clones obtained from heat-shock transformation of the respective E. coli strain were 
picked for performing a colony PCR to screen for positive clones carrying the plasmid 
with insert. The picked colony was suspended in a total volume of 25 µl of the 
reaction mixture containing 10 pmol of sense and antisense primer. 
The mixture was set up in reaction tubes supplemented with PureTaq™ Ready-
ToGo™ PCR beads (GE Healthcare) that contain Taq DNA polymerase, dNTPs, 
stabilizers and buffers. The Taq-PCR program was used as follows: 
95°C 5 min 
95°C 1 min 
55°C 1 min        x 25  
72°C 2 min 
72°C 10 min 
10°C forever 
An agarose gel electrophoresis was conducted to analyze if the picked colony 
contains the plasmid with the cloned insert.  
 
2.2.2.10 DNA sequencing 
Purified plasmid DNA (2.2.2.2) of positive clones was enriched to a concentration of 
100 ng per µl by lyophilization and a total volume of 10 µl were used for sequencing. 
BigDye® Terminator v3.1 Cycle Sequencing Kit (Thermo Scientific) was used 
according to manufacturer’s instruction. 3.2 pmol of a vector-specific PCR primer was 
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added to each sample. The mixtures were sequenced by LGC Genomics, Berlin 
performing the chain-termination method of Sanger. 
 
2.2.2.11 Preparation of glycerol stocks 
The respective clones were ON cultured in LB medium supplemented with the 
appropriate antibiotic and incubated at 37 °C. Aliquots of 750 µl of the ON culture 
were mixed with 750 µl glycerol (50 %) in a Cryo.s™ tube and stored at -80 °C. 
 
2.2.3 Protein biochemical methods 
2.2.3.1 Production of S. aureus whole cell lysates (WCL) 
S. aureus from ON culture was inoculated 1:100 into LB broth. Bacteria were cultured 
until different ODs. Bacteria were harvested by centrifugation at 10 000 x g and the 
pellet was washed in 1 x PBS and resuspended in 1 x PBS containing EDTA-free 
complete protease inhibitor (Roche), 5 % Glycerol and LysonaseTM. 0.2 mg/ml 
lysostaphin was added and the pellet was incubated for 15 min at room temperature 
and then for 30 min on ice. After the incubation steps bacteria cells were disrupted 
using the Cell Disrupter (6 times at 2 bar). The cell lysate was then centrifuged for 30 
min at 10 000 x g. The supernatant was taken for a determination of the protein 
concentration using the BioRad DC assay in dilutions between 1:10 and 1:30 
according to the manufacturer’s instructions and for a following Western blot analysis. 
 
2.2.3.2 Isolation of S. aureus cell wall associated proteins 
S. aureus from ON culture was inoculated 1:100 into LB broth. Bacteria were cultured 
until an OD600 of 0.3. Cell wall associated proteins were extracted from bacterial 
pellet using a modified protocol of a previously described method (Antelmann et al., 
2002). The pellet was washed, resuspended in 1.5 M LiCl, 25 mM Tris-HCl (pH 7.2) 
containing complete protease inhibitors and incubated on ice for 30 min. Subsequent 
to centrifugation, non-enzymatic cell-wall supernatant (neCWS) was precipitated with 
10 % (w/v) trichloroacetic acid ON at 4 °C. After a centrifugation at 13 000 x g and    
4 °C the precipitate was washed twice with ice-cold ethanol and dried under vacuum. 
The neCWS was dissolved in 8 M urea and insoluble aggregates were removed by 
centrifugation. Protein concentration was determined using the BCA Protein Assay 
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Kit in dilutions between 1:2 and 1:20 according to the manufacturer’s instructions for 
Western blot analysis. 
 
2.2.3.3 Overexpression and affinity purification of vaccine candidates 
The respective E.coli BL21 expression clone (stored at -80 °C) was plated out on 
Mueller-Hinton or LB agar. After ON growth one colony was inoculated into LB         
(+ Kanamycin). Next day the clone was inoculated 1:100 in 400 ml LB (+ Kanamycin) 
and cultured until an OD600 of 0.6. Then IPTG (final concentration 1 mM) was added 
and the culture was incubated for additional 4 h at 37 °C (Triiso, hp2160) or ON at   
30 °C (pOxi, Diepitope- and Triepitope peptides). Bacteria were harvested at 17 000 
x g at room temperature, washed twice in PBS and stored in 1 x PBS buffer 
containing EDTA-free complete protease inhibitor (Roche), 5 % Glycerol and 
LysonaseTM at -20 °C until lysis of the cells using the cell disrupter as described 
above. Upon disruption of the cells, cell debris was eliminated by centrifugation at   
17 000 x g. Prior to loading onto equilibrated HisTrapTM FF crude column (GE 
Healthcare), lysates were adjusted to a final concentration of 500 mM NaCl and      
40 mM Imidazole pH 7.4. Protein was loaded onto the column by ON recirculation at 
a flowrate of 1 ml per minute at 4 °C using a peristaltic pump. The loaded column 
was transferred to the pre-equilibrated FPLC system, washed with binding buffer   
(40 mM imidazole) and fusion protein was eluted with elution buffer (250 mM 
imidazole). 
To eliminate imidazole, eluates were pooled and buffer was exchanged against 1 x 
PBS containing 10 % Glycerol by centrifugal filters (Centricon, Millipore). Protein 
concentration was determined using the BCA Protein Assay Kit according to the 
manufacturer’s instructions and sterile filtered purified proteins were stored at -20 °C. 
 
2.2.3.4 SDS-polyacrylamide-gelelectrophoresis (SDS-PAGE) 
Proteins were adjusted to 5-10 µg for subsequent Coomassie staining or 1-5 µg for 
Western Blot analyses per lane with H2O and 5 x Laemmli buffer and subsequently 
boiled at 95 °C for 5 min. WCLs and neCWS were adjusted to 40-50 µg per lane for 
Western blot analyses. Insoluble aggregates were removed by centrifugation at        
10 000 x g, RT. Proteins were separated by SDS-PAGE with the Criterion gel system 
(Bio-Rad) in a Criterion electrophoresis chamber using a constant voltage of 120 V.  
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Protein gels were stained with Coomassie solution or were used for immunoblotting. 
2.2.3.5 Western blot 
Subsequent to protein separation by SDS-PAGE, proteins were transferred to a 
nitrocellulose membrane using Criterion Midi Tank-Blotsystem with a constant current 
of 250 mA for 70-90 min. Afterwards, the membrane was blocked with blocking 
solution for 1 h at room temperature to prevent non-specific binding of antibodies. 
Primary and HRP-conjugated secondary antibodies diluted in blocking solution were 
used for specific protein detection. Incubation with a primary antibody was carried out 
overnight at 4 °C, secondary antibody was applied for 1-1.5 h at room temperature. 
In order to remove unbound antibodies the membrane was washed three times for  
10 min with 1x TBST buffer between incubation with antibodies. Bound proteins were 
detected using chemiluminescence reagent (ECL) or LumiGlo ReserveTM 
Chemiluminescent substrate. Chemiluminescence was imaged using the MF-
ChemiBIS 3.2 Imager (Berthold Technologies) or the blot was developed with AGFA 
Curix (AGFA) using an X-ray film. 
 
2.2.3.6 Interaction between Triiso and plasminogen by Far-Western blot 
Detection of an interaction between human plasminogen and Triiso was performed 
by Far-Western blotting, according to Furuya and Ikeda (2011). With this method a 
protein 1 that was blotted on a membrane was then incubated with another protein 2. 
Protein 1 was then identified by an antibody that is specific for the protein 2 which 
proves the interaction between protein 1 and 2. 
Recombinant Triiso was separated by SDS-PAGE and blotted onto nitrocellulose 
membranes. The membranes were blocked and then treated with 100 nM human 
plasminogen (Roche) diluted in blocking milk. Detection of Triiso by bound 
plasminogen was performed by goat anti-plasminogen-HRP (Abcam). For the 
investigation of a moAb-based inhibition of this interaction membrane was incubated 
with different concentrations of α-Triiso moAb H8 before plasminogen was added. 
 
2.2.3.7 Interaction between Triiso and plasminogen by ELISA 
The interaction analysis described in 2.2.3.6 was also conducted by ELISA. 
Plasminogen was coated in a final concentration of 5 µg/ml on a Maxisorp plate. 
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After blocking plate was incubated with recombinant Triiso in different concentrations 
that was then detected with anti-6-His-tag antibody. For the investigation of a moAb-
based inhibition of the Triiso-plasminogen interaction Triiso was first incubated with 
α-Triiso moAb H8 for 30 min at room temperature. The mixture was then added to 
the plate. Incubation with anti-6-His-tag antibody followed and the change in 
absorbance was measured at 450 nm. 
 
2.2.3.8 Enzymatic activity of Triiso 
Enzymatic activity of native or recombinant Triiso was coupled to the oxidation of 
NADH by glycerol-3-phosphate dehydrogenase, according to the method of Furuya 
and Ikeda (2009) with some modifications in enzyme concentration.  
Recombinant Triiso, S. aureus whole cell lysate or non-covalently bound surface 
protein fraction was incubated in different concentrations with 0.45 mM DL-
glyceraldehyde-3-phosphate as substrate, 0.03 mg NADH and 3 mg glycerol-3-
phsophate dehydrogenase in a final volume of 300 µl. The change in absorbance 
was measured at 340 nm. 
 
2.2.3.9 Enzymatic activity of plasmin 
Activation of plasminogen into plasmin was catalyzed by the S. aureus enzyme 
staphylokinase (SAK).  
For the measurement of plasmin activity 40 µl of 500 nM human plasminogen, 40 µl 
of the 0.5 mM substrate S-2251 and 25 ng of human recombinant SAK in a final 
volume of 100 µl were mixed and the reaction was started by adding SAK. The 
increase in absorbance was measured at 405 nm. All reagents were diluted in 50 mM 
Tris-HCl buffer (pH 7.4).  
 
2.2.3.10 Effects of native and recombinant Triiso on plasminogen activation 
An influence of Triiso on plasminogen activation was proved by Furuya and Ikeda 
(2011). To examine an effect of recombinant Triiso on plasminogen activation the 
assay in 2.2.3.9 was performed in the presence of Triiso. 40 µl of 500 nM 
plasminogen, different dilutions of Triiso between 0 and 16 µg (10 µl volume), 40 µl of 
the 0.5 mM substrate S-2251 and 25 ng of human recombinant SAK (10 µl volume) 
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in a final volume of 100 µl were mixed and the increase in absorbance was measured 
at 405 nm. The reaction was started after adding SAK.  
The same procedure was performed with 2-10 µg S. aureus cell lysate and 2-5 µg 
neCWS. To examine the effect of α-Triiso moAb H8 in this assay it was incubated 
with Triiso for 30 min at room temperature before the addition of Triiso to the reaction 
mixture. 
 
2.2.3.11 Effects of intact live S. aureus on plasminogen activation 
To examine the effects of intact live S. aureus cell were added to the plasmin activity 
assay system. After S. aureus USA300 had been cultured at 37 °C for 18 h in TSB 
under planktonic or biofilm conditions, respectively, cell suspensions (10 µl) at 
various concentrations (1 x 1010, 5 x 109, 1 x 109, 1 x 108, and 1 x 107/ ml) were 
incubated with 40 µl of 500 nM plasminogen for 30 min at 37 °C in a 96-well 
microtiter plate. After incubation with SAK for 10 min at 37 °C, reaction was started 
by adding substrate S-2251 and the absorbance at 405 nm was measured. 
 
2.2.3.12 Enrichment of specific IgGs from IVIG 
For enrichment of S. aureus specific IgGs, 1 mg of the purified recombinant protein 
was covalently linked to N-hydroxysuccinimide-activated Sepharose columns (NHS; 
HiTrapTM NHS activated HP columns) according to manufacturer’s instructions (GE 
Healthcare). IVIG solution was diluted 1:3 with binding buffer. Binding of IgGs was 
performed ON at 4 °C by slow recirculation of IVIG solution. Specifically bound IgGs 
were eluted from the column by pH shift using 0.1 M glycine-HCl (pH 2.7). The pH of 
the eluted fractions was neutralized by addition of a sufficient amount of 1 M Tris-HCl 
(pH 9.0). IgG-containing fractions were pooled and, after buffer exchange into PBS 
(pH 7.5) and concentration using Centricon Plus-70, 30 kDa cut off centrifugal filters 
(Millipore), stored sterile filtered at 4 °C. 
 
2.2.3.13 Surface localization of vaccine candidates 
To localize the antigens on the surface of whole S. aureus cells by the monoclonal 
antibodies (moAbs), strain JE2 or ΔspA was grown in LB broth at 37 °C to an OD600 
of 0.3 or for 24-72 h under biofilm conditions (see 2.2.2.3). Bacteria were harvested, 
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washed and adjusted to 1 x 108 CFU/ml (correlates with an OD600 of 0.3) in PBS 
containing 1 % bovine serum albumin (BSA). The respective moAb was added at a 
concentration of 0.1-0.5 mg/ml as primary antibody, incubated for 30 min at 37 °C 
and washed with PBS-1 % BSA to remove free antibodies. A 1:100 dilution of a 
phycoerythrin-conjugated or a FITC-conjugated goat anti-mouse F(ab’)2 fragment 
(Life Technologies)  was used as secondary antibody and was incubated for 30 min 
at 37 °C. When humanized antibodies were used the phycoerythrin-conjugated goat 
anti-human F(ab’)2 fragment (Dianova) was added as secondary antibody in a 1:100 
dilution. After a washing step to remove unbound secondary antibody, samples were 
diluted 1:2 in FACS buffer and analyzed by flow cytometry using the FACSCalibur 
system and CELLQuestPro software (BD Biosciences). 
 
2.2.4 Cell culture  
2.2.4.1 Cultivation of HeLa cells 
Cells were cultured in DMEM containing 10 % FCS and 1 % P/S under sterile 
conditions at 37 °C in a humidified atmosphere containing 5 % CO2. Cells were 
passaged every 3 days. To detach cells from culture dishes, medium was removed 
and cells were washed once with PBS. The cells were then incubated with trypsin-
EDTA at 37 °C until detachment was visible. The reaction was stopped by the 
addition of medium containing 10 % FCS. For long term storage, cells were 
suspended in FCS containing 10 % DMSO and frozen at -160 °C.  
 
2.2.4.2 Interaction between S. aureus and HeLa cells 
When cells were passaged 3 days prior to infection medium was replaced with 
antibiotic free DMEM medium + 10 % FCS.  
For the measurement of an interaction between S. aureus and HeLa cells by flow 
cytometry, the HeLa cells were harvested, washed and adjusted to 1 x 107 cells per 
ml. S. aureus ATCC-GFP was grown for 48 h under biofilm conditions (see 2.2.2.3), 
harvested, washed in PBS (pH 5.0) and adjusted to 1 x 108 CFU/ml. 500 µl of 1 x 108 
CFU/ml bacteria were incubated with 50 µg of recombinant protein (pOxi, Triiso) or 
moAb (anti-pOxi D3, anti-Triiso H8) or 50 µl of PBS (negative control) at 37 °C for   
30 min. Bacteria were then centrifuged and washed twice in PBS (pH 5.0).  
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HeLa cells were infected with S. aureus ATCC 29213-GFP MOI of 2, 5 and 10, 
respectively and incubated for 15 min at 37 °C. HeLa cells were centrifuged and 
pellet was fixed with 3 % paraformaldehyde for 20 min. Pellet was washed thrice and 
resuspended in 1 ml of FACS buffer for flow cytometric measurement.  
 
2.2.4.3 Isolation of human neutrophils 
Human polymorphonuclear cells (PMNs) were isolated by dextran sedimentation and 
Ficoll Hypaque gradient centrifugation from 20 ml of fresh blood. Blood was collected 
from a healthy donor and mixed 1:1 with a solution of 2 % citrate-dextrose + 7 % 
Dextran 70. After sedimentation (60 min) at room temperature leucocyte rich plasma 
was isolated and sublayered 1:1 with Ficoll. After centrifugation at 700 x g without 
brake the lymphocyte and monocyte rich supernatant was removed and the 
neutrophil rich pellet was incubated for 20 sec in 0.2 % NaCl and for 20 sec in 1.6 % 
NaCl to lyse the red blood cells. After addition of 40-50 ml 1 x HBSS - Mg2+ - Ca2+ + 
0.1 % chicken egg albumin (Sigma) and a centrifugation step the isolated human 
PMNs were resuspended in 1 x HBSS pH 7.3, and number of cells was determined 
by trypan blue exclusion in a Neubauer chamber.  
 
2.2.4.4 Preparation of bone marrow-derived macrophages 
Bone marrow derived macrophages (BMDM) were prepared from the femurs and 
tibias of mice. The bone marrow was flushed with plain RPMI, and subsequently 
erythrocytes were lysed by incubation for 5 min in RBC lysis buffer at RT. Lysis was 
stopped by addition of RPMI and after centrifugation at 800 x g at RT cells were 
seeded in BMDM culture medium (RPMI supplemented with 10 % FCS, 1 % P/S, 1 % 
HEPES and 1 % sodium-pyruvate and 20 ng/ml recombinant murine mCSF 
(Peprotech)), in 10 cm non-cell culture treated petri-dishes. Cells were supplemented 
with BMDM culture medium after 5 days of differentiation. 24 h prior to infection of 
BMDMs, medium was replaced with antibiotic free RPMI medium. Infections were 
performed on day 8-10 upon isolation. 
 
2.2.4.5 Investigation of T-cell response in mice post immunization 
Aseptically isolated spleens were mashed through a 100 µm cell strainer to 
dissociate splenocytes. After centrifugation the pellet was incubated for 20 sec in 0.2 
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% NaCl and for 20 sec in 1.6 % NaCl to lyse the red blood cells. Cells were washed 
three times in 5 ml of plain DMEM medium. Cells resuspended in splenocyte medium 
(RPMI + 1 % FCS, 1 % Pen/Strep, 1 % 50 mM β-mercaptoethanol) were counted in 
trypan blue solution. Cells were counted in a Neubauer cell chamber. Cell 
concentration was adjusted with splenocyte medium to required cell numbers. 3 x 106 
cells per well were seeded in 96-well plates in a total volume of 100 µl. Cells were 
stimulated with 2 µg/ml of the respective peptide. Splenocyte medium was used as 
negative control and 2 µg/ml of Concanavalin A (ConA) was positive control. Cell 
culture supernatants were collected 72 h post stimulation and stored at -20°C until 
measuring of cytokine concentration in supernatant by DuoSet ELISA (R & D 
Systems) according to manufacturer’s instructions. BrdU Cell Proliferation Assay 
(Abcam) was also conducted according to manufacturer’s instructions. 
 
2.2.5 Immunological methods 
2.2.5.1 In vitro opsonophagocytosis of S. aureus by human neutrophils 
S. aureus ATCC 29213-GFP was inoculated into LB broth and grown at 37 °C to an 
OD600 of 0.3. Bacteria were harvested, washed and adjusted to 1 x 109 CFU/ml. IVIG 
(positive control), isolated specific human IgGs (α-pOxi and α-Triiso) enriched from 
IVIG and human monoclonal IgGs (α-pOxi humAb D3, α-Triiso humAb H8, α-hp2160 
humAb 16-2) were added at a concentration of 50 µg/ml and pre-opsonization of 
bacteria was allowed for 30 min at 37 °C. 2.5 x 106 human PMNs and bacteria at a 
MOI of 10 were incubated for 2-10 min at 37 °C with slow rotation upon initial 
synchronization of infection by centrifugation at 700 x g for 2 min. Phagocytosis was 
stopped by centrifugation for 2 min at 150  x g at 4 °C, and samples were washed 
three times, resuspended in 1 x HBSS and samples were taken for FACS analysis 
(1:5 dilution in PBS-0.5 % BSA (pH 7.3); kept on ice until measurement) using the 
FACSCalibur and Cellquest Pro Software. 
 
2.2.5.2 In vitro opsonophagocytosis of S. aureus by BMDM’s 
S. aureus ATCC 29213-GFP was inoculated into LB broth and grown at 37 °C to an 
OD 600 of 0.3. Bacteria were harvested, washed and adjusted to 1 x 109 CFU/ml. 
Murine monoclonal IgGs (anti-pOxi moAb D3, anti-Triiso moAb H8, anti-hp2160 
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moAb 16-2) were added in a concentration of 50 µg/ml and pre-opsonization of 
bacteria was allowed for 30 min at 37 °C. 
BMDM’s in petri dishes were incubated in 1 x PBS + 1 mM EDTA and harvested by a 
cell scraper. Detached cells were diluted with plain RPMI and after centrifugation at 
800 x g at RT cell pellets were pooled. Cells were resuspended in a defined volume 
of antibiotic free RPMI medium. An aliquot was stained with trypan blue and counted.  
Cells were infected with a MOI of 15. In order to synchronize the uptake of S. aureus, 
host cells were incubated on ice with bacteria and were subsequently centrifuged for 
5 min at 800 x g, 4 °C. After adhesion of S. aureus, the temperature was increased to 
37 °C for 45 min. Thereafter the supernatant containing non-internalized bacteria was 
removed and cells were washed twice by centrifugation at 800 x g and 4 °C with ice-
cold PBS. For the degradation of remaining extracellular bacteria, cells were 
incubated with 200 µg/ml lysostaphin on ice for 20 min. Thereafter cells were washed 
twice with PBS in order to remove lysostaphin and dead bacteria and fresh medium 
supplemented with antibiotics was added. Infected cells were incubated at 37 °C until 
indicated time points. 
 
2.2.5.3 Competition ELISA 
To determine epitope-peptide functionality a competition ELISA was performed. For 
the competition of moAb binding by epitope peptides 5 µg/ml antigen was 
immobilized at a maxisorp plate. The competitor (peptide) was pre-diluted in a 96-
well plate from 500 µg/ml to 0.8 µg/ml and the dilutions were added to the blocked 
ELISA plate in a total volume of 50 µl per well. MoAbs were diluted 1:500 and 50µl 
were added to the competitor in a total volume of 50 µl. The plate was incubated for  
1 h. The secondary antibody (goat anti-mouse or goat anti-human-HRP) was diluted 
1:3000. All dilutions were prepared in blocking buffer. For 3x washing between the 
incubation steps 1 x PBST was used. For the reaction TMB substrate reagent kit was 
used according to the manufacturer’s instructions. The absorbance was measured at 
450 nm. 
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2.2.5.4 Immunization of mice 
Epitope peptides were conjugated to the carrier proteins KLH or BSA using a 
corresponding conjugation kit (Thermo Fisher) according to manufacturer’s 
instructions. 
Female BALB/c mice (6 to 10 weeks old) were purchased from ZMMK (UK Köln). 
Mice were injected subcutaneously with a 1:1 emulsion (total volume: 200 µl) 
containing 70-80 µg recombinant peptide-conjugate and complete Freund’s adjuvant 
(Sigma) on day 0, followed by subcutaneous administration of two booster doses 
using an emulsion containing 50 µg antigen and incomplete Freund’s adjuvant (1:1) 
on days 28 and 56. Mice immunized with KLH or BSA as non-specific antigen served 
as controls. For the bivalent immunization 40 µg of each antigen was used for initial 
and 25 µg for booster immunization. For immunization with rAAV or rMVA vectors 
mice were anesthetized by an i.p. injection with Ketamine + Rompun (10:1), diluted 
1:10 with sterile 0.9 % NaCl (Ketamine/Rompun 100 mg/kg and 10 mg/kg body 
weight). Each vector was diluted in 0.9 % NaCl to a titer of 1x 1010 pfu (rAAV) or 1 x 
108 pfu (rMVA) per mouse. Vectors were administrated by intramuscular injection into 
the back thighs.  
 
2.2.5.5 Serum preparation and IgG titer determination 
For the determination of the specific antibody titer, blood samples were taken on 
days 14, 42 and 66 by bleeding at the vena facialis and analyzing by ELISA on         
5 µg/ml of the respective antigen and 500- to 1.000.000-fold serial dilution using TMB 
substrate reagent set. The titer is given as the dilution corresponding to the half 
maximal OD. 
 
2.2.5.6 Murine model of sepsis 
Two weeks after the last booster immunization BALB/c mice were challenged by i.p. 
injection with S. aureus USA300 mixed with 5 % mucin from porcine stomach 
(Sigma). For organ preparation mice were challenged with a sublethal dose and for 
survival experiments with LD50 of 3.3 x 107 CFU in 300 µl PBS. For organ preparation 
mice were sacrificed after 24-48 hours and for survival experiments mice were 
monitored daily for clinical signs of infection and mortality for 8 days. 
 
2 Material and Methods 
 
50 
 
2.2.5.7 Preparation of organs for a determination of the bacterial density 
Mice were sacrificed by cervical dislocation and liver, spleen and kidneys were 
isolated. After preparation of all mice organs were weighted and subsequently 
homogenized in dH2O containing 0.1 % Triton X-100 by OctoMACS (Miltenyi) and 
then centrifuged for 5 min at 300 x g. All samples were diluted in 0.1 % Triton X-100 
and immediately plated out on Mueller-Hinton agar. After ON incubation at 37 °C 
colonies were counted by a colony counter (IUL) using the program Flash & Grow 
Advanced Colony Counting. Organ CFU was calculated as colony numbers per 
organ mass. 
 
2.2.6 Statistical analysis 
If not stated otherwise, results were statistically analyzed by unpaired two-tailed 
Student´s t-test using GraphPad Prism version 5.03 for Windows (GraphPad 
Software, www.praphpad.com).  
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3 Results 
 
3.1 Characterization of S. aureus antigens and generated specific  
      monoclonal antibodies 
Anchorless cell wall proteins were identified as vaccine candidates by subtractive 
proteome and MALDI-TOF analysis (Glowalla et al., 2009). Some of them, namely 
protoporphyrinogen oxidase (pOxi), triosephosphate isomerase (Triiso) and the 
hypothetical protein 2160 (hp2160), used as vaccines achieved a repetitive 
protection in murine sepsis model. Monoclonal antibodies (moAbs) against these 
antigens were generated in our lab by hybridoma technology and some of these 
purified moAbs D3 (pOxi), H8 (Triiso) and 16-2 (hp2160) used as passive 
immunization demonstrated a repetitive protection in the murine sepsis model as 
well.  
We were interested in the characterization of the antigens as potential virulence 
factors and in the mode of action of the respective moAbs. The focus was set on 
pOxi because it was previously decided to use first the anti-pOxi moAb D3 in clinical 
studies to treat MRSA-based bacteremia in the next years. The second focus was set 
on Triiso because its occurrence on the S. aureus surface was already known 
(Furuya et al., 2009). In contrast to Triiso, hp2160 is not characterized, so far and 
was used as a third choice.  
A further aim was the identification and analysis of the epitopes of the protective 
moAbs to be used as a combined, polyepitope-peptide vaccine against S. aureus 
infection. 
 
3.1.1 Identification and verification of linear epitopes 
The epitopes of anti-pOxi moAb D3 and anti-hp2160 moAb 16-2 were identified by 
microarray analyses performed mainly by the Pepperprint GmbH, Heidelberg. The 
respective antigen was synthesized as peptide-fragments of 13 amino acids spotted 
on a chip with overlapping sequences of 12 amino acids. The array was incubated 
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with the respective monoclonal antibody as primary and with goat anti-mouse IgG - 
DyLight680 conjugate (Thermo Scientific).  
Read-out was done with an Odyssey Imaging System to detect antibody interactions 
with the 13mer peptides of pOxi or hp2160 (Figure 3.1). A response of anti-hp2160 
moAb 16-2 (A), as well as anti-pOxi moAb D3 (B) with the linear peptides KNDQD 
VERFFYK and TDNELVSIVRRD was identified, respectively.  
 
 A            B 
              
 
Figure 3.1: Microarray to identify the epitopes of anti-hp2160 moAb 16-2 (A) and anti-pOxi-moAb D3 (B). 
Respective antigen was synthesized in fragments of 13 amino acids on a chip with overlapping of 12 amino acids. 
Array was incubated with moAb and goat anti-mouse IgG-DyLight680 conjugate. Read-out followed with an 
Odyssey Imaging System. 
 
The epitope identification of anti-Triiso moAb H8 was more complicated because 
three different signals were detected in the antigen Triiso (not shown).  
Additionally, the linear epitope within the peptide LADLGVKYVVIGHSERRELFHETD 
of anti-Triiso moAb C4 was identified by microarrays. This anti-Triiso moAb showed 
only minor protection in the murine sepsis model after passive immunization, but was 
not tested as often as moAb H8. 
The three resulting epitope peptides were synthesized by JPT Peptide Technologies 
GmbH, Berlin or Intavis AG, Cologne and were named hp2160 epitope-peptide        
(= anti-hp2160 moAb 16-2 epitope), pOxi epitope-peptide (= anti-pOxi moAb D3 
epitope) and TriisoC4 epitope-peptide (= anti-Triiso moAb C4 epitope). Because of 
precipitation problems with the peptides synthesized by JPT Peptide Technologies 
GmbH, we switched later to Intavis AG. 
The verification and functionality of the synthesized epitope peptides was analyzed 
by competition ELISA (Figure 3.2). With this method, the binding of moAbs to their 
respective antigen was competed by the respective peptide. The immobilized antigen 
was incubated with the respective moAb and different concentrations of the 
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anticipated epitope-peptide. Compared to the whole, recombinant protein, the 
hp2160 epitope-peptide showed a strong competition effect at a concentration of 
0.16 µg/ml (A). At 20 µg/ml no binding of moAb 16-2 to hp2160 could be detected 
anymore. A stronger competition of moAb D3 by pOxi peptide in a dose-dependent 
manner was analyzed (B). The whole, recombinant protein pOxi showed a 
competition effect that didn’t seem to be concentration dependent. The synthesized 
TriisoC4 epitope peptide also showed a competition effect that was stronger as the 
competition with recombinant Triiso (C).     
Five different peptides of the anticipated TriisoH8 epitope were synthesized but none 
of them was able to compete the binding of moAb H8 (not shown). Further analysis 
of the moAb H8 epitope is depicted in 3.1.2. 
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More detailed analysis of hp2160 and pOxi epitopes followed by alanine scanning. 
With this systematical replacement of one amino acid by alanine, amino acids that 
are essential for moAb binding could be detected. 12 peptides of each epitope 
Figure 3.2: Competition of moAb binding to 
recombinant protein by linear epitope 
peptides. 5 µg/mL of the respective antigen 
(A: hp2160, B: pOxi, C: Triiso) was coated on 
a maxisorp plate. The respective peptide was 
diluted and added to the plate. The respective 
moAb (A: anti-hp2160 moAb 16-2, B: anti-pOxi 
moAb D3, C: anti-Triiso moAb C4) was added. 
Incubation with goat anti-mouse-HRP followed. 
ELISA was developed using TMB substrate 
and absorbance was measured at 450 nm. 
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sequence were synthesized (JPT GmbH, Berlin). Because these peptides were too 
small for coating on a maxisorp plate they were biotinylated for a binding to a 
streptavidin-coated 96-well plate. After incubation with anti-hp2160 moAb 16-2 and 
anti-mouse-HRP no binding to the hp2160 peptide without glutamic acid, which was 
replaced by alanine and just a weak binding without the amino acids glutamine and 
arginine was measured (Figure 3.3A). Binding of anti-pOxi moAb D3 to the pOxi 
peptide was completely inhibited, if isoleucine was replaced by alanine. A weak 
binding could be detected, if the second of the two arginine residues was absent (B). 
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Figure 3.3: Alanine scan of epitope peptides for binding analysis of moAbs. Synthesis of 12 biotinylated 
peptides by JPT GmbH, where consecutively one amino acid is replaced by alanine. Maxisorp plates with 
immobilized streptavidin were used for ELISA. Plates were incubated first with the peptides for immobilization, 
then with the respective moAb and finally with goat anti-mouse-HRP. A: linear hp2160 peptide, anti-hp2160 moAb 
16-2 as 1st antibody; B: linear pOxi peptide, anti-pOxi moAb D3 as 1st antibody. 
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The fact that no or just a weak binding was detected in absence of the mentioned 
amino acids indicate that these amino acids are essential for the binding of the 
respective antibody to its epitope peptide. 
 
3.1.2 Analysis of discontinuous epitope of anti-Triiso moAb H8  
An analysis of the synthesized peptides (shown in green in figure 3.5) of the potential 
H8 epitope by competition ELISA showed that none of them were able to react with 
moAb H8 as mentioned in 3.1.1. Neither a single nor peptide combinations were 
detected by moAb H8. Several signals detected by microarray analysis indicated a 
conformational or discontinuous epitope. For an identification of this kind of epitope a 
different strategy several cloning procedures of different fragments of the Triiso 
molecule and following binding analysis with anti-Triiso moAb H8 was pursued. After 
cloning (fusion to Strep-tag) and overexpression in E. coli BL21, bacteria cells were 
harvested and lysed. Equal amounts were blotted on nitrocellulose for the analysis of 
moAb binding. In figure 3.4 binding analysis of moAb H8 to produced fragments of 
Triiso is exemplary shown. After the lysis of E. coli cells expressing fragments 3, 4 
and 5, respectively, preparations of inclusion bodies (IP) and cytoplasmic fractions 
(CF) were blotted. A binding of moAb H8 to fragment 5 but not to fragment 3 and 4 
was detected (A). The expression of the peptides was controlled by detection with 
Strep-Tactin-HRP. Figure 3.5B showed an expression of all peptides that were found 
in the cytoplasm, as well as in inclusion bodies. Fragment 14 was the shortest 
analyzed Triiso fragment that was bound by moAb H8 (C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: Western blot analysis of anti-Triiso moAb H8 binding to Triiso fragments. Different sections of 
the Triiso molecule were cloned (fused with Strep-tag) and overexpressed in E. coli BL21. Lysates were blotted 
and analyzed for antibody binding. A + B: Peptides 3, 4 and 5; C: Peptide 14. A + C: anti-Triiso moAb H8 as 1st 
antibody, goat anti-mouse-HRP as 2nd antibody; B: Strep-Tactin-HRP conjugate. IB: Preparation of inclusion 
bodies. CF: Cytoplasmic fraction. 
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Figure 3.5 shows a schematic overview about all binding analyses of the cloned 
Triiso fragments. The first analysis of fragment 1 and 2 showed that parts of both 
fragments are essential for binding of moAb H8. The following constructed fragments 
3 to 5 showed an involvement of the C-terminus. Fragment 6 with a shorter C-
terminus as fragment 5 is still able to react with the moAb, identifying the C-terminal 
part of the moAb H8 epitope.  
Fragment 7 with a shorter N-terminus and fragment 8 with a shorter C-terminus were 
still detected by moAb H8. Fragment 9 was cloned with both, a shorter N- and C-
terminus. In the following fragment clonings the C-terminus was left in its length to 
prevent problems in expression because of the small sizes of the protein fragments. 
With peptide 10 to 16 the N-terminus was shortened until no binding was detected 
anymore (see peptide 15 and 16).  
With these final fragment clonings it was possible to localize the epitope of moAb H8 
within an 11 kDa molecule. 
 
 
 
 
 
Figure 3.5: Schematic overview of Triiso fragment cloning for binding analysis of anti-Triiso moAb H8. 
Synthesized small peptides (green) based on microarray analysis did not show any competitive effect in 
competition ELISA. Fragments of different Triiso sections (blue) were cloned and overexpressed in E.coli BL21. 
Bacteria cells were harvested and lysed for binding of moAb H8 by Western blot. The essential parts for moAb 
binding were marked in red. 
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Because of the binding of moAb H8 to the different fragments in Western blot, it is 
certain that the moAb’s binding did not depend on the conformation of the epitope 
within the Triiso molecule. It was confirmed that two different parts of the antigen are 
necessary for the binding of moAb H8 which indicates a discontinuous epitope of 
anti-Triiso moAb H8. A further identification of the discontinuous epitope of moAb H8 
in the resulting Triiso fragment will follow by CLIPS technology of Pepscan B.V., 
Netherlands (Timmerman et al., 2007). 
 
3.1.3 Binding analysis of moAb to the recombinant proteins 
The genes encoding the three vaccine candidates hp2160, Triiso and pOxi identified 
by Glowalla et al. (2009) were cloned in our group and fused with a C-terminal His-
tag. After an overexpression in E. coli the purified proteins hp2160 and Triiso led to a 
high amount between 20-30 mg. The overexpression of pOxi led to a red colored     
E. coli culture because of an accumulation of protoporphyrin IX. The protein pOxi is a 
part of the heme pathway and converts protoporphyrinogen IX to protoporphyrin IX. 
In contrast to the other two candidates the purification of pOxi led to a lower amount 
of approximately 5-8 mg. The monoclonal antibodies generated by our group were 
selected by their binding affinity to the respective recombinant protein. Figure 3.6 
shows the detection of the overexpressed and purified proteins hp2160 (A), Triiso (B) 
and pOxi (C) by their respective moAb.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: Specific binding of monoclonal antibodies to the respective recombinant protein. A-C: The 
gene encoding the respective S. aureus protein was cloned and overexpressed in E. coli BL21. Proteins were 
purified by its C-terminal His-tag. 1 µg of each protein was blotted on a nitrocellulose membrane. The membrane 
was first incubated with the respective moAb. A chemiluminescent detection followed after incubation with anti-
mouse-HRP conjugate.  
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3.1.4 Binding analysis of moAbs after planktonic growth of S. aureus 
Even though binding to the recombinant protein was proven, an analysis of the moAb 
binding to the native protein from S. aureus has to be analyzed.  Therefore, the cell 
wall-associated protein fraction was isolated because these three proteins of 
cytoplasmic origin were also identified as non-covalently bound surface proteins by 
2D-gel electrophoresis and MALDI-TOF analysis (Glowalla et al., 2009). As an 
additional detection method of the S. aureus proteins a whole cell lysate of S. aureus 
was prepared. Furthermore, binding of moAbs to the surface of whole S. aureus cells 
was analyzed under various conditions using flow cytometry. 
 
3.1.4.1 Binding to isolated surface protein fractions and cell lysate of S. aureus 
For an isolation of the non-covalently bound surface protein fraction S. aureus was 
grown in LB medium at 37 °C and 220 rpm (planktonic growth). A similar molecular 
weight of the protein pOxi and protein A (binds IgGs with a high affinity by their Fc 
region) makes it difficult to differ between these two proteins. Thus, the two S. aureus 
strains JE2 (wildtype) and a protein A deletion mutant (ΔspA) were used. Both strains 
were obtained from Network on Antimicrobial Resistance in Staphylococcus aureus 
(NARSA) data bank. Strain JE2 is an USA300 derivative and ΔspA was derived from 
JE2 by transposon mutagenesis (Fey et al., 2013).  
The cultures were harvested at an OD600 of 0.6-0.8. The protein fraction was isolated 
by a non-enzymatic cell wall preparation containing LiCl as already described by 
Glowalla et al., 2009 and therefore used for the identification of these proteins as 
potential vaccine candidates. With this kind of method the anchorless surface protein 
fraction can be isolated without damaging the whole cell. After TCA precipitation of 
the isolated fraction the protein concentration of the non-enzymatic cell wall 
supernatant (neCWS) was measured and approximately 30 µg was blotted.  
Hp2160 (35.5 kDa), as well as Triiso (27 kDa) was detected with the respective 
moAb in the neCWS of S. aureus JE2 and ΔspA (Figure 3.7A, B). The weak band 
above 55 kDa in the wildtype preparation is supposedly protein A. 
It was not possible to detect the 52 kDa protein pOxi with anti-pOxi moAb D3 in the 
separated cell wall supernatant. In the wildtype preparation a double band between 
55 and 70 kDa was detected (C). One of the bands was protein A. As an antibody of 
the subclass IgG2a moAb D3 has a higher affinity to bind protein A as moAb 16-2 
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and H8 that are both IgG1 antibodies. The second of the double band was possibly 
pOxi but could not be detected in the preparation of ΔspA.  
Because the three S. aureus proteins usually occur in the cytoplasm cell lysates were 
prepared for the detection by the respective moAb. The two S. aureus strains and 
additionally pOxi and hp2160 deletion mutants obtained from NARSA were incubated 
with lysostaphin, followed by mechanical disruption (D-F). A deletion mutant of Triiso 
is not available. The four lysates were blotted and incubated with moAb 16-2 (D), 
moAb D3 (E) and anti-Protein A antibody (F). In figure 3.7D hp2160 was not detected 
anymore in the lysate of Δhp2160 in contrast to the remaining strains. The binding of 
moAb 16-2 (IgG1) to protein A was very weak. In 7E a band above 55 kDa has been 
detected by moAb D3 (IgG2a) in ΔpOxi, but not in ΔspA. Compared to 7F this blot 
looks very similar which suggests a binding of moAb D3 to protein A. Unexpectedly, 
the protein pOxi was not detected in the whole cell lysate of S. aureus.     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
 
 
 
Figure 3.7: Specific binding of monoclonal antibodies to the isolated cell wall-associated protein fraction 
and to whole cell lysates of S. aureus. A-C: Cell wall-associated protein fraction was isolated from S. aureus 
JE2 (wt) and a protein A deletion mutant (ΔspA) by a LiCl method und was precipitated with 10 % TCA. 30 µg of 
non-enzymatic cell wall supernatant (neCWS) was blotted on a nitrocellulose membrane. NeCWS was incubated 
with anti-hp2160 moAb 16-2 (A), anti-Triiso moAb H8 (B) and anti-pOxi moAb D3 (C), respectively. D-F: Whole 
cell lysates (WCL) of wt and mutants were prepared by lysostaphin incubation and mechanical disruption. 30 µg 
of WCLs were blotted and incubated with anti-hp2160 moAb 16-2 (D), anti-pOxi moAb D3 (E) and anti-Protein A 
antibody (F). A chemiluminescent detection followed after incubation with anti-mouse-HRP conjugate. 
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3.1.4.2 Specific binding of anti-pOxi moAb D3 to the S. aureus surface 
The detection of the proteins on the surface of whole S. aureus cells was measured 
by flow cytometry. S. aureus was grown under planktonic conditions to an OD600 of 
0.3 (exponential growth phase). Cells were harvested and washed in PBS + 1 % 
BSA. To prevent an unspecific binding of antibodies to protein A the wildtype strain 
JE2 was blocked with a human Fc fragment. An incubation with the respective moAb 
and then with an anti-mouse F(ab)2 fragment conjugated to phycoerythrin (PE) 
followed. As a negative control just the PE-conjugate was used (Figure 3.8, black 
line). As shown in figure 3.8A binding of anti-pOxi moAb D3 (red line) to the surface 
of S. aureus JE2 was detected. A weak competition was detectable with the pOxi 
epitope peptide (blue line), but not with an irrelevant peptide (here the hp2160 
epitope peptide (green line)). A comparison to figure 3.8B, where S. aureus ΔspA 
was used, demonstrated a strong unspecific binding of moAb D3 to protein A at the 
surface of the wildtype, although it was incubated with the human Fc fragment for 
blocking this interaction. Therefore, ΔspA was used for the consecutive 
measurements. In this case the binding signal was not as strong as with the wildtype 
surface, but the competition with the pOxi epitope peptide resulted in a complete 
abolishment of the binding signal which proves again the specific binding of moAb D3 
to pOxi on the bacterial surface. With the hp2160 peptide no competition of the anti-
pOxi binding of moAb D3 was detectable. 
 
 
 
 
 
 
 
Figure 3.8: Specific binding of anti-pOxi moAb D3 to the surface of S. aureus. S. aureus ΔspA was grown to 
an OD600 of 0.3. Harvested and washed cells were incubated with 50 µg of anti-pOxi moAb D3 (red line), 50 µg 
moAb D3 + 100 µg pOxi epitope peptide as competitor (blue line), 50 µg moAb D3 + 100 µg hp2160 epitope 
peptide (green line) or with just an equal volume of PBS (black line) in PBS + 1 % BSA. All samples were then 
incubated with F(ab)2 anti-mouse-IgG-PE-Cy5.5. A: S. aureus JE2 (wildtype), B: S. aureus JE2-ΔspA. Samples 
were measured by flow cytometry. 
 
Although anti-Triiso moAb H8 showed a strong binding to wildtype, no binding to the 
surface of ΔspA was detected (data not shown). With anti-hp2160 moAb 16-2 only a 
weak binding to the wildtype was detected. As an IgG1 antibody moAb 16-2 has the 
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same subclass as moAb H8 but showed a different binding affinity to protein A. 
Binding to the surface of ΔspA was also negative.  
S. aureus was harvested at different growth phases to test if it has an influence on 
the expression of pOxi, Triiso or hp2160 or on the epitope accessibility. The ODs 0.1, 
0.3, 0.6, 1.0, 2.0, 3.0 and 6.0 were tested. The ODs 0.1, 0.3 and 3.0 were presented 
in figure 3.9. A binding of moAb D3 to the S. aureus surface (A) was measured in all 
growth phases but the strongest signal was detected at 0.3. Neither moAb 16-2 (B) 
nor moAb H8 (C) showed a binding signal at all tested growth phases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9: Binding analysis of moAbs to the surface of S. aureus harvested at different growth phases.   
S. aureus ΔspA was grown to the ODs600 0.1 (blue line), 0.3 (red line) and 3.0 (green line). Harvested and washed 
cells were first incubated with 50 µg of anti-pOxi moAb D3 (A), anti-Triiso moAb H8 (B) and anti-hp2160 moAb 16-
2 (C) and then with 2 µg of F(ab)2 anti-mouse-IgG-PE-Cy5.5. Samples were measured by flow cytometry. 
 
Although it was possible to extract Triiso and hp2160 from the surface a binding of 
moAbs H8 and 16-2 to the surface of whole S. aureus cells was not measured by 
FACS. Hereupon some other generated moAbs against Triiso were analyzed for 
surface binding and a comparison to the non-reactive moAb H8. In figure 3.10 
binding of anti-Triiso moAbs C4 (see 3.1.2) and C8 were exemplarily shown. While 
the binding signal of moAb H8 (red line) was again negative, moAb C4 (IgG1, blue 
line), as well as C8 (IgG2b, green line) indicated a weak binding to the bacterial 
surface. This indicates an occurrence of Triiso on the bacterial cell surface but the 
epitope of moAb H8 is not accessible at these growth conditions. 
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Figure 3.10: Binding analysis of anti-
Triiso moAbs H8, C4 and C8 to the 
surface of S. aureus. S. aureus ΔspA 
was grown to an OD600 of 0.3. Harvested 
and washed cells were first incubated 
with 50 µg of moAb H8 (red line), 50 µg 
moAb C4 (blue line) or moAb C8 (green 
line) and then with 2 µg of F(ab)2 anti-
mouse-IgG-PE-Cy5.5. Samples were 
measured by flow cytometry. 
 
3 Results 
 
62 
 
For their influence on antigen expression or presence on the bacterial cell surface 
different growth media were also tested, such as TSB and the cell-culture medium 
RPMI which is iron-deficient and human serum as culture medium to simulate in vivo 
conditions. Because blood is a natural environment of S. aureus it was possible that 
the proteins Triiso and hp2160 as potential virulence factors were different 
expressed. The growth media TSB and RPMI did not influence the moAb binding on 
the surface (not shown). After growth of ΔspA in serum a strong binding of moAb   
16-2 was detected compared to the negative control and other anti-S. aureus moAbs. 
However, no competition effect with the hp2160 peptide could be shown, indicating 
an unspecific binding event (not shown).   
 
3.1.5 Influence of biofilm conditions and low pH on surface proteins   
Foulston et al. (2014) describes that cytoplasmic proteins are present in the 
extracellular matrix of S. aureus biofilms and that the cell wall association is pH-
dependent. Therefore, the occurrence of the proteins under biofilm conditions was 
analyzed. Finally, binding analysis of moAbs H8 and 16-2 to whole S. aureus cells 
after biofilm growth have been tested.  
 
3.1.5.1 Quantitative determination of biofilm viability 
First the ability to form biofilms of the different strains MW2, USA300, ATCC29213, 
ΔspA and Δagr and of three clinical isolates (K180, K183 and K209) that are 
available in our institute was analyzed. To initiate biofilm formation S. aureus was 
grown in 96-well cell culture plates containing TSB medium and 0.5 % Glucose. The 
culture was incubated at 37 °C for 24 h without shaking (Figure 3.11A). The TSB 
medium was carefully removed after biofilm growth and a pH of 5 was measured. 
Bacterial cells were fixed and stained with crystal violet. After washing the cells 
bound crystal violet was extracted and quantified at an absorbance of 590 nm. A 
similar biofilm formation was detected with the common strains of our lab. The lowest 
biofilm formation was detected with the clinical isolate K209 (B).  
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Figure 3.11: Biofilm formation by different S. aureus strains. S. aureus JE2 was grown under biofilm 
conditions in TSB + 0.5 % Glucose for 24 h (A). Biofilm growth was quantified by staining with 0.2 % crystal violet 
(B). Plates were washed 10 x after the staining and bound crystal violet was extracted with 10 % acetic acid / 40 
% ethanol. The absorbance of a 1:10 dilution was measured at 590 nm. Error bars indicate mean value of 
triplicates ± SEM.  
 
3.1.5.2 Biofilm growth of S. aureus influences the occurrence of Triiso and pOxi  
            on the bacterial surface  
To investigate, if the pH has an influence on the retention of the proteins on the 
bacterial surface, strain JE2 was grown under biofilm conditions. The detached and 
resuspended culture was divided into two samples and the harvested cell pellets 
were incubated in PBS with pH values of 5 and 7.5, respectively for one hour. After 
centrifugation the supernatants were collected and precipitated with TCA. Equal 
volumes of both resuspended precipitates were blotted on nitrocellulose.  
Although both samples were treated equally, as expected a higher amount of Triiso 
was detected in the sample washed at neutral pH (Figure 3.12A).  
With the biofilm conditions it was possible to identify pOxi with a size of 52 kDa (B). 
Compared to the experiments after planktonic growth described in 3.1.4.1, where 
neCWS was prepared (see figure 3.7C), pOxi could be detected with anti-pOxi moAb 
D3 in such a cell surface protein fraction for the first time. However, no differences in 
the two samples treated with the two different pH values were observed. 
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Figure 3.12: Comparison of Triiso’s occurrence in the isolated cell wall-associated protein fraction at low 
and neutral pH after biofilm growth of S. aureus. S. aureus was grown under biofilm conditions in TSB + 0.5 % 
Glucose for 24 h. The harvested cell pellet was resuspended in PBS of a pH of 5 and 7.5, respectively for 1 h. 
After centrifugation the supernatants were collected and precipitated with 10 % TCA. The precipitates were 
washed and dissolved in 8 M Urea. 30 µl of each sample was blotted on nitrocellulose and incubated with first the 
respective moAb and then anti-mouse-HRP conjugate. The blot was developed by chemiluminescence.                          
A: S. aureus ATCC29213, anti-Triiso moAb H8; B: S. aureus ΔspA, anti-pOxi moAb D3. 
 
In summary, biofilm conditions have an influence on the occurrence of the cell wall-
associated proteins Triiso and pOxi. At low pH conditions that are present in the 
medium after biofilm growth, a higher amount of Triiso remains on the S. aureus 
surface, compared to the conditions at neutral pH.  
In contrast, changes in the pH have no influence on the occurrence of pOxi, whereas 
biofilm conditions are required for its detection by Western blot.  
 
3.1.5.3 Binding of moAbs H8 and 16-2 to the S. aureus surface after biofilm  
            growth 
It was not possible to detect a binding of anti-Triiso moAb H8 and anti-hp2160 moAb 
16-2 to the surface of whole S. aureus cells after planktonic growth. For further 
binding analyses of moAbs H8 and 16-2 by flow cytometry, strain ΔspA was grown 
for 40 h under biofilm conditions. Additionally, binding of anti-pOxi moAb D3 and anti-
Triiso moAb C4 were also analyzed after biofilm growth, although these moAbs 
already showed a surface binding after planktonic growth (compare figures 3.8, 
3.10). The detached biofilm cells were harvested and washed at a pH of 5.0 for a few 
times. The cell pellet was then fixed with 3 % paraformaldehyde and then incubated 
with the respective moAb and the PE-conjugated secondary antibody. 
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Compared to negative control (black line) a strong binding was detected with anti-
Triiso moAb H8 (red line in figure 3.13A), as well as with anti-hp2160 moAb 16-2 (red 
line in B). Because the moAb H8 epitope peptide was not characterized yet, a 
competition experiment of moAb H8 binding was excluded. To prove a specific 
binding of the moAbs a monoclonal antibody against 6 x histidine produced in mouse 
was used as a negative control (green line). The signal was as negative as the 
sample with just the secondary antibody, which demonstrates the specific binding of 
moAbs H8 and 16-2 to the S. aureus cell surface grown under biofilm conditions. 
A binding of anti-Triiso moAb C4 (orange line) and anti-pOxi moAb D3 (blue line) to 
the S. aureus surface was presented in figures C-D. To prove a specific binding to 
biofilm grown S. aureus a competition with the available pOxi and TriisoC4 epitope 
peptides (green lines) was done. The respective antibody was preincubated with the 
epitope peptide and then added to the bacterial cells. In comparison to the bacteria 
where just the moAb was added the fluorescent signal was decreased.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13: Specific binding of moAbs to the surface of S. aureus ΔspA after biofilm growth. S. aureus 
ΔspA was grown for 24 h under biofilm conditions. A-B: Detached and washed cells (pH 5.0) were fixed and 
incubated with the respective anti-S. aureus moAb (red line), mouse anti-His-tag moAb (green line) or the same 
volume of PBS (black line) for 30 min at 37 °C. C-D: Cells were incubated with anti-Triiso moAb C4 (orange line) 
or anti-pOxi-moAb D3 (blue line). For a competition of moAb binding they were incubated by the respective 
epitope peptide (green line). An incubation with 2 µg of F(ab)2 anti-mouse-IgG-PE-Cy5.5 followed. Samples were 
measured by flow cytometry. 
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3.1.6 Antigen function on surface and mode of action of monoclonal  
         antibodies 
The three moAbs D3 (pOxi), H8 (Triiso) and 16-2 (hp2160) were selected because of 
their protective function in the murine sepsis models after passive immunization.  
The binding of the three moAbs have been detected on the S. aureus surface, so a 
further in vitro characterization of the potential antigen function and the influence of 
the moAbs towards these functions was started. This included an analysis, if moAbs 
trigger opsonophagocytosis by phagocytic cells isolated from eukaryotes. 
Additionally, an investigation of the moonlighting function of the respective antigen as 
a kind of virulence factor and a possible inhibition by its moAb was performed.     
 
3.1.6.1 MoAbs do not promote opsonophagocytosis by human neutrophils 
The three humanized moAb candidates (humAbs) were first analyzed regarding their 
potential to induce an opsonophagocytosis by human neutrophils.  
Additionally, anti-pOxi and anti-Triiso IgGs were enriched from polyclonal human 
intravenous IgG preparation (IVIG) for a comparison to the monoclonal antibodies. 
The enrichment was executed by affinity chromatography using a NHS-column 
coupled with the respective recombinant proteins pOxi or Triiso. Bound IgGs from 
IVIG were eluted by a low pH and buffered to neutral pH. IVIG was used as a positive 
control because it was already proven that it contains opsonizing antibodies to         
S. aureus (Glowalla et al., 2009). Human PMNs were isolated from whole blood of a 
volunteer using a Ficoll gradient. S. aureus ATCC 29213-GFP (MOI 10) was 
incubated with the neutrophils without addition of any antibody source, as a negative 
control. The investigated antibodies were pre-incubated with ATCC 29213-GFP in a 
concentration of 100 µg/ml for opsonization. Neutrophils were analyzed by flow 
cytometry. A positive signal describes the fraction of cells with internalized ATCC 
29213-GFP. The percentage of fluorescent particles was calculated (subtraction of 
negative control from the respective GFP-positive sample), as shown in the 
histograms of figure 3.14. IVIG preparation (A) efficiently triggered opsonophago-
cytosis, resulting in 54 % GFP-positive neutrophils. A similar result was detected with 
anti-Triiso IgGs (C) isolated from IVIG preparation (55 % GFP-positive neutrophils). 
With specific IgGs for pOxi (B) opsonophagocytosis was increased (66 % GFP-
positive neutrophils).  
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Although polyclonal IgGs clearly promote phagocytosis no enhanced uptake of GFP-
positive S. aureus in neutrophils was detected with the humanized monoclonal 
antibodies against hp2160, pOxi and Triiso (D-F).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14: Opsonophagocytosis of S. aureus ATCC 29213-GFP by human neutrophils. Bacteria were 
grown to an OD600 of 0.3 and opsonized with 100 µg/ml of human intravenous immunoglobulin preparation (IVIG), 
polyclonal antibody enriched from IVIG (blue line), humanized monoclonal antibody (red line) or without antibody 
as negative control (black line) for 30 min at 37 °C. Opsonized bacteria (MOI 10) were incubated with human 
PMNs three times for 2 min at 37 °C. Before every incubation step they were centrifuged at 300 x g for 2 min. 
Grey filled lines represent just human PMNs. Green fluorescence was measured by flow cytometry. Given 
percentages of GFP-positive human PMNs (marked region) represent the fraction of cells with internalized              
S. aureus. 
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3.1.6.2 MoAbs do not promote opsonophagocytosis by murine BMDM’s 
The potential of the three moAbs to induce the opsonophagocytic activity by murine 
bone marrow-derived macrophages was also investigated. 
Tibia and femur of BALB/c mice were prepared for the isolation of bone marrow. 
Monocytes were differentiated by recombinant macrophage colony-stimulating factor 
(mCSF). S. aureus ATCC 29213-GFP was opsonized for 30 min with the moAbs, 
respectively. ATCC-GFP (MOI 15) was then incubated with the macrophages for     
90 min at 37 °C. Samples were measured every 15 min by flow cytometry. 
As shown in figure 3.15 an uptake of GFP-expressing bacteria in macrophages was 
measured after 30 min (A). This uptake was stronger after 90 min (B). The grey filled 
line respresents BMDM’s that were not incubated with bacteria. No differences 
between the negative control where non-opsonized bacteria were incubated with 
BMDM’s and the samples opsonized with moAb D3 (blue), moAb H8 (red) or moAb 
16-2 (green) were detected, which proves that the generated moAbs do not trigger 
the uptake of S. aureus by phagocytic cells.  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15: Opsonophagocytosis of S. aureus ATCC 29213-GFP by murine BMDM’s. Bacteria were grown 
to an OD600 of 0.3 and opsonized with 100 µg/ml of a murine antibody or without an antibody as negative control 
(black line) for 30 min at 37 °C. Opsonized bacteria (MOI 15) were incubated with BMDM’s for 30-90 min at 37 °C. 
Grey filled line represents BMDM’s without bacteria. Green fluorescence was measured by flow cytometry. A: 30 
min incubation; B: 90 min incubation. Green line: anti-hp2160 moAb16-2; red line: anti-Triiso moAb 16-2; blue 
line: anti-pOxi moAb D3. 
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3.1.6.3 Enzymatic activity of Triiso 
For a further characterization, the enzymatic activity of Triiso was analyzed. Triiso 
catalyzes the reversible conversion of dihydroxyacetone-phosphate into 
glycerinaldhyde-3-phosphate as a part of the glycolysis. Although Triiso usually acts 
as a cytoplasmic protein, it was identified on the cell surface of S. aureus (Furuya et 
al., 2009; compare to 3.1.5.1). Besides Triiso, several enzymes of the glycolysis were 
detected on the surface, such as GAPDH and enolase. According to Henderson and 
Martin (2011), glycolysis might also happen on the cell surface for ATP generation. 
After the determination of an enzymatic activity it should be proven, if anti-Triiso 
moAb H8 influences Triiso’s activity by a possible binding at the active site of the 
enzyme.  
The in vitro activity assay was coupled to the oxidation of NADH by glycerin-3-
phosphate dehydrogenase and measured as change in absorbance at 340 nm. The 
activity of recombinant Triiso as well as in whole cell lysate (WCL) and cell wall 
associated protein fraction (neCWS) of strain USA300 was measured as 
demonstrated in figure 3.16A. An enzymatic activity was measured in all samples, 
which proved enzymatically the occurrence of Triiso in WCL and neCWS. 
In figure 3.16B the enzymatic activity of recombinant Triiso was analyzed after a 
preincubation of 30 ng Triiso with 1.25 - 40 µg of moAb H8. As shown in the graph 
moAb H8 was not able to inhibit the enzymatic activity of recombinant Triiso. 
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Figure 3.16: Enzymatic activity of Triiso. A: 0.9 mM glycerinaldehyde-3-phosphate, 25 µg NADH and 4 ng 
recombinant Triiso or 4 µg non-enzymatic cell wall supernatant (neCWS) or whole cell lysate (WCL) were 
incubated in a final volume of 250 µl in a 96-well-plate (duplicates). Reaction was started after adding 2.5 mg 
glycerin-3-phosphate dehydrogenase. B: 30 ng of recombinant Triiso was incubated with 1.25-40 µg of anti-Triiso 
moAb H8. Then the same reaction as described in A was started. The absorbance was measured at 340 nm. 
A B 
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3.1.6.4 Secretion of Triiso  
For a further characterization of S. aureus’ Triiso it was analyzed if the protein is 
secreted from the bacterial cell. Triiso’s sequence does not contain any known signal 
motif, which is responsible for a secretion, such as LPXTG.  
While preparing the extracts of the cell wall-associated protein fraction in 3.1.4.1 after 
planktonic growth, the medium supernatant was collected, sterile filtrated and 
precipitated over night with 10 % TCA. The resulting pellet was washed and 
resuspended in 8 M urea.  The medium supernatant containing the secreted protein 
fraction (sPF) was blotted together with neCWS on a membrane, followed by an 
incubation with one of the moAbs. In contrast to hp2160 and pOxi (not shown), Triiso 
was detected as a secreted exoenzyme in the medium (Figure 3.17).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.1.6.5 Interaction between Triiso and plasminogen  
According to Furuya and Ikeda (2011) Triiso from S. aureus is able to bind 
plasminogen from human blood. Plasminogen can be activated to plasmin by the 
staphylococcal enzyme staphylokinase (SAK), which initiates fibrinolysis. Together 
with the process of blood coagulation by the enzyme coagulase, the initiation of 
fibrinolysis is important for the proliferation of S. aureus in human blood and tissues. 
Because of its moonlighting function of plasminogen binding at the bacterial cell 
surface Triiso seems to interact in the process of plasminogen activation. In this 
case, Triiso would be a virulence factor, which possibly can be inhibited by anti-Triiso 
moAb H8.  
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Figure 3.17: Extracellular Triiso from         
S. aureus. S. aureus ΔspA was grown to an 
OD600 of 0.6. The harvested cell pellet was 
resuspended and prepared with LiCl. The 
medium supernatant was precipitated with    
10 % TCA. The precipitates were washed and 
dissolved in 8 M Urea. 30 µl of each sample 
was blotted on nitrocellulose and incubated 
with moAb H8 as primary and anti-mouse-
HRP conjugate as secondary antibody. The 
blot was developed by chemiluminescence.  
1: non-enzymatic cell wall supernatant;           
2: Secreted protein fraction derived from 
medium supernatant. 
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The binding of plasminogen to Triiso had to be confirmed before a possible inhibition 
of this interaction by anti-Triiso moAb H8 was investigated. Figure 3.18 shows a Far 
Western blot, where 0.5 and 2 µg of recombinant Triiso were blotted. In figure 3.18B 
the blot was incubated with 500 nM of human plasminogen. An interaction between 
Triiso and plasminogen was proved, because bound plasminogen could be detected 
by anti-plasminogen-HRP conjugate. The blotted amount of 0.5 µg of Triiso was the 
lowest amount where an interaction with plasminogen was detected.  
In 18A the blot was incubated with anti-Triiso moAb H8 before the same amount of 
plasminogen was added while the blot on the right side remained in blocking milk 
without antibody. Although both blots were developed together a lower signal was 
measured in figure 3.18A. This result was a positive hint for an inhibition of 
plasminogen binding by moAb H8, but a quantification and a titration with different 
dilutions was easier in ELISA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.18: Interaction between Triiso and plasminogen in Far Western blot analysis. 2 µg and 0.5 µg of 
recombinant Triiso were blotted on nitrocellulose. The membrane was blocked and incubated with 500 nM of 
human plasminogen. A: The blot was incubated with anti-Triiso moAb H8. B: Incubation in blocking milk w/o 
antibody. Both blots were then incubates with human plasminogen. Detection of bound plasminogen was 
performed with anti-plasminogen-HRP. For a comparison both blots were developed together under exactly same 
conditions.  
 
For an analysis of an interaction between plasminogen and Triiso by ELISA 
plasminogen was immobilized in different concentrations between 0 and 10 µ/ml to a 
maxisorp 96-well plate. The plate was incubated with different dilutions of Triiso to 
titrate the best conditions for the plasminogen interaction. A detection followed by 
anti-His-tag-HRP conjugate that binds to recombinant His-tagged Triiso. As shown in 
figure 3.19A, binding of Triiso to coated plasminogen was weak but increased in a 
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dose-dependent manner with rising the Triiso concentration. The binding signal was 
not dependent on the plasminogen concentrations used. The different concentrations 
of Triiso did not show any binding signals without plasminogen. 
In a further experiment a concentration of 5 µg/ml plasminogen for coating and a 
concentration of 150 µg/ml Triiso was used for the incubation. Before Triiso was 
added the coated plasminogen was preincubated with different dilutions of moAb H8 
(0 and 150 µg/ml). As shown in figure 3.19B, a decrease in absorbance in presence 
of moAb H8 was not detected.   
 
 
 
1 10 100 1000
0.0
0.1
0.2
0.3
0.4
5 µg/ml plg 10 µg/ml plgw/o plg
µg/ml Triiso
A4
50
0 µ
g/m
l
0.0
5 µ
g/m
l
1.2
5 µ
g/m
l
0.2
4 µ
g/m
l
6 µ
g/m
l
30
 
µg
/m
l
15
0 µ
g/m
l
0.00
0.05
0.10
0.15
0.20
0.25
moAb H8 concentration
A4
50
 
 
Figure 3.19: Interaction between Triiso and Plasminogen in ELISA. A: 0, 5 or 10 µg/ml of human plasminogen 
was immobilized to a maxisorp plate. After blocking, the plate was incubated with different concentrations of 
recombinant Triiso. For a detection of bound Triiso anti-His-tag-HRP was used. B: The same protocol as in A in 
the presence of anti-Triiso moAb H8. A Triiso concentration of 150 µg/ml was used. Before Triiso was added to 
the plate it was supplemented with different concentrations of moAb H8 for 30 °C at room temperature. 
 
The experiment presented in figure 3.19B showed a binding of Triiso to human 
plasminogen but no inhibition of this binding with moAb H8 was detected. Therefore, 
moAb H8 does not seem to interfere with the plasminogen binding site. If the 
activation of plasminogen was nevertheless impaired needs to be further examined. 
Furuya and Ikeda (2011) already showed an inhibition of the plasminogen activation 
in presence of Triiso from S. aureus.  
To investigate the effects of recombinant Triiso on the activation of plasminogen, an 
enzymatic activity assay was performed according to Furuya and Ikeda (2011) with 
modifications. Plasminogen was activated by SAK into plasmin that hydrolyses the 
substrate S-2251. This could be measured as a change in absorbance at 405 nm. An 
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increase in absorbance indicated plasmin activity. In figure 3.20A the amount of SAK 
that is necessary for an activation of plasminogen was titrated. With a final 
concentration between 250-500 ng/ml a plasmin activity was measurable. Below 250 
ng/ml of SAK the plasmin activity would be too low to see an effect of recombinant 
Triiso in the following assay. So, 300 ng/ml of SAK was used for further tests. 
Therefore, Triiso was preincubated with plasminogen for 30 min at room 
temperature. Then 300 ng/ml of SAK were added. 
In the presence of Triiso no changes in plasmin activity were measured, compared to 
the sample without Triiso (B). Different amounts of Triiso were tested up to a final 
concentration of 160 µg/ml. In contradiction to Furuya and Ikeda (2011), Triiso does 
not influence plasminogen activation in this set-up. Because of the results further 
investigations of the influence of moAb H8 could not be performed. The activation of 
plasminogen was also not affected by different concentrations of whole S. aureus 
ATCC29213 cells (planktonic growth) that were pre-incubated with plasminogen (C). 
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Figure 3.20: Effect of Triiso on plasminogen 
activation by staphylokinase (SAK).  
A: Different concentrations of recombinant 
human SAK between 31.25-500 ng/ml were 
incubated with 0.02 nmol human plasminogen 
(plg). B: Different concentrations of Triiso 
between 10-160 µg/ml were pre-incubated with 
plg. 300 µg/ml of SAK were added. C: Different 
concentrations of S. aureus ATCC29213 cells 
between 1x107 and 2x109 CFU/ml were pre-
incubated with plg. 500 µg/ml of SAK were 
added. The reaction was started after adding 
0.12 nmol substrate S-2251 in a final volume of 
100 µl. The absorbance at 405 nm was 
measured for 3 h at 10 min intervals. 
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3.1.6.6 Deletion of pOxi leads to an impaired growth and virulence of S. aureus  
Because of the existence of the deletion mutants ΔpOxi and Δhp2160 the two 
antigens did not seem to be essential, whereas a Triiso deletion mutant was not 
found. The exponential growth rate of the two deletion mutants ΔpOxi and Δhp2160 
compared to the wildtype strain JE2 (Figure 3.21A) was analyzed by measuring the 
OD at 600 nm. Compared to the wildtype, Δhp2160 showed a similar growth rate, 
whereas the growth rate of ΔpOxi was strongly retarded but not completely inhibited. 
The protein pOxi converts protoporphyrinogen to XI protoporphyrin XI that is the 
precursor of protoheme, also called hemin. Hemin is the precursor of heme, an 
important cofactor of several proteins, such as cytochrome or catalase, which are 
required for the aerobic growth of S. aureus.  
The ΔpOxi mutant also showed a slow growth on agar plates. After 2-3 days of 
growth at 37 °C small colony variants were detected on the plate. 
In figure 3.21B different concentrations of hemin were added to the medium before 
inoculation with ΔpOxi and wildtype. Whereas hemin does not influence the growth 
rate of the wildtype, ΔpOxi’s growth rate picked up by increasing the hemin 
concentration.  
Because of the negative influence of the pOxi deletion on S. aureus growth the 
protein seems to be important for the vitality of the organism. In a further experiment 
it was tested in vivo, if the pOxi deletion also influences the virulence of S. aureus. 
Therefore, BALB/c mice (n = 6) were challenged i.p. with 6 x 106 CFU of S. aureus 
JE2. A second group received an equal dose of ΔpOxi. Mice were monitored for two 
days. After the first day 50 % of mice challenged with wildtype died, whereas every 
mouse of the ΔpOxi group survived (Figure 3.22). Even inocula of 1.2 x 107 ΔpOxi 
did not lead to a lethal effect (data not shown). This proved an influence of pOxi on 
the virulence of S. aureus. 
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Figure 3.21: Comparison between exponential growth of S. aureus wildtype and deletion mutants.                     
A: Overnight cultures of S. aureus JE2 and ΔpOxi and Δhp2160 were inoculated 1:100 into LB medium and 
incubated at 37 °C and 220 rpm. Optical density was measured every hour at 600 nm. The samples were diluted 
1:10 for the measurement. B: Same procedure as described in A, but hemin was added in different concentrations 
to a respective culture of JE2 and ΔpOxi before inoculation. 
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Figure 3.22: Survival of mice challenged with S. aureus ΔpOxi and wildtype. BALB/c mice (n = 6) were 
challenged i.p. with 6 x 106 CFU of S. aureus JE2 (red line) or ΔpOxi (blue line). Survival was monitored for 2 
days. P-value was determined by Mantel-Cox test: p = 0.055. 
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3.1.6.7 Binding of recombinant proteins to the surface of S. aureus upon  
            biofilm growth 
In 3.1.5.3 it was shown that binding of moAbs to the cell surface of biofilm grown     
S. aureus was competed by the available epitope peptides. For a competition of anti-
Triiso moAb H8 binding the whole protein should be used as a competitor.  
The recombinant protein Triiso was preincubated with moAb H8 and then added to 
biofilm grown S. aureus ΔspA. For a comparison moAb H8 was incubated with ΔspA 
on its own. Unexpectedly, compared to the moAb H8 binding at the bacterial surface 
as presented in figure 3.23A (orange line), the fluorescence signal in presence of 
Triiso (red) was slightly increased. A similar result was also shown with pOxi, which 
was preincubated with moAb D3 (B). Compared to moAb D3 on its own (green), the 
binding to the S. aureus surface was strongly increased upon preincubation of moAb 
D3 with recombinant pOxi (light blue). The binding of the recombinant proteins to the 
bacterial surface was also detected with a murine anti-His6-tag antibody as shown in 
figures C-D. Instead of moAbs H8 and D3, this antibody can only bind to the 
recombinant proteins, but it is not able to bind to the surface on its own (dark blue 
line in C and D). An increased fluorescence signal in presence of Triiso (red), as well 
as pOxi (light blue) incubated with anti-His6-tag antibody was measured. These 
results are a clear hint that the recombinant proteins are both able to bind to the      
S. aureus surface after adding them from outside. 
 
 
 
 
 
 
 
 
 
 
 
 
 
             
  
 
 
Figure 3.23: Specific binding of recombinant Triiso and pOxi to the S. aureus surface upon biofilm 
growth. Strain ΔspA was grown for 24 h under biofilm conditions. Bacteria were detached and washed. A-B: 
Bacterial cells were incubated with moAb H8 (orange) or D3 (green). Triiso or pOxi was preincubated with moAb 
H8 (red) or D3 (light blue). C-D: Bacteria were first incubated with Triiso (red) or pOxi (light blue) and then with 2 
µg of anti-His-tag moAb or just with murine anti-His-tag moAb alone (dark blue). An incubation with anti-mouse-
IgG-AlexaFluor488 followed for a detection by flow cytometry. Black line: anti-ms-IgG-AlexaFluor488. 
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3.1.6.8 Adherence of pOxi to eukaryotic cells 
Recombinant pOxi showed a strong binding to the surface of S. aureus after biofilm 
growth. A specific binding of pOxi to HeLa cells as shown in figure 3.24 was already 
proven in our lab by Dr. Sonja Mertins. A monolayer of HeLa cells was incubated with 
different amounts of recombinant pOxi and washed then three times. The cells were 
detached and lysed. Equal amounts of the lysate were blotted on a nitrocellulose 
membrane. The membrane was then incubated with anti-His-tag-HRP conjugate for 
the detection of pOxi and with anti-β-Actin-HRP conjugate to ensure that equal 
amounts of the cell lysate were used. The binding of pOxi was inhibited after the 
addition of 10 µg of anti-pOxi moAb D3, whereas the addition of an irrelevant IgG2a 
antibody does not influence the binding of pOxi to the cells. The same experiment 
was done with Huvec cells (endothelial). Triiso did not show any or just a very weak 
binding to eukaryotic cells.  
 
 
 
 
   
 
 
Figure 3.24: Specific binding of recombinant pOxi to the surface of HeLa cells and inhibition by anti-pOxi 
moAb D3. 100 µg/ml of recombinant pOxiHis6 was preincubated for 15 min at 37 °C with different concentrations 
of moAb D3, an irrelevant IgG2a antibody or just PBS. A monolayer of HeLa cells was then incubated with this 
mix for 5h and washed 3x. Cells were detached and lysed. Equal amounts of the lysates were blotted on a 
nitrocellulose membrane. The membrane was then incubated with anti-His-tag HRP conjugate. The same 
membrane was stripped and incubated with anti-β-Actin-HRP. Data from S. Mertins. 
 
To investigate the binding of S. aureus to eukaryotic cells, both were mixed, 
incubated and then analyzed by flow cytometry as shown in figure 3.25. In 3.25A the 
gated population of HeLa cells is shown as a control. Strain ATCC 29213-GFP was 
grown under biofilm conditions. The detached and washed bacteria were added to 
the HeLa cells at different MOI’s. Figure 3.25B shows ATCC 29213-GFP incubated 
with the cells at a MOI of 5. The percentage of fluorescent bacteria bound to HeLa 
cells was shown by dot plots. By increasing the MOI a higher percentage of positive 
particles was measured in the HeLa population. Pretests showed that no binding 
could be measured anymore with a MOI below 5 (data not shown). Therefore, MOI 5 
was chosen to demonstrate a competition effect after adding the moAbs to S. aureus.  
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In presence of anti-pOxi moAb D3, binding of GFP-expressing S. aureus to HeLa 
cells was reduced from 21.2 % to 13.7 % (C) and with anti-Triiso moAb H8 to 17.6 % 
(F). To analyze an influence of the proteins on host cell adherence the bacteria were 
incubated with recombinant Triiso or pOxi, respectively. An increase to from 21.2 % 
to 44.4 % of S. aureus binding to HeLa cells after the incubation with pOxi (D) was 
shown, in contrast to Triiso (G), where no increase was measured. A preincubation of 
pOxi with moAb D3 (before added to S. aureus) lead to a reduced binding from    
44.4 % to 2.1 % (E). This proves the specific interaction of recombinant pOxi 
between S. aureus and HeLa cells, which can be inhibited by moAb D3. A pre-
incubation of Triiso with moAb H8 does not show any changes in binding of             
S. aureus to HeLa cells (H). In summary, the protein pOxi showed an influence on 
the adhesion of S. aureus to eukaryotic cell lines, whereas Triiso does not seem to 
influence an interaction with the host. After addition of anti-pOxi moAb D3 the binding 
to HeLa cells was strongly decreased. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.25: Influence of the interaction between S. aureus and HeLa cells in presence of moAbs and 
recombinant proteins. S. aureus ATCC29213-GFP was grown under biofilm conditions. The bacteria were 
preincubated with PBS (B) moAb D3 (C) or H8 (F), the recombinant protein pOxi (D) or Triiso (G) or a mix of 
preincubated pOxi with moAb D3 (E) or Triiso with moAb H8 (H). The bacteria were then incubated with HeLa 
cells (MOI 5). The HeLa cells were fixed and analyzed by flow cytometry. The percentage of fluorescent bacteria 
bound to HeLa cells was shown in the dot plots. HeLa cells w/o bacteria served as control for analysis set-up (A). 
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3.2 Active immunization with epitope peptides 
3.2.1 Immunization with epitope peptides induces an antigen-specific immune  
         response 
The strategy described here, is an active immunization with the epitopes of our 
already investigated monoclonal antibodies (moAbs) that showed protection in our 
murine sepsis model after passive immunization. Vaccination with the synthesized 
epitope peptides shown in chapter 3.1 should induce the production of the same 
protective IgGs by the organism’s immune system itself.   
Synthesized pOxi-, hp2160- and TriisoC4-peptides were either conjugated to the 
carrier protein bovine serum albumin (BSA) or the protein keyhole limpet hemocyanin 
(KLH) isolated from Megathura crenulata because the peptides themselves were too 
small for the generation of an immune response.  
Groups of BALB/c mice (n = 2) were initial immunized with 80 µg of the respective 
peptide-conjugate using Freund’s complete adjuvant (FCA) and boosted twice after 
four weeks with 50 µg of peptide-conjugate using Freund’s incomplete adjuvant 
(FIA).  
 
 
 
Figure 3.26: Schematic overview of the immunization model to investigate IgG humoral immune 
response. BALB/c mice (n = 2) received s.c. an initial and two booster immunizations every four weeks. Blood 
samples were collected two weeks post immunization and every week until 50 days post last boost for an analysis 
of serum IgG titer.  
 
Blood samples from mice were collected at vena facialis prior to immunization 
(negative control) and at indicated time points post immunization until 50 days post 
last boost (Figure 3.26). Serum IgG titer against the whole respective antigen was 
quantified by serial dilutions in ELISA. Therefore, recombinant hp2160, pOxi or Triiso 
was immobilized on a 96-well maxisorp plate, which was then incubated with the 
different serum dilutions. Anti-mouse-HRP was used as detection antibody.  
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The titer is given as the dilution corresponding to the half maximal absorbance at 450 
nm. The serum titer of mice treated with BSA as a control group remained non-
reactive for the proteins hp2160, pOxi and Triiso. An induction of an antigen-specific 
IgG production by vaccination with peptide-conjugates pOxi-BSA, hp2160-BSA and 
TriisoC4-BSA was already detected after the initial immunization (Figure 3.27). A 
rapid increase after the first boost was measured with all peptides followed by a 
moderate increase of half a log after the second boost. The antigen-specific IgG titer 
in murine blood still remained at the same level 50 days after the last booster 
immunization.  
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Figure 3.27: Antigen-specific IgG titer kinetic 
during active immunization with epitope 
peptides. BALB/c mice (n = 2) were vaccinated 
with the respective peptide-conjugate pOxi-BSA, 
hp2160-BSA or TriisoC4-BSA emulsified with FA 
and boosted twice. Blood was collected prior to 
(not shown) and post immunization and every 
week after the last boost. Sera were analyzed for 
antigen-specific IgGs by ELISA. A-C: Logarithmic 
IgG titer kinetic during immunization. IgG titer is 
calculated by multiplication of the half maximal 
absorbance at 450 nm with the corresponding 
dilution factor. Error bars indicate mean value of 
mouse serum titers ± SEM. 
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3.2.2 Mono- and bivalent immunization with epitope peptides leads to signifi- 
          cant higher bacterial clearance in organs after S. aureus infection 
Larger groups of mice (n = 10-12) were immunized with the respective epitope 
peptide conjugated to BSA or KLH emulsified with Freund’s adjuvant (FA). The 
number of mice in one experiment was conformed to the availability of mice at the 
ZMMK. 80 µg of antigen for the initial and 50 µg for the booster immunizations were 
used. After determination of an antigen-specific immune response of every mouse, 
all groups were challenged i.p. with a sublethal dose of the clinically relevant 
community-acquired (CA) MRSA strain USA300. The bacterial titer was calculated by 
Casy Cell Counter and mixed with 5 % mucin from porcine stomach. This method is 
based on our already established infection model after passive immunization, where 
mucin was used to increase bacterial virulence allowing application of a lower          
S. aureus CFU-titer.  Mice were sacrificed after 24 h, organs were prepared and 
homogenized. Several dilutions were plated out to determine bacterial density the 
following day (Figure 3.28).  
 
     
 
Figure 3.28: Schematic overview of the immunization model to investigate the bacterial load in organs or 
survival of mice after S. aureus infection. BALB/c mice (n = 10-12) received s.c. an initial and two booster 
immunizations every four weeks. Blood samples were collected two weeks post immunization. After the last boost 
mice were challenged i.p. with a sublethal dose of S. aureus USA300. After 24 h mice were sacrificed and organs 
were prepared for a determination of the bacterial density. In case of a survival experiment mice were infected 
with a lethal dose and they were monitored for 6 days. 
 
3.2.2.1 Vaccination with hp2160 peptide 
Mice were vaccinated with the corresponding epitope of anti-hp2160 moAb 16-2. The 
synthesized peptide was conjugated to KLH, and therefore the control group was 
immunized solely with the protein KLH. Serum of every mouse was analyzed two 
weeks after the last booster immunization to determine a specific IgG titer against the 
whole protein hp2160 (Figure 3.29A). Every hp2160-KLH immunized mouse showed 
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an antigen-specific immune response. The control mice sera showed specific IgGs 
against KLH (not shown), but they were non-reactive for hp2160 (hp2160-KLH vs. 
KLH, p = 0.0002). The sera of mice were pooled and used for detection of hp2160 in 
the cell wall-associated protein fraction (neCWS) of S. aureus ΔspA, as well as in the 
whole cell lysate (WCL) of S. aureus JE2, as presented in figure 3.29B. The serum 
IgGs showed an unspecific binding to protein A in WCL of the wildtype strain JE2 but 
also a specific binding to staphylococcal hp2160. 
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Figure 3.29: Immune response after immunization with hp2160-KLH. BALB/c mice (n = 10) were vaccinated 
with hp2160 epitope peptide conjugated to KLH or with KLH as a control emulsified with FA. Serum of every 
mouse was collected after the last boost and analyzed for hp2160-specific IgGs by ELISA and Western blot. A: 
Logarithmic antigen-specific IgG titer. The titer is given as the dilution corresponding to the half maximal 
absorbance at 450 nm. P-value was analyzed by Mann-Whitney test: p ≤ 0.001 = ***. Each data point represents 
an individual animal. B: neCWS and whole cell lysate (WCL) of S. aureus ΔspA or wt, respectively, were blotted 
on a nitrocellulose membrane. Serum was pooled and incubated with the membrane, followed by detection with 
anti-mouse-HRP. 
 
 
After the last booster immunization mice were challenged i.p. with 4.5 x 106 CFU of 
S. aureus USA300. After infection with this sublethal dose, mice were monitored for 
24 h and then sacrificed for preparation of liver, spleen and kidneys.     
The quantification of the CFU presented in individual organs of immunized mice post 
S. aureus infection demonstrated that immunization with hp2160 epitope peptide 
resulted in lower bacterial densities in all prepared organs (Figure 3.30). Compared 
to spleen (p = 0.0892) and kidneys (p = 0.2176) these reductions were statistically 
significant in liver (p = 0.0355).  
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Figure 3.30: Bacterial load in organs of mice 
after challenge with S. aureus upon monovalent 
immunization with hp2160 peptide.  
BALB/c mice (n = 10) were immunized with hp2160 
epitope peptide conjugated to KLH (green) or with 
KLH alone (black) as a control. After the second 
boost, mice were challenged i.p. with 4.5 x 106 CFU 
of S. aureus USA300 mixed with 5 % mucin from 
porcine stomach. Bacterial density of liver (A), 
spleen (B) and kidneys (C) was determined. Each 
data point represents an individual animal. P-values 
were analyzed by Mann-Whitney test. p ≤ 0.001 = 
***; p = 0.01 = **; p ≤ 0.05 = *; ns = not significant. 
 
Two following experiments with a comparable set up (BSA as conjugate, different 
amounts of antigen) revealed the same trend, but with a significance just once in the 
spleen (p = 0.0422, not shown). 
In order to achieve a clearer difference between peptide and control group after 
challenge we also prepared organs after 48 hours in further in vivo experiments, 
compared to the preparation after 24 hours. The bacterial load was lower in liver and 
spleen and higher in kidneys. The results between peptide and control group looked 
very similar, but the colony counting after 24 h was more exactly. With these 
conclusions, we went on with organ preparation after 24 h. 
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3.2.2.2 Vaccination with pOxi peptide 
The pOxi epitope peptide conjugated to KLH produced by JPT Peptide Technologies 
arrived our lab already precipitated, so we assumed that the actual concentration of 
peptide-conjugate and therefore the available amount of peptide-conjugate per 
immunization was lower as expected.  
Groups of mice (n = 10) were vaccinated with pOxi-KLH and KLH, respectively.        
Initial and first booster immunization with pOxi-KLH resulted in a low anti-pOxi IgG 
titer (data not shown) but it was increased after the last boost (Figure 3.31A). Mice 
immunized with KLH did not show an immune response against pOxi. 
As a further analysis recombinant pOxi and KLH were blotted on a nitrocellulose 
membrane that was then incubated with the pooled serum of the mice immunized 
with pOxi-KLH. As shown in 3.31B the serum IgGs showed a specific binding to 
recombinant pOxi. A binding to KLH was also detected. Binding of serum antibodies 
to WCL and neCWS was not detected, as already described for anti-pOxi moAb D3 
(see 3.1.4.1) 
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Figure 3.31: Immune response after immunization with pOxi-KLH. BALB/c mice (n = 10) were vaccinated with 
pOxi epitope peptide conjugated to KLH or with KLH as a control. Serum of every mouse was collected after the 
last booster immunization and analyzed for pOxi-specific IgGs by ELISA and Western blot. A: Logarithmic 
antigen-specific IgG titer. The titer is given as the dilution corresponding to the half maximal absorbance at 450 
nm. Each data point represents an individual animal. P-value was analyzed by Mann-Whitney test: p ≤ 0.001 = 
***. B: Recombinant pOxi and KLH protein were blotted on a nitrocellulose membrane. Serum was pooled and 
incubated with the membrane, followed by detection with anti-mouse-HRP. 
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Figure 3.32: Bacterial load in organs of mice 
after challenge with S. aureus upon monovalent 
immunization with pOxi peptide.  
BALB/c mice (n = 10) were immunized with pOxi 
epitope peptide conjugated to KLH (blue) or with 
KLH (black) as a control. After the second boost 
mice were challenged i.p. with 4.2 x 106 CFU of S. 
aureus USA300 mixed with 5 % mucin from porcine 
stomach. Bacterial density of liver (A), spleen (B) 
and kidneys (C) was determined. Each data point 
represents an individual animal. P-values were 
analyzed by Mann-Whitney test. p ≤ 0.001 = ***; p = 
0.01 = **; p ≤ 0.05 = *; ns = not significant. 
 
After infection with 4.2 x 106 CFU of S. aureus USA300 a significant higher bacterial 
clearance in liver (p = 0.0029), spleen (p = 0.0005) and kidneys (p < 0.0001) of mice 
vaccinated with pOxi-KLH was determined, compared to the control group (Figure 
3.32). Additionally mentionable is that all mice of the pOxi-KLH group showed a 
much healthier phenotype before organ preparation compared to the mice 
immunized with KLH, which showed ruffled fur, hunched posture, loss of movement 
and weight loss. 
Comparable vaccination experiments with divergent antigen amounts and conjugates 
often demonstrated a trend for a lower bacterial load in organs of the pOxi-KLH 
group after infection but statistical significance was not reached every time (not 
shown).  
In conclusion, in vivo experiments using pOxi-KLH as vaccine resulted in a stronger 
protective effect after infection with the MRSA strain compared to hp2160-KLH 
immunization studies (see 3.2.2.1).     
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3.2.2.3 Vaccination with hp2160 and pOxi peptides  
Comparable to the animal experiment in 3.2.2.2 a third group was vaccinated with a 
combination of hp2160-KLH and pOxi-KLH to observe, whether immunization with 
both peptides potentiate the bacterial clearance in the murine tissues. 
The group was immunized with a mixture of both peptide-conjugates. Compared to 
3.2.2.2 a higher spread of the anti-pOxi IgG serum titer within the group was 
measured (Figure 3.33).  
For a comparison of serum IgG titer and CFU after infection, the same KLH control 
group as in 3.2.2.2 was used because these groups were vaccinated at the same 
time. Serum of the control group was non-reactive against hp2160 and pOxi, 
respectively (hp2160-KLH vs. KLH, p = 0.0002; pOxi-KLH vs. KLH, p = 0.0001).  
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Figure 3.33: Antigen-specific IgG titer after immunization with hp2160-KLH + pOxi-KLH. BALB/c mice (n = 
10) were vaccinated with a combination of hp2160 and pOxi epitope peptide conjugated to KLH or with KLH as a 
control. Serum of every mouse was collected after the last booster immunization and analyzed for hp2160- (A) 
and pOxi-specific IgGs (B) by ELISA. The IgG titer is given as the dilution corresponding to the half maximal 
absorbance at 450 nm. Each data point represents an individual animal. P-value was analyzed by Mann-Whitney 
test: p ≤ 0.001 = ***. 
 
 
Mice were challenged with 4.2 x 106 CFU of S. aureus USA300 as already described 
in 3.2.2.2. Compared to the control group a significant lower bacterial density was 
measured in all prepared organs of bivalently immunized mice. Statistical analysis of 
p-values (p = 0.0039 in liver, p = 0.0015 in spleen and p = 0.0468 in kidneys) 
indicates in this experiment that monovalent immunization from 3.2.2.2 with only 
pOxi-KLH (same control group) resulted in a higher significance than bivalent 
immunization (Figure 3.34). Because of a more protective effect of the pOxi peptide 
hp2160-specific IgGs pOxi-specific IgGs 
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compared to the hp2160 peptide in several experiments, pOxi was chosen to be 
used later in 3.2.2.6 (diepitope-peptide).         
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3.2.2.4 Vaccination with TriisoC4 peptide 
Immunization with the linear epitope of anti-Triiso moAb C4 was tested as a further 
candidate for an active peptide vaccine because the discontinuous epitope of anti-
Triiso moAb H8 was not determined at this time. Anti-Triiso moAb C4 achieved only a 
minor or no protective effect in the sepsis model after passive immunization but was 
not tested as often as the most protective candidate moAb H8 (unpublished data).  
The synthesized epitope peptide was conjugated to BSA and stable at 4 °C, 
compared to pOxi-KLH. Vaccination of BALB/c mice (n = 11) resulted in a strong and 
consistent IgG titer in all mouse sera against recombinant Triiso (Figure 3.35A). Two 
mice of the control group vaccinated with BSA showed a very low immune response 
against Triiso that is probably unspecific.   
Figure 3.34: Bacterial load in organs of mice 
after challenge with S. aureus upon bivalent 
immunization with pOxi and hp2160 peptide. 
BALB/c mice (n=10) were immunized with hp2160 
and pOxi epitope peptides conjugated to KLH (dark 
blue) or with KLH (black) as a control. After the 
second boost mice were challenged i.p. with 4.2 x 
106 CFU of S. aureus USA300 mixed with 5 % 
mucin from porcine stomach. Bacterial density of 
liver (A), spleen (B) and kidneys (C) was 
determined. Each data point represents an 
individual animal. P-values were analyzed by Mann-
Whitney test. p ≤ 0.001 = ***; p = 0.01 = **; p ≤ 0.05 
= *; ns = not significant. 
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In figure 3.35B recombinant Triiso as well as neCWS of S. aureus ΔspA was blotted 
on nitrocellulose, followed by incubation with the pooled serum of the TriisoC4-BSA 
immunized mice. Both, recombinant and native Triiso of S. aureus were detected by 
the serum.    
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Figure 3.35: Immune response after immunization with TriisoC4-BSA. BALB/c mice (n = 11) were vaccinated 
with TriisoC4 epitope peptide conjugated to BSA or with BSA as a control. Serum of every mouse was collected 
after the last booster immunization and analyzed for Triiso-specific IgGs by ELISA and Western blot. A: 
Logarithmic antigen-specific IgG titer. The titer is given as the dilution corresponding to the half maximal 
absorbance at 450 nm. Each data point represents an individual animal. P-value was analyzed by Mann-Whitney 
test: p ≤ 0.001 = ***. B: Recombinant Triiso and neCWS were blotted on a nitrocellulose membrane. Serum after 
the 1st boost was pooled and incubated with the membrane, followed by detection with anti-mouse-HRP. 
 
 
 
Infection with 4.75 x 106 CFU of S. aureus USA300 resulted in a lower bacterial 
density in the kidneys of TriisoC4-BSA immunized mice without any statistical 
significance as shown in figure 3.36 (p = 0.29). Bacterial load in liver and spleens of 
both groups look very similar. A possible reason is the moderate total bacterial load 
of the control group of between 1 x 103 and 1 x 105 CFU/g in liver, 1 x 102 and 5 x 104 
CFU/g in spleen and between 1 x 102 and 1 x 105 CFU/g in kidneys whereas 
bacterial loads of former experiments were showed a minimum of 5 x 104 and a 
maximum of 1 x 107 CFU/g. Although a higher bacterial titer was used for challenge 
as in the former infections, the mice showed a much healthier phenotype here.  
Altogether, vaccination with TriisoC4 peptide resulted in a very strong immune 
response it does not seem to have a protective effect after S. aureus infection. 
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3.2.3 Construction of a recombinant triepitope fusion peptide 
Using fragment-cloning, the epitope of anti-Triiso moAb H8 could be localized within 
an 11.3 kDa Triiso fragment (3.1.2), but it was still too large for a chemical peptide 
synthesis. While single hp2160 and pOxi epitope peptides were still tested in vivo, 
the genetic information encoding a triepitope peptide containing pOxi and hp2160 
epitope peptides and the Triiso fragment that includes the epitope of moAb H8 was 
cloned for expression in E. coli. With this strategy the protective effect using a 
trivalent peptide vaccine should be investigated. Furthermore, the epitope of moAb 
H8 could be tested for the first time in active immunization.  
 
3.2.3.1 Cloning, overexpression and purification of triepitope peptide 
As shown in figure 3.37 the sequences encoding the three epitopes were cloned 
consecutively in the expression vector pPSG-IBA43 containing a T7 promoter, N-
terminal Strep-tag and C-terminal His-tag. As primers pOxipep-TriisoN sense 
containing the sequence encoding the pOxi epitope and Hp2160pepTriisoC 
Figure 3.36: Bacterial load in organs challenged 
with a sublethal dose of S. aureus upon 
TriisoC4 peptide immunization. BALB/c mice 
(n=11) were immunized with TriisoC4 epitope 
peptide conjugated to BSA (orange) or with BSA 
(black) as a control. After the second boost mice 
were challenged i.p. with 4.75 x 106 CFU of           
S. aureus USA300 mixed with 5 % mucin from 
porcine stomach. Bacterial density of liver (A), 
spleen (B) and kidneys (C) was determined. Each 
data point represents an individual animal. P-values 
were analyzed by Mann-Whitney test. ns= not 
significant. 
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antisense containing the sequence encoding the hp2160 epitope were used. With 
peptide 14 (compare 3.1.2) as template, the triepitope peptide coding sequence was 
amplified and cloned into the donor vector pENTRY-IBA51 followed by homologue 
recombination into the destination vector pPSG-IBA43 using the StarGate cloning 
system according to manufacturer’s instructions (IBA, Göttingen, Germany). The 
resulting plasmid was sequenced and did not show any mutations. 
 
         
 
Figure 3.37: Cloning strategy of triepitope fusion-peptide. Sequences encoding the epitopes of anti-pOxi 
moAb D3, anti-hp2160 moAb 16-2 and Triiso fragment where epitope of anti-Triiso moAb H8 is located were 
cloned consecutively and N-terminal fused to Strep-tag and C-terminal fused to His-tag. 
 
After the cloning procedure was finished the plasmid IBA-Triepitop was transformed 
into the expression strain E. coli BL21. Overexpression of triepitope peptide was 
induced by IPTG at an OD600 of 0.6. Bacteria were cultured ON at 30 °C. The highest 
amount of peptide was found in inclusion bodies, which were prepared for affinity 
purification. While Strep-tag purification leads to a peptide yield of only 3 mg, His-tag 
purification yielded to 9 mg of triepitope peptide (14.3 kDa) (Figure 3.38). Elution 
fractions were pooled, adjusted to a concentration of 2.5 mg/ml, sterile filtrated and 
stored at 4 °C in 1 x PBS, pH = 7.5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.38: Purification of triepitope peptide via His-tag. Coomassie stained SDS-PAGE of triepitope 
purification via His-tag after heterologous overexpression and preparation of inclusion bodies. 15 µl of each 
sample was used for the protein gel. IB: inclusion body preparation, FT: flow through, W: wash fraction, E: elution 
fraction.  
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3.2.3.2 Binding analysis of moAbs to triepitope peptide 
Before vaccinating groups of mice with the purified triepitope peptide, the quality had 
to be analyzed. It had to be clarified that just this kind of specific antibodies would be 
produced in the organism that formerly provided protection against S. aureus by 
passive immunization.  First, binding of the three moAbs to the triepitope peptide was 
analyzed (Figure 3.39). The peptide was blotted onto nitrocellulose and incubated 
with the respective moAb as first and with anti-mouse-HRP as secondary antibody.  
Anti-pOxi moAb D3 (A), anti-hp2160 moAb 16-2 (B) and anti-Triiso moAb H8 (C) are 
able to bind the triepitope peptide (below 25 kDa). There were also some strong 
binding signals detected with proteins of 40 kDa and above 55 kDa. All moAbs 
showed these signals that were not unspecific signals of the secondary antibody (D). 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.39: Binding of monoclonal antibodies to triepitope peptide. 10 µg of purified triepitope peptide was 
blotted on a nitrocellulose membrane. Membrane was incubated with anti-pOxi moAb D3 (A), anti-hp2160 moAb 
16-2 (B), anti-Triiso moAb H8 (C) and without a moAb (D). Incubation with goat anti-mouse-HRP membrane 
followed. Membrane was developed using chemiluminescence reagent (ECL).  
 
 
3.2.3.3 Competition of moAb binding to the antigen by triepitope peptide 
The verification and functionality of the constructed triepitope peptides was further 
analyzed by its binding specificity to the respective moAbs anti-pOxi D3, anti-Triiso 
H8 and anti-hp2160 16-2 in competitive ELISA (Figure 3.40). The three recombinant 
proteins hp2160, pOxi and Triiso were immobilized on a maxisorp plate that was 
incubated with their respective moAb and different concentrations of triepitope 
peptide as competitor (compare to single peptides in 3.1.1, Figure 3.2).   
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A strong competition of moAb-binding to hp2160 as well as to pOxi by triepitope 
peptide was detected. The competitive ELISA also worked with Triiso, but just a 
moderate competition of moAb H8 binding was caused by the triepitope. 
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3.2.3.4 Specific IgG titer against recombinant hp2160, pOxi and Triiso after  
            immunization with triepitope peptide 
Recombinant triepitope peptide was conjugated to KLH for active immunization.  
The peptide was large enough to generate an immune response by itself. This was 
first analyzed in a small test immunization with two mice (not shown). However, the 
high immunogenicity of KLH additionally triggers the humoral as well as cellular 
immune response. For an IgG titer kinetic as already explained in 3.2.1 a group of 
mice (n = 2) was immunized with the triepitope-peptide-KLH conjugate and serum 
samples were collected for a following analysis by ELISA (Figure 3.41). It was 
possible to detect a specific IgG titer against all three antigens by immunization with 
the conjugated triepitope peptide. As presented previously for synthetic single 
peptides (see 3.2.1), serum titer also achieved the highest peak after the second 
Figure 3.40: Competition of moAb binding to 
recombinant protein by triepitope peptide.  
5 µg/mL of the respective antigen (A: hp2160, B: 
pOxi, C: Triiso) was coated on a maxisorp plate. 
Triepitope peptide was diluted and added to the 
plate. The respective moAb (A: anti-hp2160 
moAb 16-2, B: anti-pOxi moAb D3, C: anti-Triiso 
moAb H8) was added. Incubation with goat anti-
mouse-HRP followed. ELISA was developed 
using TMB substrate and absorbance was 
measured at 450 nm. 
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boost and remained high for at least 45 days. Compared to hp2160 and pOxi Triiso-
specific titer was much higher during whole immunization procedure.   
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3.2.3.5 Significant lower bacterial load in organs of mice challenged with           
            S. aureus upon immunization with triepitope peptide 
Larger groups of mice were immunized with triepitope-KLH (n = 11) and KLH (n = 12) 
as a control group. Total anti-pOxi-, anti-Triiso and anti-hp2160-IgG titer of every 
mouse was determined after the last boost (Figure 3.42). As already described in 
3.2.3.4 IgG titer against hp210 and pOxi was lower in contrast to Triiso. The serum 
IgG titer against pOxi showed a high spread between 10 and 105. Sera of KLH 
immunized mice were non-reactive for the three antigens.  
 
Figure 3.41: Antigen-specific IgG titer 
kinetic during active immunization with 
epitope peptides. BALB/c mice (n = 2) 
were vaccinated with triepitope peptide 
conjugated to KLH and boosted twice. 
Blood was collected post immunization 
and every week after the last boost. Sera 
were analyzed for antigen-specific IgGs  
(A: anti-hp2160, B: anti-pOxi, C: anti-
Triiso) by ELISA. The IgG titer is given as 
the dilution corresponding to the half 
maximal absorbance at 450 nm. Error 
bars indicate mean value of mouse serum 
titers ± SEM.  
3 Results 
 
94 
 
Tri
-
KL
H
KL
H
Tri
-
KL
H
KL
H
Tri
-
KL
H
KL
H
0
1
2
3
4
5
6
anti-pOxi anti-Triiso anti-hp2160
*** *** ***
lo
g 
10
 
Ig
G
 
tit
er
 
 
Figure 3.42: Antigen-specific IgG titer after immunization with triepitope-KLH. BALB/c mice were vaccinated 
with triepitope peptide (n = 11) conjugated to KLH (Tri-KLH) or with KLH (n = 12) as a control. Serum of every 
mouse was collected after the last booster immunization and analyzed for pOxi-, Triiso and hp2160-specific IgGs 
by ELISA. The IgG titer is given as the dilution corresponding to the half maximal absorbance at 450 nm. P-values 
were analyzed by Mann-Whitney test. p ≤ 0.001 = ***. 
 
Three days after the last blood collection, mice were i.p. challenged with 5.19 x 106 
CFU of S. aureus USA300. Organs were prepared after 24 hours. The bacterial 
colonization was significantly lower in liver and spleen, as well as in kidneys of mice 
vaccinated with triepitope peptide (Figure 3.43) compared to the KLH-immunized 
control group. In this animal experiment a third group immunized with hp2160-KLH 
was also challenged with S. aureus, which showed a higher bacterial load in the 
prepared organs, compared to the triepitope peptide (hp2160-KLH vs. KLH: p = 0,218 
in liver, p = 0,073 in spleen and p = 0,062 in kidneys, data not shown).  
In following experiments, triepitope concentration and protein carrier were changed. 
Immunization with the triepitope peptide always resulted in a significant higher 
bacterial clearance in the mouse organs, compared to control groups and a higher 
clearance compared to the groups immunized with pOxi or hp2160 peptide 
conjugates which demonstrates a more protective effect of the triepitope peptide. In 
one experiment the triepitope group just could be compared with one of these two 
groups because of the capacity of materials and executing persons in the lab. 
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3.2.4 Construction of recombinant diepitope fusion peptides 
3.2.4.1 Cloning, overexpression and purification of diepitope peptides 
 
Because of the reduced protective effect in the sublethal mouse model concerning 
the hp2160 peptide shown in 3.2.2.1, new fusion peptides were cloned that only 
included the pOxi epitope- and the Triiso fragment-encoding sequence in different 
orders. The construct OTO contains pOxi both at the C-terminus and the N-terminus. 
In the pOT construct pOxi is located at the N-terminus and in TpO at the C-terminus 
(Figure 3.44). Primers pOxipep senseTriisoN, ASP-C-17-MibIII (pOT), pOxipep 
senseTriisoN, pOxi-antisenseTriisoC (OTO), SP-Pep5-MibIII, pOxi-antisenseTriisoC 
(TpO) and peptide 14 as template were used to amplify diepitope sequences. 
These diepitope sequences were cloned into pPSG-IBA45 from IBA StarGate fusion 
cloning system as described in 3.2.3.1 and fused to Strep- and His-tag. The resulting 
Figure 3.43: Bacterial load in organs 
challenged with a sublethal dose of S. aureus 
upon triepitope peptide immunization.  
BALB/c mice (n=11-12) were immunized with 
recombinant triepitope peptide conjugated to 
KLH (red) or with KLH (black) as a control group. 
After the second boost mice were challenged i.p. 
with 5.19 x 106 CFU of S. aureus USA300 mixed 
with 5 % mucin from porcine stomach. Bacterial 
density of liver (A), spleen (B) and kidneys (C) 
was determined. Each data point represents an 
individual animal. P-values were analyzed by 
Mann-Whitney test. p ≤ 0.001 = ***; p = 0.01 = **; 
p ≤ 0.05 = *; ns = not significant. 
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plasmids were sequenced. One clone without any mutations was chosen, 
respectively, and transformed in E. coli BL21 for expression. 
 
 
 
 
Figure 3.44: Cloning strategy of diepitope fusion-peptides OTO, pOT and TpO. Sequences encoding the 
epitopes of anti-pOxi moAb D3 and of anti-Triiso moAb H8 (Triiso fragment) were cloned consecutively into 
pPSG-IBA43 resulting in N-terminal fusion to Strep-tag and C-terminal fusion to His-tag. OTO: Triiso fragment 
surrounded by C- and N-terminal pOxi epitope; pOT: N-terminal pOxi epitope; TpO: N-terminal pOxi epitope. 
 
 
Western blot analysis of the bacteria cell lysates after expression ON at 30 °C 
showed that OTO (14.1 kDa)  as well as pOT (12.7 kDa) were overexpressed, but 
not TpO (12.7 kDa) (Figure 3.45, 3 and 6 in A-C). 
Additionally, binding of anti-pOxi moAb D3 (B) and anti-Triiso moAb H8 (C) to 
overexpressed OTO and pOT was proven by Western blot analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.45: Expression of diepitope peptides prior to and post induction. E. coli BL21 containing respective 
plasmid was grown to an OD600 = 0.6 and induced with 1 mM IPTG for an overexpression ON at 30 °C. Lysates 
were blotted on nitrocellulose. 1 and 4: OTO, 2 and 5: pOT, 3 and 6: TpO. 1-3: prior to induction, 4-6: post 
induction. A: Ponceau staining, B: anti-pOxi moAb D3, C: anti-Triiso moAb H8. Incubation with goat anti-mouse 
HRP and development by ECL reagent followed. 
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The highest amount of OTO as well as pOT was detected in the soluble fraction, in 
contrast to triepitope overexpression in 3.2.3. So purification via His-tag was 
performed. Elution fractions were pooled and concentrated (Figure 3.46). A high yield 
of 25 mg of pOT peptide and 13 mg of OTO peptide was produced (800 ml culture 
volume). After buffer exchange and sterile filtration peptides were ready for in vivo 
use and stored at 4 °C. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2.4.2 Competition of moAb binding to the antigen by diepitope peptide 
To prove the binding specificity of anti-pOxi moAb D3 and anti-Triiso moAb H8 to 
bind the different diepitope peptides, a competition ELISA was performed (Figure 
3.47). Recombinant pOxi as well as Triiso were immobilized to a maxisorp plate. The 
respective moAb together with different concentrations of one of the diepitope 
peptides as a competitor (compare to single peptides in 3.1.1, figure 3.2) was added.  
As shown in figure 3.47A, the absorbance decreased by increasing the concentration 
of OTO, as well as pOT. A competition effect of moAb D3 binding to pOxi with both 
peptides has been proven. With regard to the two curves of OTO and pOT, both 
peptides showed a similar affinity to moAb D3. At a peptide concentration of 1 mg/ml 
no binding of moAb D3 to the coated protein was detected anymore. The competition 
effect of OTO and pOT was even stronger than the competition with the whole 
protein pOxi.  
A competition of the moAb H8 binding to Triiso with both, OTO and pOT was also 
measured in a dose-dependent manner. However, the competition with the diepitope 
peptides was not as strong as with the whole protein Triiso (B). With competitor 
concentrations between 350 and 600 µg/ml, the decrease in absorbance in presence 
of recombinant Triiso was stronger.   
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Figure 3.46: Purification of diepitope 
peptides via His-tag. Coomassie 
stained SDS-PAGE of purification of 
OTO and pOT peptides via His-tag after 
heterologous overexpression. 15 µl of 
each sample and 7 µl of PAGE Ruler 
prestained protein ladder was pipetted 
on the protein gel. IB: inclusion body 
preparation. FT: flow through. Tri: final 
triepitope peptide (see 3.2.3) used for 
immunization. OTO: final OTO peptide. 
pOT: final pOT peptide. 
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Figure 3.47: Competition of moAb binding to recombinant protein by diepitope peptides. 5 µg/mL of the 
respective antigen (A: pOxi, B: Triiso) was coated on a maxisorp plate. Respective diepitope peptide was diluted 
and added to the plate. The respective moAb (A: anti-pOxi moAb D3, B: anti-Triiso moAb H8) was added. 
Incubation with goat anti-mouse-HRP followed. ELISA was developed using TMB substrate and absorbance was 
measured at 450 nm. 
 
3.2.4.3 Antigen-specific immune response and significant lower bacterial load  
            in organs of mice immunized with diepitope peptide pOT 
After binding and competition analysis of the two unconjugated diepitope peptides 
using moAbs D3 and H8, an immunization with groups of 10 mice, each following the 
standard protocol, was performed. The control group was vaccinated with PBS and 
Freund’s adjuvant. The IgG serum titer against recombinant Triiso protein was equal 
for both constructs. Anti-pOxi IgG titer was slightly lower in the pOT group (Figure 
3.48). The serum of the control group was non-reactive for both recombinant proteins 
(not shown). 
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Figure 3.48: Antigen-specific IgG titer 
after immunization with diepitopes. 
BALB/c mice (n = 11) were vaccinated with 
unconjugated diepitope peptides OTO and 
pOT. Serum of every mouse was collected 
after the last booster immunization and 
analyzed for pOxi-, Triiso and hp2160-
specific IgGs by ELISA. The IgG titer is given 
as the dilution corresponding to the half 
maximal absorbance at 450 nm. Each data 
point represents an individual animal. P-
values were analyzed by Mann-Whitney test. 
p ≤ 0.001 = ***. 
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For the i.p. infection of mice 5.4 x 106 CFU of S. aureus USA300 was used, which 
was higher as in the former animal experiments. It was observed that the mice 
tolerated the last used infection doses better and looked healthier as in the previous 
experiments, without any relieving postures, ruffled fur or diminished activity. The 
mice were purchased from the ZMMK as in the former in vivo experiments. The 
usage of new infection aliquots of strain USA300 in this experiment did not change 
these observations.  
By CFU determination a higher bacterial clearance was determined in every organ in 
mice of pOT group in comparison to the control group (Figure 3.49). P-values of pOT 
vs. control group showed significance in all prepared organs (liver: p = 0.0068, 
spleen: p = 0.0185, kidneys: p = 0.0015). Whereas immunization with OTO peptide 
did not improve bacterial clearance compared to infected control mice. Therefore, we 
decided to focus on pOT peptide in the following experiments.   
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Figure 3.49: Bacterial load in organs challenged 
with a sublethal dose of S. aureus upon 
immunization with diepitope peptides OTO and 
pOT. BALB/c mice (n=10) were immunized with 
recombinant epitope peptides OTO (dark red) and 
pOT (green) or with PBS (black) as a control. After 
the second boost, mice were challenged i.p. with 5.4 
x 106 CFU of S. aureus USA300 mixed with 5 % 
mucin from porcine stomach. Bacterial density of 
liver (A), spleen (B) and kidneys (C) was 
determined. Each data point represents an individual 
animal. P-values were analyzed by Mann-Whitney 
test. p ≤ 0.001 = ***; p = 0.01 = **; p ≤ 0.05 = *; ns = 
not significant. 
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3.2.5 Efficacy of immunization upon sublethal S. aureus infection 
Table 3.1 presents the results of the described organ-CFU experiments in summary.  
Except TriisoC4 peptide-conjugate and OTO diepitope, all peptide immunizations led 
to a lower bacterial load in the prepared organs after S. aureus infection. 
Immunization with the pOxi peptide resulted in the highest significance. The 
combination of hp2160- and pOxi-conjugate, as well as the triepitope-conjugate and 
pOT diepitope showed a significant reduced colonization of S. aureus with a lower p-
value in every organ.  
 
 
 
Table 3.1: Efficacy of immunization upon sublethal challenge with S. aureus. The significance of the 
analyzed organs of the former described experiments was tabulated for a comparison of the peptide vaccine 
candidates. 
  
Peptide Liver Spleen  Kidneys 
Hp2160-KLH * Ns ns 
pOxi-KLH ** *** *** 
Hp2160-KLH + pOxi-KLH *** ** * 
TriisoC4-BSA ns Ns ns 
Triepitope-KLH ** * ** 
Diepitope pOT ** * ** 
Diepitope OTO ns Ns ns 
 
 
3.2.6 Survival of mice upon lethal challenge with S. aureus USA300 
In further experiments the survival of mice immunized with peptides of table 3.1 upon 
lethal challenge with S. aureus have been analyzed. Therefore, the inoculum of 
infection was determined. Groups of mice (n = 10) were immunized with KLH and 
then i.p. challenged with different doses of strain USA300 + 5 % mucin (Figure 3.50). 
The infected mice were monitored for six days. After infection with 1.5 x 107 CFU four 
of ten mice survived. 20 % survived after a challenge with 1.78 x 107 CFU and only 
10 % survived after a challenge with 1.6 x 107 CFU. 
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The titer of 1.5 x 107 CFU approaches an LD50 and was chosen to be used for 
following experiments. Except in 3.2.7.1, mice used in following experiments better 
coped with the chosen titer. Hence, the LD50 after an infection with higher doses of 
strain USA300 was titrated again as shown in figure 3.51 (n = 6). The results showed 
that four of six mice of the group challenged with 2.9 x 107 CFU survived, as well as 
with 3.01 x 107 CFU and only one of six mice survived after a challenge with 3.27 x 
107 CFU. The highest titer of 3.27 x 107 CFU was used for further challenges (see 
3.2.7.2). 
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3.2.7 pOxi epitope and pOT diepitope protect mice from death upon lethal  
         challenge with S. aureus 
3.2.7.1 Significant protection of mice immunized with pOT-KLH 
In 3.2.4 it was determined that immunization with recombinant diepitope-peptide pOT 
leads to a reduced bacterial colonization in organs of mice after infection with a 
sublethal dose of S. aureus. Compared to OTO it led to statistical better results. The 
triepitope peptide showed comparable results, but it contains the hp2160 epitope that 
Figure 3.50: Survival of mice 
challenged with different doses of 
S. aureus upon KLH immunization. 
BALB/c mice (n=10) immunized with 
KLH were infected i.p. with 1.5 x 107 
CFU (blue), 1.78 x 107 CFU (green) 
and 1.6 x 107 CFU (red) of S. aureus 
USA300 mixed with 5 % mucin from 
porcine stomach. Survival was 
monitored for 6 days.  
 
Figure 3.51: Survival of mice 
challenged with different doses of 
S. aureus upon KLH immunization. 
BALB/c mice (n=6) immunized with 
KLH were infected i.p. with 2.9 x 107 
CFU (blue), 3.02 x 107 CFU (green) 
and 3.27 x 107 CFU (red) of S. aureus 
USA300 mixed with 5 % mucin from 
porcine stomach. Survival was 
monitored for 6 days.  
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was less significant in organ-CFU experiments. So, it was decided to work on first 
with pOT as a candidate of a higher priority. 
In the next step it should be examined, if a pOT immunization also protects mice 
against a lethal challenge of S. aureus. The immunization procedure followed the 
protocol as explained in figure 3.28. 
In order to achieve a stronger immune response, pOT was conjugated to KLH and 
control group was immunized with KLH alone as unspecific antigen. Compared to 
3.2.4, the immune response after the last boost was slightly increased in every 
mouse serum and constantly distributed.  
To reach an LD50 the mice immunized with pOT-KLH and KLH were i.p. challenged 
with 1.2 x 107 CFU of strain USA300 + 5 % mucin and monitored for six days. 
As shown in figure 3.52, immunization with pOT peptide leads to a survival of 100 % 
in contrast to only 45.5 % surviving mice in the control group. The experiment also 
showed significance with a p-value of 0.005 determined by Gehan-Breslow test. 
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Figure 3.52: Survival of mice challenged with an LD50 of S. aureus upon diepitope peptide immunization. 
BALB/c mice (n=11) immunized with pOT-KLH (green) or KLH (black) as a control were infected i.p. with 1.2 x 107 
CFU S. aureus USA300 mixed with 5 % mucin from porcine stomach. Survival was monitored for 6 days. P-value 
was determined by Gehan-Breslow test (p = 0.005). 
 
3.2.7.2 Significant protection of mice immunized with pOxi-BSA compared to  
           pOT-KLH upon lethal challenge with S. aureus 
It was proven that the generated diepitope peptide pOT containing pOxi and Triiso 
epitopes protected mice from death although they received a lethal dose of              
S. aureus. In further survival experiments also the single peptide was tested for a 
protection effect after immunization. Therefore, a group of mice (n = 11) was 
immunized with pOxi-BSA and a second group received pOT-KLH. Because of the 
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different carriers the control group was immunized with a combination of both carrier 
proteins BSA and KLH. 
The initial immunization and the two boosts resulted in a strong immune response: 
The pOxi peptide achieved a high IgG titer against recombinant pOxi and pOT 
against both antigens, Triiso and pOxi. The control group showed an immune 
response against BSA and KLH but was not reactive against the vaccine candidates. 
The mice immunized with pOT-KLH, pOxi-BSA and KLH/BSA were then challenged 
with 3.3 x 107 CFU S. aureus USA300. 
After one day the bacterial burden for the control group was very high, so that 8 mice 
from 11 died (Figure 3.53). A further mouse died at the second day, so that the 
control group resulted in a survival of 18 %. In comparison to the control group 90 % 
of the mice immunized with pOT (p = 0.0017) and 100 % of the pOxi group (p = 
0.0001) survived. At the first day after challenge the surviving mice showed an 
affected phenotype with scrubby fur and weight loss but on the second day they fully 
recovered.  
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Figure 3.53: Survival of mice challenged with S. aureus upon immunization with pOxi-BSA or pOT-KLH. 
BALB/c mice (n=11) immunized with pOxi-BSA (blue), pOT-KLH (green) or a combination of BSA and KLH (black) 
as a control group, were infected i.p. with 3.3 x 107 CFU S. aureus USA300 mixed with 5 % mucin from porcine 
stomach. Survival was monitored for 6 days. P-values were determined by Gehan-Breslow test. 
 
 
Once again, this experiment underlines the importance of the pOxi epitope as 
vaccine candidate to achieve a protection against MRSA infection. The diepitope 
pOT also showed a repetitive protection and will be a good candidate for active 
immunization. The two peptide candidates will now be tested with alternative 
adjuvants, which are approved for humans. Once, the epitope of anti-Triiso moAb H8 
is determined for a synthesis as single peptide. Mice will be immunized with TriisoH8 
peptide for a comparison with the diepitope pOT. 
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3.2.7.3 Survival of mice immunized with hp2160-BSA and Triepitope-BSA upon  
            lethal challenge with S. aureus 
In further in vivo experiments groups of mice were immunized with hp2160-BSA (n = 
10) and BSA (n = 11) as a control. After a challenge with a lethal dose of S. aureus 
only three mice of the control group died, whereas all mice of the hp2160 group 
survived. This resulted in a non-significant experiment. In a comparable experiment 
groups of mice (n = 11) were immunized with Triepitope-BSA, pOxi-BSA, hp2160-
BSA and BSA, respectively. However, only two of eleven control mice died. One 
mice of hp2160 group and none of the mice of Triepitope and pOxi groups died which 
also led to a non-significant result. 
 
3.2.8 Immunization with Modified Vaccinia virus Ankara (MVA) encoding  
         triepitope peptide 
With the aim to develop a different and above all established strategy of vaccine-
delivery in humans against S. aureus we focused on Modified Vaccinia virus Ankara 
(MVA) encoding our triepitope construct. MVA is a vaccinia virus strain that was 
generated thirty years ago and used very successful as a vaccine against smallpox 
(Mayr et al., 1964). Our construct was generated by cooperation with the laboratory 
of Prof. Gerd Sutter (LMU München). 
In case of vaccination against S. aureus by using MVA as a vector, a recombinant 
MVA encoding the DNA sequence of the triepitope peptide was generated (MVA-SA-
Triepitope). The triepitope peptide was cloned into an MVA shuttle plasmid 
containing flanking ends to allow recombination into the genome of MVA. Cloning 
and recombinant MVA generation was performed by the laboratory of G. Sutter 
according to the strategy of Kremer et al. (2012). A second recombinant MVA 
encoding the triepitope fused with Vaccinia Virus Hemagglutinin (HA) that leads to  
the presentation of the triepitope on the outer cell membrane of host cells was 
additionally constructed (MVA-HA-SA-Triepitope). The shuttle vector was then 
transfected into cells infected with MVA. Through homologous recombination the 
gene encoding the antigen was inserted into the genome of MVA. MVA-HA-SA-
Triepitope was clonally isolated and amplified in chicken embryo fibroblasts. 
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To verify whether the generated viral vectors are able to express the triepitope 
peptide, baby hamster kidney (BHK) cells were infected. Cells were lysed and equal 
amounts of cell lysates were run on a 4-20% polyacrylamide SDS gel. Then proteins 
were blotted on a nitrocellulose membrane. As a control for equal protein loading, the 
membrane was incubated with an anti-GAPDH antibody as shown in figure 3.54 
(Data provided by M.H.Lehmann and G. Sutter). The triepitope (14.3 kDa) and the 
HA-SA-triepitope fusion protein (∼80 kDa) were detected by Western blot using our 
anti-pOxi moAb D3 in the cell lysate upon infection of BHK cells with recombinant 
MVA-SA-Triepitope or MVA-HA-SA-Triepitope, respectively. This confirmed the 
antigen expression after infection of eukaryotic cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
To investigate an immune response in vivo, groups of mice (n = 3) were immunized 
intramuscularly with 1 x 108 plaque forming units (pfu) of one of the two recombinant 
MVA constructs, respectively. An adjuvant was not used. According to our 
conventional immunization model, the mice received an initial immunization and two 
following boosts with equal amounts of recombinant virus particles.  
Serum samples were collected between boosts and IgG titer against the three 
antigen pOxi, hp2160 and Triiso, as well as against the triepitope peptide were 
analyzed by ELISA. As shown in figure 3.55A the immunization with MVA-SA-
Triepitope resulted in a very weak immune response. The first clear signal was 
detected after the first boost against Triiso and the triepitope peptide. A very weak 
signal against pOxi and hp2160 was measured after the second boost. 
 1    2    3    4 
     anti-GAPDH ab 
 anti-pOxi moAb D3 
 Triepitope 
 GAPDH 
 HA-Triepitope Figure 3.54: Expression of triepitope 
peptide in eukaryotic cells infected 
with recombinant MVA viruses. BHK 
cells were infected with MVA viruses. 
Cells were lysed and equal protein 
amounts were blotted on nitrocellulose, 
followed by incubation with anti-GAPDH 
and anti-pOxi moAb D3. Detection 
followed by anti-mouse-HRP. 1: Mock; 2: 
MVA; 3: MVA-SA-Triepitope; 4: MVA-HA-
SA-Triepitope. Data provided by 
M.H.Lehmann and G. Sutter, LMU 
München.  
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Immunization with MVA-HA-SA-Triepitope led to a much stronger immune response 
as shown in figure 3.55B. A first booster immunization is necessary because an IgG 
titer against the recombinant proteins as well as the triepitope peptide was not 
detected after the initial vaccination. After the second boost, the titer was only slightly 
increased compared to the first boost.  
In summary, MVA-HA-SA-Triepitope should be used for the following immunizations 
that will include a challenge with S. aureus to look for a protective effect, although the 
antigen-specific humoral immune response was not as strong as with the triepitope-
peptide itself (see 3.2.3.4).  
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Figure 3.55: Antigen-specific IgG titer after immunization with recombinant MVA vectors encoding 
triepitope BALB/c mice (n = 3) were vaccinated with 1 x 108 pfu of MVA-SA-Triepitope (A) and MVA-HA-SA-
Triepitope (B), respectively. Serum of both mice was collected between the immunizations and analyzed for  
pOxi-, hp2160-, Triiso- and triepitope-specific IgGs by ELISA. The IgG titer is given as the dilution corresponding 
to the half maximal absorbance at 450 nm.  
 
3.2.9 Immunization with Adeno-Associated-Virus (AAV) encoding the  
         triepitope peptide 
In cooperation with the laboratory of Prof. Hildegard Büning (Medizinische 
Hochschule Hannover) we focused on vector constructs based on Adeno-
Associated-Virus encoding the triepitope peptide with the aim to use an additional 
vaccine platform against S. aureus. Two vector constructs were generated: The 
conventional recombinant AAV (rAAV) containing an expression cassette encoding 
the triepitope and a capsid-modified rAAV containing the triepitope expression 
cassette and additionally displays the triepitope on the vector capsid by fusion with 
the VP2 capsid protein.  
A B 
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In this work AAV serotype 2 (AAV2) was used. A triepitope peptide expression 
plasmid and a plasmid for expression of the fusion construct of triepitope peptide and 
viral capsid protein VP2 were cloned using the primers AAV-Triepitop-KpnI Sense 
and AAV-Triepitop-NotI AS and the plasmid IBA-Triepitop (see 3.2.3.1) as template. 
The restriction sides KpnI and NotI were used to insert the triepitope in the plasmid 
pGFP-Anne. In order to generate the fusion construct of triepitope and VP2 the 
primers AAV-Triepitop-AgeI Sense and AAV-Triepitop-BsrGI AS were used 
introducing AgeI and BsrGI restriction sides. The amplified triepitope was inserted in 
the plasmid pEGFP-VP2. Both plasmids were transformed in E. coli. Positive clones 
were picked from agar plates for a colony PCR and plasmids were isolated for a 
control digest. Figure 3.56 shows the restriction digest of the generated plasmids 
AAV-pTriepitop-Anne and AAV-pTriepitop-VP2 with KpnI and NotI for the detection of 
the insert (392 bp).  
 
 
 
 
 
 
 
               
 
Figure 3.56: Restriction digest of cloned plasmids AAV-pTriepitop-Anne and AAV-pTriepitop-VP2 200 ng 
of AAV-pTriepitop-Anne was digested with KpnI and NotI and 200 ng of AAV-pTriepitop-VP2 was digested with 
AgeI and Bsp140171. Both are loaded on an 1 % agarose gel. 100 + 500 bp marker was used. 
 
After sequencing the plasmid-DNA was prepared by an endotoxin-free purification kit 
(Qiagen, Hilden) and the plasmids were sent to AG Büning for AAV packaging and 
purification. AAV particles were produced in HEK293 cells transfected with either 
AAV-pTriepitop-Anne or both, AAV-pTriepitop-Anne and AAV-pTriepitop-VP2 and 
additionally, with the helper plasmids encoding the adenoviral helper functions 
(helper-virus-free method of Rybniker et al., 2012, see 1.7.3). Cells were lysed and 
the recombinant AAV’s were purified by an iodixanol gradient.  The resulting vaccine 
vectors arrived our lab and were called rAAV2:Tri (unmodified capsid) and 
rAAV2:TriTri (vector with modified capsid). Genomic and capsid titers of the vector 
preparations were determined (Table 3.2). The genomic titer determined by RT-PCR 
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using a primer specific for CMV promotor reveals the number of vector genome 
containing viral particles per microliter vector solution (data of AG Büning).  
The packaging efficiency for the capsid-modified vector rAAV2:TriTri was quantified 
by calculating the ratio of capsids to genomes and was compared to that of vector 
rAAV2:Tri containing wild type capsids. The capsid titer, determined by ELISA using 
an anti-capsid-specific antibody, reveals the amount of capsid (DNA containing as 
well as empty) per microliter vector solution. The two very similar capsid to genomic 
particle ratios indicate that incorporation of triepitope peptide into the AAV capsid by 
fusion to VP2 did not affect the vector packaging efficacy. 
 
Table 3.2: Determination of genomic and capsid titer of generated rAAV vectors All titers refer to the volume 
of 1 µl. Capsid to genomic particle ratio enables judgement on the quality of the vector preparation in a volume 
independent manner 
 
Vector genomic titer  (RT-PCR)  
capsid titer  
(ELISA) capsid titer / genomic Titer 
AAV2:TriTri 1.97 x 109 2.73 x 109 1,39 
AAV2:Tri 1.93 x 109 2.17 x 109 1,12 
 
To investigate, if the generated vectors are able to express the triepitope peptide, 
human monocytic cells were transduced with the constructs. Equal amounts of the 
cell lysates were blotted (Figure 3.57). Anti-β-Actin antibody bound to the 
housekeeping protein actin was used as a loading control of cell lysates and their blot 
transfer. With anti-pOxi moAb D3 the triepitope (14.3 kDa) was identified in the lysate 
of cells transduced with recombinant rAAV2: Tri and rAAV2:Tri:Tri. This verified the 
antigen expression after transduction of eukaryotic cells.  
 
 
 
 
 
 
 
 
To investigate the capsid protein composition, denatured capsids of the vector 
AAV2:TriTri containing the VP2-triepitope fusion and the conventional vector 
AAV2:Tri containing the wildtype capsid denatured capsids of both virus-constructs 
kDa 
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Figure 3.57: Expression of triepitope peptide 
in eukaryotic cells transduced with recombi-
nant AAV2 viruses. Human monocytic cells 
were transduced with rAAV viruses. Cells were 
lysed and blotted on nitrocellulose, followed by 
incubation with anti-pOxi moAb D3 and anti-β-
Actin antibody. Detection with anti-mouse-HRP. 
1: cells not transduced; 2: transduced with 
rAAV2:Tri; 3: transduced with rAAV2:TriTri.  
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were blotted and immunostained with one of the three respective moAbs anti-Triiso 
H8, anti-pOxi D3, anti-hp2160 16-2 and with mouse anti-AAV capsid protein antibody 
B1 that binds a sequence located at the C’ terminus of all AAV capsid proteins 
(Figure 3.58), respectively. The triepitope-VP2 fusion protein with a size of nearly 
86.3 kDa was detected with all three moAbs. As expected, AAV2:Tri with the wildtype 
capsid did not show any binding signals with the anti-triepitope antibodies. The 
capsid proteins VP1 (90 kDa), VP2 (72 kDa), VP3 (60 kDa) of AAV2:Tri were 
detected by B1 antibody. The VP2 protein showed a different molecular weight 
because of the fusion with triepitope peptide 
72 kDa in the preparation of vectors with wild type capsid was ablated and a band 
with a size of about 100 kDa corresponding to the fusion of triepitope and VP2 
protein was detected. As expected, detection of the fusion protein by B1 antibody 
was unclear because of similar molecular weights of VP1 (90 kDa) and the fusion 
protein (86.3 kDa). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.58: Western Blot of recombinant AAV2 vector preparations encoding triepitope peptide 
1 x 109 of denatured vector capsids per preparation were blotted on a nitrocellulose membrane in order to analyze 
capsid composition and a possible incorporation of the VP2-triepitope fusion protein. The blots were incubated 
with the respective moAb and with capsid-specific B1 antibody. The band with a size of 83.3 kDa corresponds to 
the fusion protein. 1: rAAV2:TriTri (capsid modified vector); 2: rAAV2:Tri (conventional vector).  
 
To investigate the potency of the generated AAV2 vectors to induce an antigen-
specific immune response, groups of mice (n = 2) were initial vaccinated 
intramuscularly with 1 x 1010 pfu of AAV2:Tri and AAV2:TriTri, respectively, followed 
by a two booster immunizations. Unfortunately, no antigen-specific immune response 
was detected in the group immunized with AAV2:Tri (data not shown). With 
AAV2:TriTri a very weak immune response after the 2nd boost against Triiso and the 
α-Triiso moAb H8 α-hp2160 moAb 16-2 α-pOxi moAb D3 α-capsid antibody 
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triepitope was measured as shown in figure 3.59. A pOxi- or hp2160-specific IgG titer 
was not measureable. 
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Figure 3.59: Antigen-specific IgG titer after immunization with recombinant AAV vectors encoding 
triepitope BALB/c mice (n = 2) were vaccinated i.m. with 1 x 1010 pfu of AAV2:TriTri. Serum of both mice was 
collected between the immunizations and analyzed for pOxi-, hp2160, Triiso- and triepitope-specific IgGs by 
ELISA. The IgG titer is given as the dilution corresponding to the half maximal absorbance at 450 nm.  
 
3.2.10 Analysis of T-cell response upon vaccination with pOT-KLH and  
           triepitope-KLH  
Vaccination with triepitope-KLH resulted in a higher bacterial clearance upon 
sublethal S. aureus challenge and pOT vaccination protected mice from dead upon 
lethal challenge. Both peptides resulted in a high antibody production. In the following 
experiment we were interested in the T-cell response upon active immunization with 
triepitope- and pOT-KLH (n = 5). At this time, the single peptides were not available 
as KLH conjugates in our lab. Immunization with BSA conjugates resulted in a re-
stimulation of splenocytes with medium containing fetal calf serum alone. Hence, 
these conjugates were excluded from these experiments.  
Before T-cell response was investigated, the antigen-specific titer of IgG subclasses 
in sera of mice and the IgG1 / IgG2a ratio was analyzed first because it gave a hint to 
the dominant class of helper T-cells. In this case, a higher IgG1/IgG2a ratio reveals a 
Th2 response and a lower ratio reveals a Th1 response.  
Twelve days after the last boost blood was collected, the specific IgG1 and IgG2a 
titer were determined by ELISA and the ratio between IgG1 and IgG2a titers was 
calculated. The respective proteins hp2160, pOxi and Triiso were immobilized, as 
well as triepitope and pOT peptides. The respective subclass was detected by anti-
mouse IgG1- or IgG2a-HRP. As presented in figure 3.60, the ratio of pOT-KLH 
immunized mice was lower, in contrast to triepitope-KLH immunized group. 
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Triepitope-KLH immunization resulted in a higher IgG1/IgG2a ratio, but also in a 
higher spread within the group.  
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Figure 3.60: Ratio of antigen-specific IgG1 and IgG2a titer upon immunization with triepitope-KLH and 
pOT-KLH. BALB/c mice (n = 6) were immunized with triepitope-KLH and pOT-KLH, respectively. IgG subclasses 
in serum were determined by ELISA. Recombinant proteins or polyepitope peptides were immobilized. After 
incubation with serum detection with anti-mouse IgG1- and IgG2a-HRP followed. 
 
Two weeks after the last boost, splenocytes were isolated aseptically, cultivated and 
re-stimulated with unconjugated pOT, triepitope, pOxi and hp2160 epitope peptides, 
respectively. Because both pOT and triepitope contain the pOxi and the 
discontinuous Triiso epitope, both of them were used for re-stimulation of 
splenocytes derived from mice immunized with triepitope-KLH, pOT-KLH and KLH. 
Splenocytes from KLH immunized mice function as a negative control. Cell culture 
medium without any stimulus was used as a second negative control. The protein 
concavalin A (ConA) that functions as a mitogen was used as positive control for the 
stimulation of splenocytes.  
Cell proliferation was measured using BrdU cell proliferation assay kit. The synthetic 
nucleoside bromodeoxyuridine (BrdU) is thereby incorporated into newly synthesized 
DNA of replicating cells by substitution of thymidine. With an antibody specific for 
BrdU the incorporated chemical was detected, thus indicating cells that were 
replicating their DNA and therefore proliferating. Immunization with triepitope-KLH 
resulted in a significantly increased proliferation of splenocytes stimulated with 
triepitope, pOT- and pOxi peptide, respectively, compared to the same group of 
splenocytes stimulated with medium and compared to triepitope stimulated cells 
isolated from KLH immunized mice (Figure 3.61). Immunization with pOT-KLH 
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resulted in a stronger cell proliferation of splenocytes after stimulation with pOT, 
triepitope and pOxi peptide. Compared to medium stimulated cells these results were 
not significant because of an unexpected increased cell proliferation in medium 
control. Compared to pOT stimulated cells from KLH immunized mice, cell 
proliferation was significantly increased.  
Altogether, a re-stimulation with the respective unconjugated epitope peptides 
induced a proliferation of splenocytes derived from mice immunized with triepitope-
KLH and pOT-KLH. Splenocyte proliferation from mice immunized with KLH alone 
was not induced after addition of epitope peptides.  
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Figure 3.61: Proliferation of splenocytes derived from triepitope-KLH, pOT-KLH and KLH vaccinated mice 
(n = 5). Cell proliferation after 72 h stimulated by triepitope-, pOT-, pOxi- and hp2160-peptides, respectively, was 
used as readout for cellular immune activation. Proliferation of splenocytes was quantified by BrdU cell 
proliferation assay kit. Unpaired two-tailed t-test: ***, p ≤ 0.001; **, p ≤ 0.01; *, p ≤ 0.05. 
 
 
The cytokines Interferon-gamma (IFN-γ), IL-4 and IL17A secreted in the supernatant 
of the stimulated splenocytes were quantified by DuoSet ELISA. Cellular immune 
activation was assessed as epitope peptide-stimulated cytokine release. As 
presented in figure 3.62, splenocytes from those mice immunized with triepitope-
KLH, as well as pOT-KLH revealed a significantly higher cytokine secretion after re-
stimulation with the respective unconjugated epitope peptides, compared to the KLH 
immunized control group. 
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Unconjugated pOT and triepitope, as well as unconjugated pOxi and hp2160 
peptides were used as stimuli. The latter was not used for re-stimulation of 
splenocytes from pOT-KLH immunized mice because pOT does not contain the 
hp2160 epitope. 
A strong release of IFN-γ was measured after 72 h indicating Th1-cell or/and CD8+ T-
cell proliferation (A). Unexpectedly, both unconjugated triepitope and pOT peptides 
stimulated IFN-γ release of splenocytes from KLH immunized mice. However, 
splenocytes of mice immunized with triepitope-KLH, as well as pOT-KLH induced a 
significantly stronger IFN-γ release post triepitope and pOT stimulation. The smaller 
unconjugated pOxi epitope and hp2160 epitope peptides were also able to induce an 
IFN-γ release. With pOxi peptide the production of IFN-γ was significantly increased 
compared to IFN-γ production of splenocytes from the KLH control group. 
A moderate release of IL-4 was measureable upon stimulation indicating a Th2-cell 
response. Compared to IFN-γ, the detection of an IL-4 concentration in the medium 
supernatant upon re-stimulation was more difficult (B). However, a significantly 
higher IL-4 secretion of splenocytes derived from triepitope-KLH and pOT-KLH 
immunized mice after re-stimulation with both unconjugated peptides was measured. 
Splenocytes from KLH immunized mice were non-reactive to re-stimulation. The 
unconjugated single pOxi- and hp2160 peptides were not able to induce a strong Th2 
response. The unconjugated single pOxi- and hp2160 peptides were not able to 
induce strong IL-4, as well as IL-17A releases (B-C).  
Re-stimulation with triepitope and pOT resulted in a strong IL-17A production (C).   
IL-17A is produced by Th17- and γδ-cells. Splenocytes of KLH immunized mice only 
showed a moderate IL-17A level post stimulation with triepitope and pOT, 
respectively. IL17-A release of splenocytes from triepitope-KLH immunized mice was 
stronger post stimulation with triepitope and significantly stronger with pOT. 
Splenocytes of one mouse did not release IL-17A post stimulation with triepitope 
peptide, which led to the non-significance. 
A significantly higher IL-17A level was measured after re-stimulation of splenocytes 
derived from mice immunized with pOT-KLH in contrast to KLH.    
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Figure 3.62: Cytokine levels measured in cell culture supernatants of splenocytes derived from 
Triepitope-KLH, pOT-KLH and KLH vaccinated mice (n = 5). Cytokine release after 72 h stimulated by 
Triepitope-, pOT-, pOxi- and hp2160-peptides (pep), respectively, was used as readout for cellular immune 
activation. Cytokines were quantified by ELISADuoSet. A: IFN-gamma release; B: IL-4 release; C: IL-17A release. 
Unpaired two-tailed t-test: ***, p ≤ 0.001; **, p ≤ 0.01; *, p ≤ 0.05. 
A 
B 
C 
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In summary, immunization with triepitope-KLH resulted in higher IgG1/IgG2a ratios 
detected in mouse sera, whereupon a higher spread within the groups was detected. 
In contrast IgG1/IgG2a ratio was much lower. 
Immunization with triepitope-KLH, as well as pOT-KLH led to a strong proliferation of 
splenocytes after re-stimulation with epitope peptides. The Th (CD4+) -cell directed 
immune response is predominantly Th1-directed (cellular) as represented by high 
concentrations of IFN-γ. However, IL-4 (Th2-directed response) and IL-17A releases 
(Th17-directed response) have also been detected.  
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4  Discussion 
 
The genetic diversity and the ability to acquire new exogenous genes allow S. aureus 
to adapt to a variety of changing environmental conditions and to modulate its 
pathogenicity. S. aureus causes a broad spectrum of diseases, reaching from minor 
skin infection to life-threatening blood stream infections (Lowy, 1998, Diekema et al., 
2001). Multidrug resistance of the hospital- and community-associated strains of this 
pathogen is increasing and thereby limiting therapeutic options, up to the point where 
none of the antibiotics will work and alternative strategies are indispensable. 
Vaccination as therapy and prophylaxis would be an expedient alternative, but there 
is currently no vaccine available. All active and passive immunization approaches to 
date have failed at the clinical trial stage. These approaches or those, who are 
currently passing through clinical trials, concentrated on well-known virulence factors, 
including proteins exhibiting the LPXTG sorting signal. LPXTG proteins are cell wall-
anchored and often covalently linked to peptidoglycan (Foster and Hook, 1998), such 
as clumping factor A (ClfA) or iron-regulated surface determinants (Isd) (DeJonge et 
al., 2007; Fowler et al., 2013).  
Alternatively, a growing number of classical cytoplasmic proteins are described to be 
found on the surface of microbial pathogens. These non-covalently bound cell wall-
associated proteins are involved in metabolic pathways but also in adhesion or 
binding of e.g. blood components, which turns them into virulence factors (Pancholi 
and Chhatwal, 2003). Glowalla et al. (2009) identified novel anchorless cell wall 
proteins that lack the conserved LPXTG signal sequence. They were identified in the 
cell wall-associated protein extract by performing a subtractive proteome analysis 
with human IgG solution (IVIG) of healthy donors, which contains antibodies against 
these candidates (see 1.5). Several of them were produced as recombinant proteins 
and tested in a murine active immunization model with a consecutive S. aureus 
challenge. This resulted in the discovery of the lead vaccine candidates Triiso, pOxi 
and hp2160 that showed the strongest protection against S. aureus infection. 
Monoclonal antibodies against the lead candidates were generated by hybridoma 
technology of which anti-pOxi moAb D3, anti-Triiso moAb H8 and anti-hp2160 moAb 
16-2 revealed protection in a murine sepsis model upon passive immunization        
(A. Klimka, unpublished data; see 1.5.3).  
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The present work focused on the characterization of these generated antigen-specific 
monoclonal antibodies, their epitope identification and application as active vaccine. 
MoAb binding to the respective antigen has been shown by varying the in vitro 
growth conditions. The mode of action of anti-pOxi moAb D3 and anti-Triiso moAb 
H8 leading to their protective effect has been investigated together with the function 
of the identified vaccine candidates as moonlighting proteins. Triiso and pOxi are 
well-known cytoplasmic proteins. Beside their cytoplasmic function, moonlighting 
proteins are described to have one or more different functions on the bacterial 
surface (Jeffery, 1999). A contribution of pOxi to host cell adhesion and an inhibition 
of this by anti-pOxi moAb D3 was demonstrated. 
Furthermore, the moAb epitopes have been identified and verified. The epitope 
application as active peptide vaccine in the preclinical mouse model induced strong 
antigen-specific humoral and T-cell mediated immune responses and gave a 
protective effect against MRSA. The epitope of anti-pOxi moAb D3, as well as a 
diepitope fusion (bivalent vaccine) of anti-pOxi moAb D3 and anti-Triiso moAb H8 
epitopes were identified as candidates with the strongest protective potential.            
A humoral immune response with the viral vector platforms MVA and AAV as 
alternative vaccination strategy has been detected and will be followed as these are 
encouraging results to proceed with the development of an efficient vaccine to 
prevent MRSA infection in human risk patients. 
 
4.1 Epitope characterization of protective monoclonal antibodies 
After identification of the novel cell wall-associated proteins Glowalla et al. (2009) 
started to use the whole, recombinant proteins as active vaccines, of which some 
already achieved protection against S. aureus infection. In this work the principle of 
peptide immunization was demonstrated. Whereas only a few immunodominant 
epitopes are sufficient to induce a protective effect, whole antigens contain many 
epitopes that are not necessary or even may be detrimental because they are 
immunodominant but not protective, which makes the antigen less potent as a 
peptide vaccine (Otto, 2010; Correia et al., 2014).  
B-cell epitopes have already been used as vaccine candidates against S. aureus 
infection. In recent studies Zhao and colleagues (2015) designed a polyepitope 
vaccine composed of B-cell epitopes of enterotoxin B (SEB) and showed protection 
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against MRSA with some of them. For B-cell epitope mapping of SEB they used an 
overlapping 18-mer peptide ELISA, which was incubated with sera of mice 
immunized with recombinant SEB and infected with strain MRSA 252. The same 
procedure was used by Yang et al. (2016), who identified some immunodominant B-
cell epitopes of manganese transport protein C, which provided protection against    
S. aureus infection.   
In the present work a “reverse immunology” approach was described using the 
protective monoclonal antibodies as a “pathfinder” towards potentially highly efficient 
peptide vaccines in terms of their respective epitopes. Active immunization with 
correctly identified epitopes of these lead candidates of passive immunization should 
provide a stronger protection as obtained with the whole antigen.  
The epitopes of moAb D3, as well as moAb 16-2 have been clearly identified by 
microarrays as the linear sequences KNDQDVERFFYK (hp2160 epitope peptide, 
essential amino acids in bold) and TDNELVSIVRRD [(pOxi epitope peptide, essential 
amino acids in bold) Fig. 3.1]. Both epitopes have been verified by competitive ELISA 
using the synthesized peptides, which was a relevant result for the upcoming animal 
trials (Fig. 3.2). With an alanine scan we got a closer look to the amino acids that are 
essential for binding of the respective moAb (Fig. 3.3). In addition, the linear epitope 
of anti-Triiso moAb C4 was identified and verified within the peptide 
LADLGVKYVVIGHSERRELFHETD. Compared to anti-Triiso moAb H8, anti-Triiso 
moAb C4 was identified as a candidate with a lower protective effect in the passive 
immunization model. It has been used to investigate, if its epitope would be an 
alternative to the unidentified discontinuous epitope of the lead candidate moAb H8. 
The three identified epitopes are conserved in different S. aureus strains, but not 
found in different species like S. epidermidis or in other gram-positives as B. subtilis 
(data not shown). These findings indicate that our moAbs and antibodies generated 
by active immunization with the identified epitopes are acting against different strains 
of S. aureus, but not against different species. In humans three isoforms of Triiso are 
found that completely differ to S. aureus Triiso concerning their amino acid 
sequences (data not shown). In humans pOxi has only 21 % similarity to S. aureus 
pOxi. The pOxi epitope was not identified. Both findings exclude a cross-reaction of 
anti-Triiso moAbs, as well as anti-pOxi moAb D3 to the human proteins. The fact that 
the three antigens were identified by using a preparation of naturally occurring IgGs 
derived from healthy humans also ensures that we do not expect a cross-reaction to 
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human tissues. During clonal selection of B-cells autoreactive lymphocyte clones are 
deleted before they develop into fully immunocompetent cells (Burnet, 1962). 
The indistinct microarray analyses of anti-Triiso moAb H8 supported a discontinuous 
epitope. A discontinuity is characterized by a cluster of residues that are brought 
together by the folding of a polypeptide chain (Arnon and van Regenmortel, 1992).  
The discontinuity of the epitope of moAb H8 has been proven by our first fragment 
cloning experiments, where moAb H8 was not able to bind neither a C-terminal nor 
N-terminal fragment of Triiso (Fig. 3.5). However, with the following fragment 
constructions of Triiso the epitope of moAb H8 has been verified within a smaller 
protein fragment of 11 kDa. According to Sharon et al. (2014) a B-cell epitope can 
contain between two up to 34 residues. Because the generated Triiso fragment is 
with 105 residues too large for an economical synthesis, a closer verification of the 
epitope of moAb H8 has been initiated. The identification of the amino acids, which 
are essential for the moAb’s binding could reduce production costs and would be 
advantageous for our further experiments. Further binding analyses of moAb H8 with 
the remaining Triiso fragment will follow by CLIPS technology of Pepscan, where 
peptides structurally fixed into defined three-dimensional structures (Timmerman et 
al., 2007).  
 
4.2 Binding of anti-pOxi moAb D3 to staphylococcal pOxi 
Binding analysis of anti-pOxi moAb D3 to pOxi showed some unexpected results. In 
contrast to the binding of moAb D3 to recombinant pOxi (Fig. 3.6), it was not possible 
to detect binding to pOxi from both, surface-associated protein fractions (neCWS) 
and whole cell lysate (WCL) in Western blot analyses (Fig. 3.7). Different growth 
phases in LB medium were tested because we assumed a dependence of the 
expression rate of pOxi as surface protein, but this did not improve the results. 
Obviously, the problem with this kind of measurement was that in vitro growth 
conditions of S. aureus are different to in vivo growth conditions. For example, the 
expression of several virulence factors, such as hemolysins, enterotoxins, proteases, 
and iron acquisition factors in growth media, such as LB or TSB is quite different from 
the expression in an in vivo situation (Oogai et al., 2011). Thus, all performed 
measurements using in vitro grown S. aureus are very likely to differ from S. aureus’ 
activities in vivo. This seems to be crucial for the conclusions drawn from our 
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experiments and it is therefore important to simulate in vitro the in vivo conditions as 
well as possible. For further analyses flow cytometric analyses were conducted, 
which confirmed a strong binding of moAb D3 to the surface (Fig. 3.8A). These 
binding analyses were done with S. aureus wildtype strain, with the addition of a 
human Fc fragment to block IgG-binding of protein A.  
Binding analyses using wildtype strains were already described for moAbs generated 
by other groups. For example, surface expression of the protein IsdB was identified 
by the strong binding of an anti-IsdB moAb to a S. aureus wildtype strain (Kuklin et 
al., 2006). However, our following flow cytometric binding analyses using a S. aureus 
protein A deletion mutant (ΔspA) showed that a huge part of moAb binding to 
wildtype was non-specific. Obviously, only a small part of protein A was blocked by 
using human Fc fragment. This was shown by a competition with the pOxi epitope 
peptide, which only moderately decreased the strong binding of moAb D3 to the 
wildtype. Especially, anti-pOxi moAb D3, which was identified as antibody of IgG2a 
subclass shows high affinity to protein A.  
Further FACS analysis with moAb D3 and whole S. aureus ΔspA cells showed a 
moderate binding signal. This weak signal was completely competed by pOxi epitope 
peptide, suggesting the specific binding of moAb D3 to pOxi on the surface of ΔspA 
(Fig. 3.8B). This notion is supported by the identification of pOxi as a surface protein 
with polyclonal pOxi-specific antibodies existing in a human immunoglobulin solution 
(IVIG).  The strongest binding of moAb D3 to surface localized pOxi was shown at an 
OD of 0.3, but lower binding was also detected in early and late-exponential growth 
phases, indicating that pOxi is mainly required at the surface during exponential 
growth. A possible reason for the non-detection of pOxi in neCWS and WCL 
(described above) would be the amount of pOxi in these fractions and the method’s 
sensitivity. Flow cytometry is known to be a more sensitive way compared to Western 
Blotting allowing the identification of low amounts of pOxi at the S. aureus surface.   
A look at subtractive proteome analysis of anchorless cell wall proteins performed by 
Glowalla et al. (2009) shows also only a very weak spot for pOxi.  
It is important to emphasize that pOxi could be detected with moAb D3 in the isolated 
and precipitated cell wall associated protein fraction blotted on nitrocellulose when  
S. aureus was grown under biofilm conditions, (Fig. 3.12B). Biofilm conditions imply a 
longer growth of approximately 24 hours without shaking (Cramton et al., 1999). 
Hence, the bacteria are in a late stationary phase with highly produced amounts of 
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biomass (Foulston et al., 2014), which obviously increases the amount of pOxi and 
making it therefore amenable for Western blot analysis.  
In flow cytometric measurements binding of moAb D3 to S. aureus surface after 
biofilm growth and competition by pOxi epitope peptide does not differ from those 
results that were obtained after planktonic growth (Fig. 3.13D).  
Altogether, these investigations established specific binding of anti-pOxi moAb D3 to 
the cell-wall associated protein fraction, as well as to the surface of whole S. aureus 
cells. 
  
4.3 Binding of anti-Triiso moAb H8 and anti-hp2160 moAb 16-2  
Both Triiso and hp2160 from S. aureus have been identified with their respective 
moAb in the non-enzymatically isolated cell wall protein fraction (neCWS), as well as 
in the cell lysate (Fig. 3.7). Concerning Triiso, an occurrence at the surface of          
S. aureus has already been proven by proteome analysis (Gatlin et al., 2006). 
Additionally, further glycolytic enzymes were identified on the S. aureus surface, such 
as GAPDH and enolase (Pancholi and Fischetti, 1992).  
In contrast to pOxi, both Triiso and hp2160 were not detectable with their respective 
moAb at the surface of S. aureus ∆spA by flow cytometry after planktonic growth 
(Fig. 3.9). Although both antibodies belong to subclass IgG1, different binding 
affinities to protein A were detected. Whereas anti-Triiso moAb H8 showed high 
affinity to protein A, no binding of anti-hp2160 moAb 16-2 to the wildtype was 
detected. Some other generated moAbs were also tested. Two anti-Triiso moAbs C4 
(lower protective efficacy as moAb H8) and C8 (non-protective) showed a weak 
binding to S. aureus (Fig. 3.10). Compared to moAb H8, the two epitopes recognized 
by moAb C4 and C8, respectively, are located at a different site of the Triiso 
molecule. A quite similar affinity to Triiso with moAb C4 was observed, compared to 
moAb H8 (data not shown). For this reason and because Triiso is a well-known 
surface associated protein, the only explanation for the non-binding of moAb H8 after 
planktonic growth was that its epitope or a part of its eptiope is not accessible at the 
bacterial surface under these growth conditions. The same was assumed for the 
epitope of anti-hp2160 moAb 16-2. In Western blot analyses Triiso and hp2160 are 
detached from the surface and denatured, which would explain the binding signals 
under these conditions.  
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In comprehensive flow cytometric analyses different growth conditions of S. aureus 
were analyzed. It was not possible to improve the binding of moAb H8 and 16-2 to          
S. aureus harvested at different growth phases (Fig. 3.9B-C), although it is known 
that many virulence factors are differently expressed at exponential and stationary 
growth phase (Loughman et al., 2009; Matsuo et al., 2011). Different culture media 
as TSB and RPMI have also been tested, as well as human serum to simulate in vivo 
conditions. Kuklin et al. (2006) showed that the surface expression of the protein 
IsdB is regulated by iron and therefore used different media, such as RPMI as iron 
deficient medium. Oogai et al. (2011) described an increased expression of surface 
occurring virulence factors after growth in serum. However, we did not detect any 
differences in binding intensity of moAbs, when serum grown S. aureus was used for 
FACS analysis. We conclude that these diverse planktonic growth conditions do not 
improve in vitro binding of our moAbs. 
Foulston et al. (2014) described that the matrix of biofilms comprises cytoplasmic 
proteins that are released from S. aureus cells and associate with the bacterial 
surface in a pH-dependent manner. They determined that biofilm matrix formation is 
triggered by a decrease in pH during mid-exponential phase in biofilm-inducing 
medium. This assembly process is reversible after manual disruption of the biofilm 
and increasing the pH.   
An upregulation of gene expression of tpiA encoding Triiso under biofilm growth 
conditions in contrast to planktonic growth has already been demonstrated by Becker 
et al., 2001. Therefore, we also tried biofilm conditions (TSB medium supplemented 
with glucose, growth without shaking) in our in vitro experiments. First, biofilm 
viability was measured by crystal violet staining according to the protocol of O’Toole 
(2011). In addition to the strains available in our lab, three clinical isolates were 
tested. For USA300 and MW2 the ability to biofilm formation was already known 
(Periasamy et al., 2012). Besides one of the clinical isolates, all strains were 
competent to form biofilms under these conditions (Fig. 3.11). A protein A deletion 
mutant derived from S. aureus HG003 was proven to be unaffected in its ability to 
form biofilms (Foulston et al., 2014), which matches the results obtained with our 
ΔspA mutant. The pH measured in biofilm cultures after 24 hours was acidic (pH 5), 
which also concurs with the findings of Foulston and colleagues.  
After biofilm growth of S. aureus ΔspA a surface binding of anti-Triiso moAb H8, as 
well as anti-hp2160 moAb 16-2 have been detected by flow cytometry (Fig. 3.13). 
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After biofilm growth bacteria cells were fixed to prevent the protein detachment from 
the surface (described by Foulston et al., 2014) and to enable moAb incubations at 
neutral pH. An irrelevant antibody was used as non-binding control to biofilm grown 
S. aureus. The detected fluorescence signal with and without the secondary antibody 
was equally negative, which demonstrates the specific binding of moAbs H8 and 16-
2 to the S. aureus cell surface grown under these biofilm conditions.  
We also grew S. aureus under biofilm conditions in the presence of moAbs, but no 
impaired growth or biofilm formation was measured after crystal violet staining (data 
not shown). This leads to the assumption that our antibodies do not have an impact 
on the bacterial growth but presumably on the S. aureus – host interaction in vivo. 
To analyze the effect of pH after biofilm growth, harvested biofilm cells were 
incubated at pHs 5 and 7.5. The supernatant was precipitated, separated by SDS-
PAGE and blotted. Although both samples were treated equally (despite the pH), a 
higher amount of Triiso was detected in the sample washed at neutral pH (Fig. 
3.12A), leading to the conclusion that the cell associated proteins detach from the 
surface under neutral pH. Thus, a higher amount of Triiso remained at the cell 
surface under acidic conditions. These results agree with Foulston et al. (2014), who 
detected the same for other glycolytic enzymes (GAPDH, enolase). This pH influence 
has also been described for enolase and GAPDH of gram-positive Lactobacillus 
crispatus (Antikainen et al., 2007). At pH 5 no release of the proteins from the 
surface was detected. A stepwise increase of the pH from 4.4 to 7 revealed that the 
release of these proteins became detectable at pH 5.2, which is close to the 
isoelectric point (pI) of enolase (4.8) and GAPDH (5.2). Both proteins are positively 
charged at lower pH values and thus bind to negatively charged cell wall 
components, such as lipoteichoic acid (LTA). This suggests that negatively charged 
LTA may be involved in the surface anchoring of these proteins. The same can be 
assumed for S. aureus Triiso with a pI of 4.8. 
In summary, both the increased expression of Triiso and the acidic growth conditions 
(< pH 5) after biofilm growth lead to an increased presentation of the protein at the  
S. aureus surface and obviously to a better accessibility of the epitope for anti-Triiso 
moAb H8. On the contrary, the pH does not seem to influence the occurrence of pOxi 
because no differences were detected in this case (Fig. 3.12B; see 4.1). In contrast 
to Triiso the pI of pOxi (6.3) is much higher. These results would also explain the 
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binding signals of anti-pOxi moAb D3 in flow cytometric analyses after planktonic 
growth conditions, compared to the non-binding of anti-Triiso moAb H8. 
 
4.4 Extracellular matrix proteins associate with the S. aureus cell surface 
Our vaccine candidates do not contain any signal motives so that it is possible that 
they do not reach the surface from the intracellular space but from the outside, where 
lysed bacterial cells act as a donor. In addition to its occurrence on the bacterial 
surface, native Triiso from S. aureus was detected by moAb H8 in the extracellular 
medium after planktonic growth to the mid-exponential phase (Fig. 3.17). In contrast, 
hp2160 and pOxi were verified at the bacterial surface, but they were not detectable 
in the medium supernatant under these conditions.  
It has previously been reported that a variety of species of gram-positive bacteria, 
including S. aureus, release cytoplasmic proteins into the external environment 
during stationary phase. It is likely that these released proteins produced by gram-
positive pathogens are an important component of an enhanced virulence (Foster et 
al., 2005). Using the CA-MRSA strains MW2 and USA300, Burlak and colleagues 
(2007) identified a range of extracellular proteins that are known to be associated 
with the virulence of S. aureus. In accordance to our results they also identified Triiso 
as an exoenzyme, as well as the glycolytic enzyme enolase. Enolase mediates 
binding to host tissues (Carneiro et al., 2004) and it is known to activate the clotting 
cascade in conjunction with the main actor coagulase, which was also identified in 
medium supernatant (Molkanen et al., 2002; Panizzi et al., 2006; see Fig.1.5).  
After biofilm growth, which creates an acidic pH, a larger amount of Triiso was found 
at the surface of S. aureus. After increasing the pH most of the protein was detected 
in the supernatant (Fig. 3.12A). In vivo the same might happen: After activation of the 
clotting-cascade by coagulase S. aureus proliferates, which decreases the pH by 
production of metabolic waste products. By an undefined way (from lysed cells or by 
secretion) Triiso reaches the surface and is anchored to surface compounds, such as 
LTA (compare 4.2).  When fibrinolysis is initiated by staphylokinase at a defined 
bacterial cell density (quorum sensing), S. aureus singularizes and can reach the 
surrounding tissue through the blood, which results in an increase of the surface pH 
and the detachment of Triiso. It is likely that anti-Triiso moAb H8 binds in vivo only to 
the secreted, but not cell wall-associated form of Triiso for inhibiting its moonlighting 
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role, which needs to be further characterized. This would also explain the non-
binding of moAb H8 to Triiso at the S. aureus surface after planktonic growth, where 
we hypothesized that the epitope of moAb H8 is not accessible (compare 4.2).  
In further experiments, we demonstrated that exogenously added S. aureus proteins 
are able to attach to the cell surface of biofilm grown S. aureus. The principle aim of 
this experiment was the detachment of bound moAbs from the surface of biofilm 
grown S. aureus by their respective epitope peptides. Performing competition 
experiments to verify specificity of moAb binding to S. aureus surface, we showed in 
contrast to pOxi- and TriisoC4 peptides that competed with binding of the respective 
moAbs to the S. aureus surface, an addition of the protein Triiso increased the 
binding of anti-Triiso moAb H8. The same was shown after trying to compete anti-
pOxi moAb D3 binding with whole pOxi protein (Fig. 3.23). Moreover, it was possible 
to spike biofilm grown S. aureus with the exogenous, recombinant proteins pOxi and 
Triiso. While it was assumed that the proteins bind non-specifically at the S. aureus 
surface, anti-His6-tag antibody by itself was not able to bind. 
In Δica mutants it has been shown that protein A (SpA) is essential for biofilm 
formation. The ica operon is important in mediating biofilm formation (Cramton et al., 
1999).  Biofilm growth in ΔspA mutants was recovered by addition of exogenous SpA 
indicating that it is not necessary for SpA to be covalently anchored to the cell wall, 
but it is also functional as an added exogenous form (Merino et al., 2009).  
The mechanism by which proteins lacking signal peptides are exported from cells is 
unclear and both mechanisms, specific by e.g. protein secretion or non-specific by 
e.g. cell lysis, are possible (Pasztor et al., 2010; Yang et al., 2011; Boel et al., 2005).  
A conceivable mechanism is also a regulated autolysis as basis of extracellular 
presence of moonlighting cytoplasmic proteins (Foulston et al., 2014).  
Because binding of anti-Triiso moAb H8 and anti-hp2160 moAb 16-2 to S. aureus 
was only detected under biofilm conditions we assume that endogenous Triiso and 
hp2160 were released from the cytoplasm after cell lysis during biofilm formation and 
associated with the surface from the extracellular space, which would explain the 
positive binding after biofilm growth.  
However, it has been described for some bacteria including S. aureus that DNA and 
signal motif lacking proteins found extracellularly are independent of cell lysis and 
instead a secretion of small lipid-bilayer vesicles is involved in this process (Brown et 
al., 2015). A clarification of the pathway and natural conditions necessary for cell wall 
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association of vaccine candidates, would give a better understanding of the mode of 
action of our protective moAbs. 
 
4.5 Analysis of opsonophagocytosis mediated by moAbs 
The main function of immunoglobulins is opsonization of pathogens and mediating 
the increased uptake by phagocytic cells, which bind IgGs via the Fc region. 
Therefore, we wanted to analyze whether our murine or humanized monoclonal 
antibodies are able to promote phagocytosis of murine macrophages or human 
neutrophils.  
With IVIG, as well as with anti-Triiso and anti-pOxi polyclonal antibodies purified from 
IVIG, opsonophagocytosis by neutrophils was measured via flow cytometry. The 
results matched with those, obtained by Glowalla et al. (2009) and Bettina Tosetti 
(PhD thesis, 2010). Polyclonal antibodies were enriched by affinity chromatography 
using Triiso or pOxi immobilized to a column medium.  
In contrast, with our monoclonal antibodies, we were not able to show an enhanced 
phagocytosis by human neutrophils, as well as by murine macrophages upon 
opsonization of S. aureus, which was an unexpected finding (Fig. 3.14, 3.15). At a 
later point of time we discovered in flow cytometric analyses by changing wildtype 
against protein A deletion mutant, a specific binding to the S. aureus surface was 
only detectable with anti-pOxi moAb D3. Especially anti-Triiso moAb or humAb H8 
showed high affinity to protein A. Thus, non-opsonization of anti-Triiso moAb/humAb 
H8 and anti-hp2160 moAb/humAb 16-2 was not surprising, while anti-pOxi 
moAb/humAb D3 should have been able to opsonize. Clearly, additional factors, 
such as complement are necessary to trigger in vitro opsonophagocytosis. 
Phagocytosis is typically promoted by complement and antibodies binding to 
receptors on the cell surface (Lee et al., 2003). However, an enhanced uptake of     
S. aureus by neutrophils was even shown without opsonins after adding baby-rabbit 
complement in previous experiments (data not shown). Because the complement 
itself was able to trigger in vitro phagocytosis it was not used in following trials, 
missing probably important factors to demonstrate phagocytic efficacy of our moAbs.  
Non-binders anti-Triiso H8 and anti-hp2160 16-2 under planktonic growth conditions 
showed a binding activity upon in vitro biofilm growth of S. aureus ΔspA.  To perform 
flow cytometric analyses with biofilm grown S. aureus remains difficult, as for these 
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analyses bacteria have to be treated under acidic pH conditions and were fixed with 
paraformaldehyde. These assay conditions are quite inappropriate for phagocytosis 
analysis.  
Binding analyses of anti-Triiso moAb H8 to whole S. aureus cells and extracellular 
occurrence of Triiso at mid-exponential phase of planktonic growth have shown that it 
is possible that moAb/humAb H8 does not bind in vivo to the surface-associated but 
to the secreted form of Triiso. In this case, it would not be possible to show an 
opsonophagocytosis in vitro.   
 Lu et al. (2014) proved that in vitro assay conditions have a significant influence on 
phagocytosis and killing of S. aureus by neutrophils. They found out that 
phagocytosis by adherent neutrophils is comparable for serum opsonized and 
unopsonized S. aureus. In vivo it is possible that human serum may provide 
adequate opsonization because of high levels of naturally occurring antibodies 
directed to S. aureus and that increasing the amount makes no appreciable 
difference for S. aureus killing (Dryla et al., 2005; Sause et al., 2016). Although 
neutrophils are essential for host defense against S. aureus infection it is known that 
all vaccine approaches that showed an opsonophagocytic activity in vitro have failed 
to demonstrate protection in human trials (Giersing et al., 2016). Therefore, 
opsonophagocytosis is not a biomarker for antibodies to be successful in clinical 
trials. Hence, we investigated the moonlighting activities of the antigens and how the 
moAbs can interfere. It is possible that our generated monoclonal antibodies do not 
promote phagocytosis but neutralize the respective protein by inactivation or 
inhibition of the antigen’s moonlighting function. To go on with opsonophagocytic or 
killing analyses, optimal in vitro assay conditions have to be found, which remains 
problematic. However, it is obvious that in vivo conditions for S. aureus and the 
interplay of phagocytic cells with additional factors occurring in blood and tissue 
completely differ from the artificially created conditions in shaking flasks using broths.    
 
4.6 Triiso’s moonlighting role and mode of action of anti-Triiso moAb H8  
Moonlighting proteins are described to have two or more different functions (Jeffery, 
1999). Because we have not identified an opsonophagocytic activity with neutrophils 
and macrophages we focused on other possible functions of anti-Triiso moAb H8. 
Therefore, the moonlighting role of Triiso had to be determined. In this context 
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Pancholi and Chhatwal (2003) described the importance of housekeeping enzymes 
as virulence factors for a variety of pathogens. 
One possible approach was the analysis of Triiso’s enzymatic activity that might be 
inhibited by moAb H8 because of a binding at the active site. The enzyme Triiso is 
part of the glycolysis, which happens in the cytoplasm. Henderson and Martin (2011) 
hypothesized that glycolysis can also happen at the pathogen’s cell surface. In 
human cells the glucose concentration of the extracellular medium is 5 mM. This 
indicates sufficient glucose to allow glycolysis on the surface of bacteria that are 
infecting or colonizing humans. The generation of ATP can be used for as yet 
undefined processes or the generated substrates of glycolysis have signaling actions 
to other bacteria.  
We measured an enzymatic activity with recombinant Triiso, as well as in cell lysate 
and in the isolated cell wall associated protein fraction (fig. 3.16A) and therefore, we 
went on with activity assays in presence of anti-Triiso moAb H8. We were able to 
demonstrate that surface occurring Triiso is enzymatically active, but could not detect 
an inhibition of its activity by moAb H8 (Fig. 3.16B). This result indicates that binding 
of moAb H8 to Triiso does not influence its active site. Therefore, inhibition of Triiso’s 
enzymatic activity does not seem to be the mode of action of moAb H8. 
It was described that the rate of nosocomial infection is higher in patients with an 
increased glucose concentration in blood (Pomposelli et al., 1998). Glycolysis and 
ATP generation increased acidification of the medium due to fermentation of glucose. 
Interestingly, acidification leads to an increased expression of a range of extracellular 
virulence factors for optimal performance in the acidic milieu. Other virulence factors 
are down-regulated allowing S. aureus to adapt to the changing environment 
conditions (Weinrick et al., 2004). We measured an acidification after biofilm growth. 
The biofilm growth medium contains a higher amount of glucose than media used for 
planktonic growth. In Fig. 4.2 it is shown that binding of moAb H8 to Triiso was only 
detected after biofilm growth. Although it does not inhibit the enzymatic activity of 
Triiso it is possible that moAb H8 is only able to act under in vivo conditions, where a 
high amount of glucose is available (such as in biofilm culture medium). Because 
Triiso is up-regulated under biofilm conditions (Becker et al., 2001), increased 
surface presentation and secretion into the extracellular space is obvious, which may 
change the binding conditions or epitope availability for moAb H8 and reveals its 
mode of action.  
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A range of S. aureus surface proteins play important roles in adherence to host cells 
and cell invasion. A moonlighting function of Triiso was identified as a host 
plasminogen binder and inhibitor (Furuya and Ikeda, 2011). Other glycolytic enzymes 
are described to have similar functions. GAPDH has been reported to be a 
transferrin-, fibronectin-, laminin- and plasmin-binding protein (Modun and Williams, 
1999; Modun et al., 2000; Gozalbo et al., 1998). Enolase of S. aureus binds host 
plasminogen and enhances the conversion to plasmin (Molkanen et al., 2002), which 
would be the antagonistic function to Triiso. The function of the activated form 
plasmin is fibrinolysis (Hekman and Loskutoff, 1987), in contrast to blood 
coagulation. The main actors of these processes are staphylokinase and coagulase 
(compare to 1.5.1). 
Concerning our results, we detected an interaction between Triiso and human 
plasminogen (Fig. 3.18, 3.19A). Binding of plasminogen to Triiso detected by ELISA 
and Far Western blot was weak, but detectable and matches to those signals, 
detected by Furuya and Ikeda (2011). An inhibition of the interaction between Triiso 
and plasminogen by moAb H8 was not measured indicating that the plasminogen 
binding site of the Triiso molecule was not blocked by moAb H8 (Fig. 3.19B). Enolase 
of Streptococci possesses two C-terminal lysine residues that were found to be 
important for plasminogen binding (Derbise et al., 2004). Two lysine residues also 
occur at the C-terminus of both S. aureus enolase and Triiso. Our anti-Triiso moAb 
H8 does not bind in this area and can therefore not directly interfere with this 
interaction. 
Furthermore, we were interested in investigating the influence of moAb H8 on Triiso’s 
inhibition of plasminogen activation. An inhibition of plasminogen activation by 
staphylococcal Triiso was described by Furuya and Ikeda (2011). Unexpectedly, we 
did not observe initially an inhibition of the conversion of plasminogen to plasmin in 
presence of recombinant Triiso (Fig. 3.20B). Therefore, we were not able to 
demonstrate any influence of our moAb to this effect. Triiso from S. aureus was used 
in the experiments of Furuya and Ikeda, whereas we used the recombinant one. 
However, when we used whole S. aureus cells, no effects of influencing plasminogen 
activation were measured (Fig. 3.20C). Although an interaction between Triiso and 
plasminogen was detected, our results did not confirm the findings of Furuya and 
Ikeda.  
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In addition to its plasmin- and plasminogen-binding, the enzyme enolase is also 
described to bind the extracellular matrix protein laminin (Carneiro et al., 2004). 
GAPDH is known to bind transferrin, a glycoprotein that transports iron from serum to 
cells (Modun and Williams, 1999; Modun et al., 2000). The glycolytic enzymes like 
GAPDH, enolase and Triiso are localized in an operon, which is conserved in 
Staphylococci (Becker et al., 2001). Hence, we suggest that further binding analyses 
are necessary. For future experiments we want to analyze the binding of Triiso to 
other blood components like transferrin, laminin, fibronectin and fibrinogen. 
Triiso is also described as a lectin that binds to the fungus Cryptococcus neoformans 
via a capsular polysaccharide and induces apoptose-like cell death of this yeast 
species by recognizing and binding to mannose residues (Furuya and Ikeda, 2009). 
We supposed that Triiso is engaged in direct adhesion to host cells. Unexpectedly, 
only detect a very weak binding of recombinant Triiso to endothelial and epithelial cell 
lines could be detected in contrast to the protein pOxi (see 4.7). This may indicate 
that Triiso plays a different role in infection of the host. 
 
4.7 Identification of pOxi as adhesion protein and mode of action of anti-pOxi   
      moAb D3 
The existence of the S. aureus deletion mutants ΔpOxi and Δhp2160 proved that 
both proteins are not essential for the bacterium. A mutant with a Triiso deletion was 
not available in the data bank of NARSA (Network on Antimicrobial Resistance in    
S. aureus), which indicates that Triiso is an essential enzyme. As a part of the 
glycolysis this seems obvious. 
We analyzed the exponential growth of the two deletion mutants compared to 
wildtype under planktonic conditions. In contrast to wildtype and Δhp2160 an 
interesting result was the impaired in vitro growth of ΔpOxi representing pOxi as an 
important protein for S. aureus (Fig. 3.21A).  
Compared to Bacillus subtilis, where pOxi is a peripheral membrane protein 
(Hansson and Hederstedt, 1994), pOxi occurs in the cytoplasm, and according to our 
experiments also on the S. aureus surface as a non-covalently bound protein. In the 
cytoplasm pOxi (= HemY) is involved in heme synthesis (Frankenberg et al., 2003).  
It is an O2-dependent protein in S. aureus and was recently described as a 
coproporphyrin synthase that oxidizes coproporphyrinogen III into coproporphyrin III 
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in heme pathway and does not oxidize protoporphyrinogen into protoporphyrin as 
thought before (Panek et al., 2002; Lobo et al., 2015). Like Lobo and colleagues, we 
also tried to measure the enzymatic activity of recombinant pOxi by using 
protoporphyrinogen as substrate. We reduced protoporphyrin, but did not measure 
any oxidation after adding pOxi to the reaction mixture. The new findings of Lobo et 
al. now explain the outcome of our experiments. 
Heme is essential for the respiratory electron transport chain as a cofactor of 
cytochromes and catalase. With the lack of pOxi, S. aureus is not able to produce 
heme endogenously. The organism is auxotrophic to hemin, the precursor of heme. 
After adding hemin to the medium ∆pOxi returned to a similar growth as the wildtype 
(Fig. 3.21B). When heme or hemin is not extracellular available S. aureus has to 
switch to fermentation, which obviously slows down the rate of expansion. 
Growth of ΔpOxi on agar plates was also decelerated. After two or three days of 
growth, small colony variants (SCV) were detected. SCVs are a subpopulation, which 
was detected to be well adapted to the intracellular milieu and described for many 
clinical isolates (Sendi et al., 2006; Proctor et al., 1995). The two subpopulations with 
different phenotypes allow S. aureus the option of both extracellular and intracellular 
survival and persistence in the host (Sendi and Proctor, 2009). Heme auxotrophy has 
an influence on colony size and doubling time because the bacteria require large 
quantities of ATP for cell wall synthesis. In accordance to our results the same 
phenotypes were obtained after deletion of hemB and hemQ, other members of the 
heme biosynthetic pathway (von Eiff et al., 1997; Mayfield et al., 2013).    
In previous experiments we looked for growth inhibition of wildtype strain JE2 in 
presence of anti-pOxi moAb D3. A neutralization of surface-associated pOxi by moAb 
D3 would have been influenced the normal growth of the wildtype strain, but we did 
not detect any specific differences in growth (data not shown). We were also 
interested in an in vivo investigation using the pOxi deletion mutant and detected that 
ΔpOxi is less virulent as the wildtype (Fig. 3.22). Although it is supposed that the 
main amount of pOxi occurs intracellular, these observations might also influence the 
moonlighting role of surface-associated pOxi.  
It is known that S. aureus is able to adhere to and invade in many different cell types, 
such as epithelial and endothelial cells (Lowy, 2000). In further analyses we 
demonstrated that recombinant pOxi is able to adhere to epithelial, as well as 
endothelial cells. This adhesion can be inhibited by our moAb D3 indicating its 
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possible mode of action (Fig. 3.24). We went on with flow cytometric analyses using 
whole S. aureus cells and showed a decrease in S. aureus adhesion upon addition of 
moAb D3 (Fig. 3.25). In 4.4 it was already explained that the S. aureus cell surface 
can be spiked with exogenously added pOxi. We proved that an addition of 
exogenous pOxi to biofilm grown S. aureus increased the binding of the bacterium to 
epithelial cells by two fold (from 21 % to 44 %). After addition of moAb D3, binding 
was decreased from 44 % to only 6 % indicating an inhibition of host cell adhesion by 
our moAb D3.  
Besides the anchorless cell wall protein pOxi, several S. aureus surface proteins are 
described to contribute to host cell adherence. Beneath cell wall-anchored adhesion 
proteins of the MSCRAMM family, S. aureus also comprises non-covalently bound 
proteins, such as the autolysins AtlA and AtlE or secreted proteins, such as Eap of 
the SERAM (= secretable expanded repertoire adhesive molecules) family that are 
involved in adhesion (Paharik and Horswill, 2016; Chavakis et al., 2005). Additionally, 
there are many structurally uncharacterized proteins, such as surface protein SasX 
that promotes aggregation on cell surfaces for biofilm formation (Foster et al., 2014).  
To clarify the function of the surface-associated pOxi to contribute to host cell 
adhesion, a deletion mutant of the major adhesion factors fibronectin-binding proteins 
(FnBPs) would be important. Many further adhesins of the MSCRAMM family are 
able to adhere directly to host cells. Previous data showed that S. aureus is able to 
bind to host cells in absence of FnBPs, but adherence as well as invasion properties 
are much reduced (Sinha et al., 2000). Thus, an inhibition of pOxi might have an 
influence on preventing host adhesion.  
We propose that pOxi plays several moonlighting roles as observed for Triiso. To 
promote adhesion to host cells is obviously one of these functions. For example, Isd 
proteins adhere to hemoglobin with the ability to capture heme, which helps the 
bacteria to survive in the iron limited environment in the host (Foster et al., 2014). 
The contribution of pOxi to host cell adherence might also support an additional 
major moonlighting function, providing a benefit for S. aureus. 
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4.8 Antibody-mediated immunity and protection against MRSA mediated by  
      vaccination with synthetic epitope peptides 
The second part of this thesis highlighted the development of an active vaccine 
against S. aureus infection. We suggested that a peptide vaccine combining the 
analyzed protective epitopes of our generated monoclonal antibodies would result in 
an effective polyvalent vaccine. Peptide vaccines under current development target 
mainly viral pathogens, such as malaria, HIV or HCV (Liu et al., 2007; Epstein et al., 
2007; Kolesanova et al., 2013). But also peptide vaccines against S. aureus were 
already described and achieved protective effects (Chen et al., 2011; Zhao et al., 
2015; Yang et al., 2016). All these approaches based on the identification of 
immunogenic epitopes with serum containing polyclonal antibodies after active 
immunization with a whole antigen. The application of epitopes derived from 
protective monoclonal antibodies was not applied so far.   
All used synthetic peptides based on the identified linear epitopes (hp2160-, pOxi- 
and TriisoC4 peptide) and conjugated to carrier proteins, a high and specific serum 
IgG titer against the whole antigen was achieved by vaccination of mice (Fig. 3.27). 
These results point out that the constructed peptide-conjugates are together with 
Freund’s adjuvant effective immunogens for the generation of antibodies. With the 
different conjugates KLH and BSA we did not observe any differences concerning the 
IgG titer in serum, although KLH is known to be more immunogenic. The only 
detected differences concerning IgG titer were related to precipitation problems with 
KLH conjugates, which is a larger and more hydrophobic protein than BSA. The 
precipitation problems led presumably to a higher spread and a lower IgG response 
within the group, which was observed with pOxi-KLH. The precipitated synthetic 
peptides only induced a moderate serum IgG level after the first boost. Therefore, we 
decided to set a second boost and measured an increase in IgG level. 
In general, we showed that IgG titers of initially immunized mice increased to 10-15-
fold after the second boost. An increase from first to second boost was especially 
measured during immunization with recombinant triepitope, where the titer has been 
increased around 1-1.5 logs after the second boost (Fig. 3.41).  
The aim for further immunization studies would be to consider setting only one boost, 
which would be advantageous for patients later on. Instead of three times patients 
would only exposed two times to the vaccine and its containing adjuvant. 
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Additionally, one boost instead of two would reduce vaccine production costs.  
Possibly, a protective effect can also be achieved with the humoral immune response 
detected after the first boost because we verified that the IgG level does not correlate 
with protection of mice.  
The IgG titers were still detectable in the serum 50 days after the last boost, 
indicating the existence of a memory response. Upon later exposure to the same 
epitope long-lived plasma cells are able to secrete large amounts of specific 
antibodies. Manz et al. (1997) determined that plasma cells in the bone marrow after 
a booster immunization survived for more than 90 days without proliferation. The 
second type of memory response describes memory B-cells that are unable to 
produce antibodies, but differentiate rapidly into antibody-secreting cells following re-
exposure to antigen (Nutt et al., 2015). Memory B-cells are generated during primary 
humoral responses to antigens and requires the help of Th-cells. T-cell epitopes are 
presented in the sequences of the protein conjugates KLH or BSA. For this reason 
our results are a first hint of a CD4+ T-cell dependent immune response achieved by 
our peptide-conjugates, which is important for our peptide vaccination model.  
The infection of mice was performed by intraperitoneal infection. Although started 
with intravenous infection we realized that intraperitoneal administering is more 
precise. Concerning our in vivo trials an application of exactly the same volume of the 
pathogen to every mouse is of great importance for comparing the protective effects 
of our vaccines. The i.p. infection of lethal doses was already used in active 
immunization trials (Stranger-Jones et al., 2006; Rauch et al., 2012).  The infection 
requires a very large inoculum to develop lethal disease of peritonitis/sepsis in mice. 
The animals typically succumb within 12-24 hours of challenge (Kim et al., 2014). We 
add 5 % mucin to the bacterial preparation because mucin from porcine stomach was 
already used for the mouse model of passive immunization. This increases the 
bacterial virulence and therefore, a lower dose of S. aureus can be applied             
(A. Klimka, unpublished data). Fattom et al. (1996) also used 5 % hog mucin in their 
mouse lethal challenge model and proved that mucin alone did not induce mortality in 
mice. The lethal inoculums of 1.1 to 3.3 x 107 CFU we used are approximately three 
logs lower compared to those of Stranger-Jones and colleagues, who did not use 
mucin. Rauch et al. used doses between 5 x 108 and 6 x 109 CFU, which are also 
much higher as our inoculums.   
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For sublethal challenge we started with half of the determined lethal dose, but 
detected in every new in vivo trial that the virulence of the used S. aureus inoculum 
decreased. To exclude a pre-immunization of mice within the breed, mice were 
ordered at the ZMMK (Uniklinik Köln). In contrast to e.g. Charles River as an animal 
provider, the ZMMK animal facility is extremely cautious and tests against S. aureus 
directly after birth. 
Immunization with the single peptides hp2160 and pOxi led to a reduction of bacterial 
colonization in all prepared organs after sublethal infection. Whereas hp2160-KLH 
conferred only statistically significant reduction of S. aureus CFU in the liver, the 
reduction was highly significant in all organs upon immunization with pOxi-KLH (Fig. 
3.30, 3.32). Bivalent immunization with both hp2160-KLH and pOxi-KLH also 
reduced the bacterial load in organs significantly (Fig. 3.34), but compared to pOxi-
KLH alone the bivalent vaccination was less significant after statistical analysis by 
Mann-Whitney test, demonstrating no synergistic effect. One reason could be that 
only half the amount of each peptide-conjugate was used for bivalent vaccination. 
However, the mean concentration of anti-pOxi IgGs in mouse sera is similar in both 
cases (Fig 3.31, 3.33). Further reasons might be a stronger protective effect of pOxi 
epitope peptide or less protection efficacy of hp2160 peptide that restrained the 
efficacy of pOxi peptide in the bivalent immunization approach. These results are 
similar to those, obtained by Bettina Tosetti (PhD thesis, 2010), who demonstrated 
that the whole antigen pOxi alone still conferred statistically significant protection 
against S. aureus, whereas bivalent immunization with pOxi and Triiso did not 
achieve significant results in protection.  
Immunization with the synthesized epitope peptide of anti-Triiso moAb C4 did not 
achieve any significant results concerning a reduction of bacterial colonization in 
organs (Fig. 3.36). Compared to synthetic pOxi- and hp2160 peptide an equal 
concentration of antigen-specific IgG titer in serum of mice was determined and also 
still remained in serum 50 days after the last boost (Fig. 3.35A). Additionally, anti-
Triiso IgGs of the pooled mouse serum were able to bind to S. aureus Triiso of 
isolated cell wall-associated protein fraction (Fig. 3.35B). In contrast to the other 
challenges (Fig. 3.30, 3.32, 3.34) the bacterial burden detected in organs of the 
control group was lower in this experiment. After analyzing and comparing the IgG 
titers of the different mouse sera we determined that a strong IgG titer does not 
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correlate with a reduced bacterial colonization. This was also determined in animal 
trials with hp2160- and pOxi peptide.  
It is obvious that the moAb C4 epitope does not reveal such a robust protection 
against MRSA as our other identified epitopes do. Interestingly, a recent passive 
immunization trial using anti-Triiso moAb C4 did not show protection in the murine 
model. These findings demonstrate that the epitope peptide of non- or low-protective 
moAb C4 is not capable of inducing a protective immune response as a vaccine and 
supports our hypothesis that a successful vaccine is epitope- rather than antigen-
specific. 
 
4.9 Polyepitope peptides as multivalent active vaccine against MRSA 
We went on with cloning of a triepitope fusion peptide containing the linear pOxi and 
hp2160 epitopes, as well as the discontinuous epitope of anti-Triiso moAb H8 within 
the analyzed Triiso fragment (N’-pOxi-Triiso fragment-hp2160-C’). As one of the 
leading candidates for passive immunization we were interested in an inclusion of the 
moAb H8 epitope for a generation of a multivalent construct. The cloning procedure 
was followed by a successful heterologous overexpression in E. coli and purification 
via its His6-tag. After expression the highest amount of the peptide was found in 
inclusion bodies, which are insoluble aggregates of non-native peptide/protein 
(Baneyx and Mujacic, 2004). A protein gel of triepitope peptide showed several 
bands above 35 kDa, in addition to the 14.3 kDa band of the fusion peptide (Fig. 
3.38). The same bands were detected with anti-pOxi moAb D3, anti-Triiso moAb H8 
and anti-hp2160 moAb 16-2 (Fig. 3.39), demonstrating that they are aggregates of 
the purified peptide.  
A strong competition of moAb-binding to hp2160, as well as to pOxi by the triepitope 
peptide was detected, indicating a successful cloning and recognition of the two 
small moAb epitopes (Fig. 3.40). The triepitope peptide also competed with moAb H8 
binding to Triiso but only moderately. A possible reason for this might be a stronger 
binding affinity of anti-Triiso moAb H8 to Triiso as to the triepitope.  
Another reason for the moderate competition effect might be that the epitope of 
moAb H8 is localized within a long amino acid sequence. This indicates that possibly 
some other kinds of anti-Triiso antibodies are produced besides moAb H8-like 
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antibodies by the immune system in vivo, because we detected a strong humoral 
immune response against recombinant Triiso. 
We achieved specific serum IgG titers against the three recombinant proteins pOxi, 
hp2160 and Triiso with the triepitope vaccination (Fig. 4.41). As already observed 
with single epitope peptides the serum IgG titer still remained at the same level 50 
days after the last booster immunization, which is a relevant result for our infection 
model. Compared to pOxi and Triiso the immune response to hp2160 was moderate. 
A reason might be that the fusion and the C’terminal His6-tag altered the structural 
properties of the hp2160 epitope peptide part in such a way that binding of anti-
hp2160 moAb 16-2 is disturbed to some extent. 
Mice immunized with the triepitope peptide that were challenged with MRSA showed 
a significantly increased bacterial clearance in the examined organs (Fig. 3.43). The 
KLH-conjugated triepitope peptide was analyzed within the same animal trial as 
hp2160-KLH. Compared to hp2160 conjugate, triepitope revealed an expected more 
protective effect. These results were the reason for cloning of diepitope peptides 
without the hp2160 epitope. The diepitopes OTO (N’-pOxi epitope-Triiso fragment-
pOxi epitope-C’) and pOT (N’-pOxi epitope -Triiso fragment-C’) were successfully 
overexpressed in E. coli, whereas TpO (N’-Triiso fragment-pOxi epitope-C’) was not 
(Fig. 3.45). All peptides are very small so that we anticipated some problems with 
overexpression and therefore designed different constructs. Small peptides undergo 
degradation by proteinases easily, which might have happened to TpO (Baneyx and 
Mujacic, 2004). The highest amount of the two other peptides was detected in the 
soluble fraction. Binding of anti-pOxi moAb D3 and anti-Triiso moAb H8 and 
competition experiments proved both diepitope peptides to contain the correct 
epitope sequences and functionality. Compared to triepitope, competition of moAb 
H8 binding to Triiso was stronger with both diepitope peptides (Fig. 3.47). Possibly, 
the relative binding affinity of OTO as well as pOT to moAb H8 is higher, which has 
not been determined. 
Immunization with the diepitope pOT was more successful in the sublethal animal 
model than with OTO, although OTO led to a stronger humoral immune response 
against recombinant pOxi (Fig. 3.48, 3.49). This difference was expected because 
OTO contains two pOxi epitopes within one molecule. Due to the high serum IgG titer 
achieved by OTO immunization, a conformational problem of OTO compared to pOT 
was excluded. The difference between the two diepitopes concerning their protective 
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effects might stem from different T-cell responses. OTO immunization possibly led to 
a T-cell independent B-cell activation, but a comparison was not further investigated 
in this work. We went on with the most promising candidate pOT. Compared to 
triepitope immunization, pOT achieved very similar results in organ-CFU trials with 
the same significance in all examined organs. Nevertheless, diepitope pOT was 
preferred for the first survival experiments. The reason was that hp2160 epitope 
peptide did not work as well as pOxi epitope in former organ CFU experiments and 
was therefore omitted in the diepitope peptides. We conclude that the hp2160 
epitope is negligible in providing protection compared to the other examined peptides 
and has instead a detrimental effect on protection efficiency. 
The diepitope peptide pOT was able to significantly protect mice from lethal 
challenge with MRSA (Fig. 3.52). A further comparison of pOT with single pOxi 
peptide resulted in 100 % protection after immunization with pOxi-BSA conjugate and 
90 % protection using pOT-KLH conjugate, which demonstrates their great protective 
effect (Fig. 3.53).  
A synergistic effect of pOT, compared to pOxi was not detected, highlighting pOxi 
epitope peptide as the most promising candidate for peptide vaccination. However, 
the development of a polyvalent vaccine is of greatest interest. This is the reason 
why we want to go on in analyzing the epitope of anti-Triiso moAb H8, reducing its 
size but retaining its specificity. We suppose that a pure and synthesized TriisoH8 
epitope peptide would provide more effective protection against MRSA and in 
combination with pOxi peptide would result in a stronger synergistic effect. A di- or 
polyepitope would also be necessary to target escape mutants. With the single 
TriisoH8 peptide it would also be possible to investigate the efficacy of monovalent 
vaccination compared to the diepitope peptide. 
Although we identified the pOxi epitope and pOT diepitope as promising candidates 
for the development of an active vaccine, the remaining epitopes hp2160 and 
triepitope should not be disregarded and additionally still further investigated. If they 
are not protective against lethal challenge, they might attenuate the infection by 
making S. aureus more sensible to antibiotics, so that patients can be treated more 
easily (adjunctive therapy). 
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4.10 Induction of T-cell-mediated immune response with polyepitope peptides  
We have determined that the IgG level detected in sera of mice upon vaccination 
does not correlate with the protection of mice against S. aureus infection. It has been 
described that the cellular immune response, with particular attention to Th1 and 
Th17 cells becomes more important in case of S. aureus infection (Moyle and Toth, 
2013; Cho et al., 2010; Brown et al., 2015; Bröker et al., 2016). We proposed that not 
only the epitope-specific antibody level supported by Th2 response, but also the 
outcome of the cellular immune response influences the obtained protection and 
therefore we were interested in analyzing the T-cell response upon vaccination with 
epitope peptides, in addition to humoral immune response. In a study, where 
immunization with IsdB revealed the generation of specific antibodies, protection 
against S. aureus was only achieved in T-cell competent but not in deficient mice, 
which additionally underlines the importance of T-cell response (Joshi et al., 2012). 
For an investigation of the T-cell response triepitope-KLH and the promising 
diepitope pOT-KLH were used. The single epitope peptides were only available as 
BSA conjugates in our lab because of precipitation problems with KLH conjugates. 
An immunization with BSA conjugates would result in an undesired re-stimulation 
with the medium supplemented with fetal calf serum (FCS) during culturing of the 
dissected splenocytes. BSA is an integral part of FCS that cannot be omitted. Due to 
this fact, our analyses could only be done upon vaccination with KLH-conjugates.  
Before analyzing the cytokine profile, we were interested in a determination of IgG 
subclasses after the second boost. The IgG subclass is a result of the subtype of 
CD4+ T-cell response (Stevens et al., 1988). It is known that the Th1 cytokine 
interferon-γ (IFN-γ) stimulates the secretion of IgG2a, whereas the Th2 cytokine 
interleukin-(IL)-4 regulates the class switch to IgG1 in activated B-cells (Snapper and 
Paul, 1987; Petit-Frere et al., 1993). A high serum IgG1 level is a hint for a Th2 
mediated response, whereas a high IgG2a level is a hint for a Th1 response.  
The analysis of IgG subclasses upon vaccination suggested a stronger Th1 response 
in pOT-immunized mice because of a lower ratio of IgG1 to IgG2a than obtained with 
triepitope-KLH immunization. A stronger Th2 response in triepitope-KLH immunized 
mice was suggested because triepitope-KLH immunization was associated with an 
increased ratio of IgG1 to IgG2a (Fig. 3.60).  
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Both triepitope and pOT immunization resulted in a significant proliferation of 
splenocytes upon re-stimulation measured by BrdU incorporation, which consist of a 
variety of T-and B-lymphocytes (Fig. 3.61). This result indicates an immune response 
upon antigen exposure and highlights vaccine efficacy.  
We further investigated the secretion of certain cytokines. A strong release of IFN-γ 
was measured after exposure of splenocytes to the relevant antigens indicating CD4+ 
(Th1) and CD8+ cell proliferation (Fig. 3.62A). A difference between triepitope- and 
pOT immunization could not be detected. Both synthesized unconjugated pOxi and 
hp2160 peptides were able to induce IFN-γ release, which indicates a T-cell epitope 
within their peptide composition. Both did not stimulate KLH-specific splenocytes 
excluding an unspecific stimulation. pOT stimulates the IFN-γ production of KLH-
immunized mice stronger that the triepitope. This is obviously related to the 
purification grade of pOT that can contain endotoxin (lipopolysaccharide, LPS) 
derived from heterologous overexpression in E. coli. Endotoxin is known to induce 
IFN-γ production (Varma et al., 2002). However, compared to pOT-immunization, 
KLH-specific splenocytes were significantly less stimulated. The same was occurred 
by comparison of triepitope- and KLH-specific splenocytes.  
Previous studies proved the essentiality of IFN-γ competent CD4+ T-cells for survival 
in blood stream infections caused by S. aureus (Lin et al., 2009). Studies of Brown et 
al. (2015) demonstrated a significantly increased IFN-γ production in the peritoneal 
cavity soon after S. aureus i.p. challenge. After comparison with CD8+ T-cells they 
detected that CD4+ T-cells (Th1) were the primary source of IFN-γ in the infected 
mice. They also showed that human S. aureus blood stream infection induces         
S. aureus antigen-specific memory Th1 cells and developed a vaccine comprising 
ClfA, combined with the Th1-driving adjuvant CpG. This Th1-inducing vaccine 
candidate conferred significant reduced bacterial colonization in peritoneal cavity and 
examined organs of mice upon S. aureus infection. In comparison to our findings we 
already achieved a protective effect with our tri- and diepitope (pOT) vaccines and 
also demonstrated here a strong IFN-γ release after subsequent antigen exposure. 
We did not differentiate between CD8+- and CD4+ T-cells that both produce IFN-γ, so 
far. The role of CD8+ mediated T-cell response would also be interesting because    
S. aureus is able to persist inside host cells, such as epithelial and endothelial cells 
and professional phagocytes (Lowy, 2000; Löffler et al., 2014; Grosz et al., 2014) as 
small colony variants that were already described in 4.7.  
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IFN-γ secreted by T-cells is a potent activator of monocytes. It was detected that pre-
treatment of monocytes with IFN-γ increased their potential to eradicate intracellular 
S. aureus (Kubica et al., 2008; Smith et al., 2010).  
In addition to IFN-γ and IL-4 release, we were interested in IL-17 production by Th17 
and γδ-cells, which are known to be important for host defense against S. aureus 
(Bröker et al., 2016; Cho et al., 2010).   
Concerning vaccination approaches, a peptide construct mimicking peptidoglycan 
was described to provide partial protection from S. aureus challenge (Wang et al., 
2015). Compared to our peptide immunization model, they applied inactivated         
S. aureus cells as booster immunization. Their results showed that protection was 
associated with increased amounts of Th1 and Th17 cells in the spleen.  
In our studies a significant IL-17A production was measured upon re-stimulation with 
antigens from pOT- and triepitope-specific splenocytes, while KLH-specific 
splenocytes were non-reactive upon antigen exposure (Fig. 3.62C). IL-17 is 
produced by CD4+ Th17 cells and γδ- cells and important for neutrophil recruitment 
and priming them for bactericidal activity (Iwakura et al., 2008). It was found that 
mice deficient in epidermal γδ- but not αβ-T cells had larger skin lesions with higher 
S. aureus colonization and impaired neutrophil recruitment than wildtype mice (Cho 
et al., 2010). In γδ-deficient mice infected with S. aureus, the treatment with 
recombinant IL-17 restored the impaired immunity of these animals. In human skin, 
γδ-T cells have been reported to be recruited to a site of infection and a large amount 
of αβ-Th17-cells are found on inflamed skin (Modlin et al., 1989; Pene et al., 2008). 
All these findings underline the importance of cytokine IL-17 for host defense against 
S. aureus and a vaccine development directed to IL-17 elicitation. We detected that 
especially splenocytes of pOT-KLH immunized mice generated a significant 
increased IL-17A rate and suppose a correlation between the protective efficacy of 
pOT and IL-17 production.  
Compared to IL-17, pOT and triepitope vaccination resulted in a moderate release of 
the Th2 cytokine IL-4 upon re-exposure of all antigens, except hp2160 peptide, while 
KLH-specific splenocytes were non-reactive upon stimulation (Fig. 3.62B). These 
results indicate a weak Th2 response that was not as strong as IFN-γ and IL-17A 
mediated T-cell response. It is described that S. aureus infection induced a Th2 
response and that IL-4 plays a role in regulation of IFN-γ in S. aureus infection 
together with IL-10 (Sasaki et al., 2000). Compared to these findings, Brown et al. 
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(2015) were not able to detect IL-4 in the peritoneal cavity after S. aureus infection of 
mice.  
Compared to our results Joshi et al. (2012) were not able to detect IL-4 upon 
immunization with IsdB. They mention that the level of IFN-γ is negligible, whereas a 
large level of IL-17A was detected. Their results suggest that IL-17A producing Th17 
cells play an essential role in IsdB mediated protection after S. aureus challenge in 
mice. It has also been shown that the lack of T-cells in IsdB immunized mice impairs 
protection upon S. aureus challenge, while the lack of B-cells does not. 
Concerning our data, we conclude that the increased level of IFN-γ and IL-17A upon 
peptide immunization together with the strong antigen-specific IgG titer confers the 
protective effect against S. aureus. Especially the lead protective vaccine candidate 
pOT achieved these high levels, measured as an elevated IgG2a titer and high 
releases of both IFN-γ and IL-17A. 
For a comparison of T-cell responses of the remaining epitope peptides upon 
vaccination, a different conjugation method is necessary. We will switch again to KLH 
conjugates by limiting precipitation through slight changes of the epitope’s amino acid 
sequence. Additionally, branched peptides of B-cell epitopes might be constructed by 
addition of a potent T-cell epitope derived from the respective antigen. These multiple 
antigenic peptides (MAP) peptides would be advantageous for an application of our 
vaccines in humans. However, the construction of MAP peptides is a very expensive 
method and the search for a qualitative relevant T-cell epitope for achieving a strong 
and long-lasting immune response possibly needs several attempts.  
Furthermore, it was shown that in combination with a Th1-driving adjuvant CpG the 
vaccine antigen ClfA conferred protection in an S. aureus peritonitis model (Brown et 
al., 2015). In ongoing studies we will compare the adjuvant alum in addition to CpG 
that are both admitted to humans, with the previous applied Freund’s adjuvant as the 
next step of our vaccine development.  
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4.11 Recombinant viral vectors as vaccine platform against S. aureus  
In addition to peptide immunization we focused on alternative vaccination strategies. 
We used the two non-replicating viral vector systems MVA and AAV encoding the 
triepitope peptide as DNA vaccine platform. 
Modified Vaccinia virus Ankara (MVA) was already used as viral vaccine platforms, 
such as influenza and HIV, which entered clinical trials (Kreijtz et al., 2014; Garcia et 
al., 2011; Volz and Sutter, 2013). Although developed for vaccination against 
intracellular pathogens, antibody-based immune responses have often been 
demonstrated. In recent studies it has been shown that DNA vaccination against 
MERS coronavirus using recombinant MVA as delivery system in mice achieved a 
strong antibody titer in mice (Song et al., 2013). Additionally, specific CD4+ and CD8+ 
T-cell responses upon DNA vaccination with recombinant MVA have been detected 
(Hillaire et al, 2013). S. aureus is not only an extracellular pathogen, but also able to 
persist intracellular upon adhesion at and invasion into host cells. This emphasizes 
the importance of the host’s cellular immune response, as already described in 4.10.    
In addition to the conventional vector expressing the triepitope peptide (rMVA-SA-
Triepitope), a fusion protein of triepitope peptide and the vaccinia virus protein 
hemagglutinin (HA) was designed, which is transported and integrated into the host’s 
cell membrane after viral infection  and expression in host cells (Lehmann and Sutter, 
unpublished data). Vaccinia virus HA is not comparable to other hemagglutinins of 
e.g. influenza virus. Because of lacking hemagglutinic functions it is not essential for 
the infection of host’s cells. The HA-triepitope fusion protein is constructed by 
presenting the triepitope peptide to the extracellular space.  
After infection of cells the triepitope peptide was expressed as conventional and as 
HA-fusion protein, respectively, indicating that immunization with these vectors 
should work (Fig. 3.54). 
Immunization with rMVA-HA-SA-Triepitope induced a strong serum IgG titer against 
the respective whole antigens Triiso, pOxi, hp2160 and against the triepitope peptide, 
while the conventional vector rMVA-SA-Triepitope only achieved a moderate titer 
(Fig. 3.55). We already assumed that the titer of the conventional method would be 
lower because the triepitope was only endogenously expressed. After expression of 
the triepitope peptide in host cells it should be degraded and presented on MHC 
class I complex that activates cytotoxic T-cells (CD8+) for lysing the infected cells. For 
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the generation of an antibody-mediated immune response the released triepitope can 
be endocytosed by antigen presenting cells (APCs) for MHC class II presentation 
after cell lysis. Additionally, endogenous antigens can be presented by MHC class II 
when they are degraded through autophagy. Macroautophagy delivers intracellular 
proteins to lysosomal degradation and contributes to the pool of MHC class II 
displayed peptides. For this process, produced autophagosomes have to fuse with 
MHC class II containing compartments (Crotzer and Blum, 2009; Münz 2012). The 
explained possibilities were obviously not performed to a great extent because the 
virus is not able to replicate. This would explain the weak humoral immune response 
obtained by rMVA-SA-Triepitope. The second vector is additionally encoding the 
fusion protein of HA and triepitope, which is integrated in the membrane of the host 
cell upon expression. Thus, it can be directly endocytosed by professional APCs for 
MHC class II presentation, which additionally triggers antibody generation. Naturally 
occurring antibodies that recognize foreign residues on the host cell surface can 
opsonize the cell and bind to the Fc receptor of macrophages, which may additionally 
enhance the uptake.  Compared to our established conventional peptide vaccination 
the humoral immune response we obtained in this animal trial was less strong. 
Nevertheless, in case of rMVA-HA vaccination there was no need of an adjuvant, 
which is very advantageous. The high immune-stimulating potential by triggering 
rapid immigration of monocytes, neutrophils and CD4+ cells to the side of inoculation 
has already been described (Lehmann et al., 2009). 
According to previous animal trials we set two booster immunizations. The second 
boost revealed as not necessary because the titer did not significantly rose. The first 
boost was essential because an IgG titer was not measureable upon initial 
immunization. For analyses of its protective effect in animal trials we will go on with 
rMVA-HA-SA-Triepitope vaccination, which revealed as a promising alternative 
strategy.  
In a second vaccination strategy we analyzed two vector constructs of Adeno 
Associated Virus (AAV). Cloning of the two plasmids encoding the triepitope and the 
triepitope-VP2 fusion protein was successful and necessary for vector packaging, 
which was performed by our cooperation group (Fig. 3.56). With the conventional 
vector AAV2:Tri expressing the triepitope peptide we expected a similar result in 
vaccine-induced humoral immune response as observed with MVA-SA-Triepitope.  
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Compared to MVA vaccination an IgG titer in mouse sera was not detected (Fig. 
3.59). The titer of capsid and genomic particles was analyzed. The similar capsid-to-
genomic-particle ratios indicate that the incorporation of the triepitope peptide into the 
AAV capsid by fusion to VP2 did not affect the vector packaging efficacy (Tab. 3.2). 
The transduction of eukaryotic cells demonstrated the expression of intracellular 
triepitope peptide (Fig. 3.57). The western blot of modified capsid proved the 
successful incorporation of the triepitope peptide in contrast to the wildtype capsid 
(Fig. 3.58). These results indicate a successful generation of recombinant AAVs. 
Based on these results the non-reactive antibody response suggests that no or too 
less expressed triepitope has been presented on MHC class II. Obviously, the 
transduced cells were not lysed by cytotoxic T-cells for releasing the triepitope 
peptide and allowing an uptake by APCs. Rybniker et al. (2012) fused their antigen to 
human tissue plasminogen activator leader peptide that induced a continuous 
release of the expressed protein to the extracellular milieu. Compared to our results 
they obtained a humoral immune response because their protein functioned as an 
exogenous antigen, which was taken up from APCs for a MHC II presentation. 
The capsid-modified vector expressing the triepitope and additionally displays the 
triepitope on the vector capsid by VP2 fusion induced a moderate humoral immune 
response after the second boost. Because the conventional vector did not reveal as 
immunogenic it is evident that the capsid incorporation of the triepitope induced the 
detected antibody-mediated immune response. The occurrence of triepitope on the 
viral surface leads to an uptake of APCs and presentation by MHC class II.  
We conclude that AAV vaccination under the demonstrated conditions was not useful 
for following experiments. As a further strategy, we cloned a new plasmid and fused 
the sequence encoding the triepitope to a an IgG-kappa signal sequence, similar to 
the method of Rybniker et al. (2012). The additional signal motif will allow the 
triepitope’s release from the host cell into the extracellular milieu, where it can act as 
an antigen, while it will be continuously expressed and exported.  
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5 Summary 
 
Patients infected with the life-threatening, methicillin-resistant, human pathogen 
Staphylococcus aureus (MRSA) can be treated only with antibiotics of last resort. The 
development of a vaccine as an alternative to antibiotics is therefore of great clinical 
importance to fight MRSA. 
Based on a S. aureus proteome screen with S. aureus specific human antiserum, 
novel surface-associated proteins were identified as vaccine candidates. Proto-
porphyrinogen oxidase (pOxi), Triosephosphate isomerase (Triiso) and the hypo-
thetical protein 2160 (hp2160) provided protection in a murine sepsis model upon 
active immunization. Monoclonal antibodies (moAbs) against these target proteins 
were generated of which three demonstrated significant, repetitive, epitope-specific 
protection against S. aureus infection in mice. 
The present work focused on the characterization of these protective moAbs and 
their epitopes. Binding of these moAbs to a preparation of cell wall-associated 
proteins as well as to the S. aureus surface depended on in vitro growth conditions. 
For binding of anti-Triiso moAb H8 and anti-hp2160 moAb 16-2 to the bacterial 
surface, biofilm growth of S. aureus was essential. Anti-pOxi moAb D3 showed a 
surface binding also after planktonic growth. In addition to biofilm conditions it was 
detected that the pH of the surrounding medium influences the occurrence of Triiso 
and the epitope accessibility for moAb H8 on the cell surface whereas it does not 
influence the pOxi presence. Triiso was also identified as exoenzyme in the medium 
supernatant and it was shown that the surface of S. aureus can be spiked with 
exogenous Triiso and pOxi.   
The moAbs’ mode of action was investigated first with regard to in vitro 
opsonophagocytosis but we did not observe this. An enzymatic activity of 
recombinant Triiso was measured, as well as an enzymatic activity of native Triiso in 
the cell wall-associated protein fraction and cell lysate. Furthermore, an interaction 
between Triiso and human plasminogen was demonstrated. These measurements 
were not influenced by moAb H8. Additional experiments with other blood 
compounds have to be performed to investigate this further. 
Using deletion mutants, an impaired in vitro growth of ΔpOxi, but not Δhp2160, 
compared to wildtype was demonstrated. In the mouse infection model the virulence 
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of ΔpOxi was also impaired, highlighting pOxi as a potential virulence factor for        
S. aureus. Moreover, we succeeded to show that the protein pOxi contributes to host 
cell adherence. This unexpected moonlighting function was identified using epithelial 
and endothelial cells and demonstrated that the addition of moAb D3 leads to a 
detachment of pOxi from these cells. Furthermore, it was detected that exogenous 
pOxi increases the binding of S. aureus to HeLa cells and that this increased binding 
was inhibited by our moAb D3. 
The identified epitopes of the three moAbs were further characterized and used in 
different approaches for active immunization of mice. Using the pOxi- and hp2160-
epitope-peptides for immunization, an antigen-specific IgG response and a significant 
higher bacterial clearance of organs after S. aureus challenge was measured. It was 
also demonstrated that the protection is epitope-specific because another epitope of 
Triiso, derived from a non-protective anti-Triiso antibody, triggered an IgG-response 
in immunized mice but failed to show protective efficacy after S. aureus challenge. 
Out of several mono- and multivalent epitope fusion peptides the pOxi epitope 
peptide and a pOxi and Triiso diepitope fusion peptide demonstrated to be the best 
candidates, providing significant protection upon lethal MRSA challenge. Additionally, 
the T-cell response was analyzed upon immunization with the fusion epitope 
peptides. The exposure of isolated splenocytes to unconjugated fusion peptides led 
to an increased cell proliferation and to a strong IFN-γ (Th1 response) and IL-17 
release (Th17), described to be important to combat S. aureus infection. 
The triepitope construct was also used as part of MVA and AAV vaccine vectors. 
Vaccination with rMVA-HA-Triepitope resulted in a strong humoral immune response. 
In addition to the viral genome encoding the triepitope peptide, the triepitope was 
also fused to a viral protein, which supports the integration into the membrane of the 
host cell. Vaccination with rAAV encoding the triepitope peptide in addition to a 
triepitope fusion with a viral capsid protein induced just a moderate IgG titer.              
The achieved results gave new insights in the moonlighting functions and surface 
occurrence of our vaccine candidates and in the mode of action of the generated, 
protective antibodies. The successful peptide vaccination underlines the feasibility of 
such a “reverse immunology”-approach and therefore the importance of 
differentiating between protective and non-protective epitopes.  
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6 Zusammenfassung 
 
Patienten, die mit dem lebensbedrohlichen, Methicillin-resistenten, humanen 
Pathogen Staphylococcus aureus (MRSA) infiziert sind, können nur noch mit 
Reserveantibiotika behandelt werden. Die Entwicklung eines Impfstoffes als 
Alternative zu Antibiotika ist daher von großer klinischer Bedeutung für die 
Bekämpfung von MRSA.  
Basierend auf einer Proteomanalyse mit einem S. aureus-spezifischen, humanen 
Antiserum, wurden neue Zellwand-assoziierte Proteine als Vakzinekandidaten 
identifiziert. Die Proteine Protoporphyrinogen Oxidase (pOxi), Triosephosphat 
Isomerase (Triiso) und das hypothetische Protein 2160 (hp2160) zeigten nach 
Immunisierung eine Protektion im Sepsis-Mausmodell. Gegen diese Zielproteine 
wurden monoklonale Antikörper (moAbs) generiert, von denen drei eine signifikante, 
wiederholbare, Epitop-spezifische Protektion gegen eine S. aureus Infektion im 
Mausmodell aufwiesen. 
Die vorliegende Arbeit war auf die Charakterisierung dieser protektiven moAbs und 
ihrer Epitope fokussiert. Die Bindung der moAbs, sowohl an die Zellwand-assoziierte 
Proteinfraktion als auch an die Oberfläche von S. aureus, war abhängig von 
bestimmten in vitro Bedingungen. Für die Bindung von anti-Triiso moAb H8 und anti-
hp2160 moAb 16-2 an die Bakterienoberfläche war ein Wachstum von S. aureus 
unter Biofilm-Bedingungen essenziell. Anti-pOxi moAb D3 hingegen zeigte auch 
unter planktonischen Wachstumsbedingungen eine Bindung an die Oberfläche. 
Zusätzlich zu den Biofilm-Bedingungen war nachweisbar, dass der pH des 
Kulturmediums das Vorhandensein von Triiso und die Epitop-Erreichbarkeit für moAb 
H8 auf der Zelloberfläche beeinflusst. Triiso wurde außerdem als Exoenzym im 
Medium-Überstand identifiziert. Darüber hinaus zeigte von außen hinzu gegebenes 
Triiso oder pOxi eine Bindung an die Oberfläche von S. aureus. 
Die Wirkungsweise unserer Antikörper wurde zunächst im Hinblick auf eine in vitro 
Opsonophagozytose untersucht, welche jedoch nicht verifizierbar war. Eine 
enzymatische Aktivität des rekombinanten Triiso war nachweisbar, die außerdem 
sowohl in der Zellwand-assoziierten Proteinfraktion als auch im Zelllysat detektiert 
wurde. Des Weiteren war eine Interaktion von Triiso und humanem Plasminogen 
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nachweisbar. Es ließ sich bei diesen Messungen jedoch kein Einfluss von moAb H8 
feststellen. Weitere Untersuchungen mit anderen Blut-Komponenten werden hier 
noch durchgeführt. 
Die Analyse von Deletionsmutanten zeigte im Vergleich zum Wildtyp ein verminder-
tes in vitro Wachstum von ΔpOxi, jedoch nicht von Δhp2160. Im Maus-Infektions-
modell war eine verminderte Virulenz von ΔpOxi nachweisbar, die pOxi als einen 
potenziellen Virulenzfaktor von S. aureus hervorhebt. Weiterhin konnte erfolgreich 
dargestellt werden, dass pOxi zur Adhäsion an Wirtszellen beiträgt. Diese 
unerwartete Nebenfunktion wurde mit Epithel- und Endothelzellen identifiziert und 
bewiesen, dass die Zugabe von moAb D3 zur Ablösung von pOxi von diesen Zellen 
beiträgt. Darüber hinaus konnte gezeigt werden, dass exogenes pOxi die Bindung 
von S. aureus an HeLa Zellen steigert, und dass diese Steigerung durch moAb D3 
inhibiert werden kann. 
Die identifizierten Epitope der drei moAbs wurden weiter charakterisiert und für die 
aktive Immunisierung von Mäusen eingesetzt. Nach Immunisierung mit den 
jeweiligen pOxi- und hp2160-Epitop-Peptiden war eine spezifische, gegen das 
Antigen gerichtete IgG-Antwort und nach einer S. aureus Infektion eine signifikant 
geringere Bakterienbelastung in den Organen nachweisbar. Es wurde belegt, dass 
diese Protektion Epitop-spezifisch ist, da ein weiteres Triiso-Epitop, das von einem 
nicht-protektiven anti-Triiso moAb stammte, zwar eine IgG-Antwort, jedoch keine 
protektive Wirksamkeit zeigte. Von mehreren mono- und multivalenten Epitop-
Fusionspeptiden stellten sich das pOxi Epitop-Peptid und ein Fusionspeptid aus den 
pOxi und Triiso Epitopen als beste Kandidaten heraus, die einen signifikanten Schutz 
gegen letale MRSA Infektionen boten. Zusätzlich wurde die T-Zell-Antwort nach 
Immunisierung mit den Fusionspeptiden untersucht. Eine Restimulation der isolierten 
Milzzellen mit den jeweiligen Fusionspeptiden führte zu einer erhöhten Zell-
Proliferation und zu einem vermehrten Ausschüttung von IFN-γ (Th1-Antwort) und  
IL-17 (Th17), die als äußerst wichtig für die Bekämpfung einer S. aureus Infektion 
beschrieben wurden.  
Das Triepitop-Konstrukt wurde als Teil einer MVA- bzw. AAV-Vakzine eingesetzt. Die 
Impfung mit rMVA-HA-Triepitop führte zu einer starken humoralen Immunantwort. 
Zusätzlich zu dem viralen Genom, das für das Triepitop-Peptid kodiert, wurde das 
Triepitop hier mit einem viralen Protein fusioniert, das nach der Expression in der 
Wirtszelle in deren Zellmembran eingebaut wird. Die Impfung mit einem für das 
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Triepitop kodierenden AAV, bei dem das Triepitop zusätzlich mit einem viralen 
Kapsidprotein fusioniert wurde, induzierte nur einen moderaten IgG-Titer.  
Die erzielten Ergebnisse ergaben neue Einblicke in die Oberflächenfunktion unserer 
Vakzinekandidaten, ihr Vorkommen auf der Zelloberfläche und in die Wirkungsweise 
unserer generierten, protektiven Antikörper. Die erfolgreiche Peptid-Impfung 
unterstreicht die Umsetzbarkeit dieses Ansatzes der „reversen Immunologie“ und die 
damit verbundene Wichtigkeit der Differenzierung von protektiven und nicht 
protektiven Epitopen.  
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